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 There has been a significant increase in the number of injectable pharmaceutical products 
over the last decade that have been incorporated into unique delivery systems such as pen 
injectors, auto-injectors, or pre-filled syringes. The advancement of these delivery systems and 
the paradigm shift towards administration of injectables in the out-of-hospital or home setting 
have introduced variables that can affect the bioavailability of injectable drugs and potential 
pharmacologic outcomes. An approach that allows for the qualitative and quantitative dispersion 
assessment of an injectable at the moment of tissue deposition coupled with an assessment of 
systemic exposure parameters could provide substantial information to researchers developing 
new injectable formulations and associated delivery systems.   
 The overall goal of this research project was to develop an approach for investigating 
various injection dynamics, more specifically, dispersion dynamics associated with the 
 administration of parenteral pharmaceutical products utilizing delivery technologies designed to 
deliver drug below the dermis. This was accomplished by first evaluating the safety and usability 
of computed tomography (CT) scanning as a novel radioimaging approach to assess qualitative 
and quantitative dispersion parameters in a cadaver study followed by a randomized, controlled, 
clinical study to assess CT tissue dispersion and the systemic exposure of iohexol, administered 
subcutaneously by two delivery systems in human volunteers. 
 The primary finding of this work was the demonstration that CT scanning may be 
combined with a systemic exposure assessment to provide an effective paradigm for 
investigating dynamics of injectable delivery impacted by a variety of factors, including the 
choice of delivery system. In this study, iohexol delivered subcutaneously by an auto-injector 
resulted in notable qualitative and quantitative dispersion differences, including a higher rate of 
iohexol loss from the extravascular tissue, as well as differences in early plasma exposure as 
compared to a pre-filled syringe delivery system. The injections and CT scanning were well 
tolerated with adverse events limited to mild injection site reactions resolving without 
intervention. This research resulted in a novel local in-vivo(extravascular disappearance), systemic in-
vivo(intravascular appearance) correlation approach that could be utilized to assess a wide variety of 
dynamics associated with injectable drug delivery below the dermis.
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CHAPTER 1. INTRODUCTION 
 
Background 
 Pharmaceuticals may be administered into the body locally or systemically through a 
variety of administration routes utilizing a variety of dosage forms. The oral and injectable routes 
of administration dominate the prescription pharmaceutical market, accounting for more than 
80% of pharmaceutical sales each year (PharmaVitae, 2009). However, as companies continue to 
lose patent protection on many of their blockbuster oral therapies, coupled with a lack of oral 
compound research and development pipeline productivity, novel injectables are projected to 
drive overall growth in the pharmaceutical and biotechnology industries through 2014 
(Datamonitor, 2009). Over 95% of biotechnologically derived drugs are injectable products 
(PCMO, 2005). In years past, many of these biotech drugs were developed for small populations 
with rare diseases which could be treated in an affordable manner. However, new injectable 
medicines have emerged that are for more common, chronic diseases including asthma, diabetes, 
and arthritis. Over 50% of these injectables are now utilized in drug delivery technologies such 
as pre-filled syringes, pen injection systems or auto-injectors (Zitter, 2008). In addition, due to, 
in-part, cost pressures on the healthcare system, many of these drug products that are 
incorporated into delivery technologies have been approved for self or caregiver administration 
in the out-of-hospital setting, especially through intramuscular (IM) or subcutaneous (SQ) routes.
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This is because there are substantial costs savings in reducing regular clinic or office visits for 
healthcare provider administration of injections. By 2012, it is estimated that over 12 million 
Americans will be utilizing some type of specialty injectable drug at home to manage their acute 
or chronic disease (Nagle, 2005). 
 Parenteral routes of drug administration such as injection into the IM or SQ tissue are as 
useful and important as other traditional administration routes, including the oral and inhalation 
routes. IM and SQ injections are administered via the extravascular system where the drug must 
leave the site of injection to enter the systemic circulation in order to distribute throughout the 
body and produce the desired pharmacological response. Because extravascularly administered 
drugs must traverse several barriers to reach the systemic circulation and/or the site of action, 
there are various factors that can affect the rate of drug elimination from the injection site. 
Conventionally, pharmaceutical companies attempting to model and conduct research on 
dynamics associated with the bioavailability of injectables have focused on factors associated 
with properties of the drug and the formulation. These include drug concentration, 
physicochemical characteristics of the active ingredient and/or excipients, and injection volume, 
among others. However, the advancement of novel delivery systems and the paradigm shift 
towards administration of injectables in the out-of-hospital or home setting has introduced other 
dynamic variables that could affect the bioavailability of injectable drugs and potential 
pharmacologic outcomes. Variables including injection device mechanics (including needle 
length, needle gauge and the kinematics of injection), administration factors (such as 
reproducibility of patient, caregiver, or healthcare provider injection technique) and certain 
unappreciated physiologic factors (such as subcutaneous or muscle tissue thickness and inter-
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individual blood flow site differences) may be as important as those dealing with the injectable 
formulation themselves and warrant investigation. As a result, there is a need to develop novel 
approaches to assist in understanding tissue dispersion and systemic exposure dynamics that may 
be introduced and associated with these additional variables. 
Specific Aims 
Aim 1. To evaluate Computed Tomography (CT) as a potential approach for 
investigating sources of variability in injectable systems and to assess the dispersion of an 
injectate beneath the dermis over time with its relative bioavailability using iohexol, a type of 
radiocontrast media (RCM), as an injectable standard. 
Aim 2. To assess the discriminatory capacity of CT for predicting systemic exposure by 
investigating the inter-individual and intra-individual variability in injectable dispersion using 
two distinct delivery systems. 
Hypotheses 
 Utilizing two FDA-approved delivery systems, it is hypothesized that Computed 
Tomography Scanning following the administration of an imaging agent, Iohexol, and its 
associated assay will result in qualitative and quantitative data that will be useable to construct 
an approach to assess variables associated with injectable drug delivery and associated delivery 
systems. It is also hypothesized that there will be a difference in iohexol dispersion between the 
two delivery systems. 
Significance 
 There has been a significant increase in biotechnologically-derived, injectable 
pharmaceutical products over the last decade that have been incorporated into unique delivery 
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systems such as pen injectors, auto-injectors, or pre-filled syringes for self or caregiver-
administration. Due to the high-cost and complex nature of many of these injectable products, a 
failure in the delivery of these drugs to a patient may have significant therapeutic and cost 
implications. 
 In-vivo models have been developed to assess exposure dynamics at the absorption site in 
the oral, inhaled, and transdermal drug delivery routes; however, in-vivo predictive models or 
approaches to assess dynamics associated with parenterally administered products at the moment 
of tissue deposition are lacking. Moreover, although some in-vitro models exist that can assess 
some of the aforementioned dynamics, there are no approaches in-vivo that specifically assess 
deposition or dispersion of an injectable and the resultant systemic exposure variability that may 
be introduced by different injectable delivery systems or that may be introduced by different 
delivery techniques. 
 Therefore, there is a need for investigations that result in a practical paradigm that may be 
utilized to assess non-traditional dynamics of injection introduced before systemic exposure can 
be measured. The overall goal of this project is to develop an approach for assessing various 
injection dynamics, more specifically, dynamics associated with the administration of parenteral 
pharmaceutical products utilizing delivery technologies below the dermis. 
 Successful realization of the project aims will result in data to support further 
development of an approach that may efficiently and effectively investigate a variety of delivery 
systems and associated injectable pharmaceutical products. This could be used by 
pharmaceutical companies undertaking research and development of parenteral products 
indicated for administration in a delivery device (pre-filled syringe, pen injector, or auto-injector) 
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and/or by academic and other pharmacotherapeutic research scientists seeking to provide 
information on these and other dynamics that may improve the health and well-being of patients.
  6 
CHAPTER 2. BACKGROUND AND REVIEW OF THE LITERATURE 
 
Factors Affecting the Systemic Exposure of Intramuscular or  
Subcutaneously Administered Drugs 
Introduction 
 Injection of a drug product intramuscularly or subcutaneously leads to the initiation of 
events that collectively make up the absorption process. From the relatively small, localized 
region where a drug depot is established following injection, a pharmaceutical product is 
absorbed into the bloodstream or lymphatic circulation (for high molecular-weight molecules) by 
means of physical penetration and permeation processes that are associated with passive 
diffusion and partitioning through the capillary membrane. Eventual drug absorption into the 
bloodstream is influenced by several physicochemical variables that affect diffusion. 
 The absorption of a pharmaceutical product into the bloodstream may be influenced by 
factors including: 
• the nature of the pharmaceutical product itself, 
• physiologic differences between subjects, 
• anatomical variations between subjects, 
• variability associated with the mechanics of administration by a patient or care provider, 
and 
• variability associated with the delivery system or vehicle.
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Each of these factors play a role in the rate and extent of injectable drug absorption and are 
discussed further below. 
Pharmaceutical Product Factors 
Drug solubility and pH. Regardless of the dosage form administered into the 
subcutaneous or intramuscular tissue, a drug must eventually be in solution in an aqueous system 
for it to be exposed to the processes that will eventually result in its absorption into the 
bloodstream. Therefore, ultimately, only the fraction of drug in solution is available for 
absorption. Differences in the pH of the administered drug product and the physiological pH at 
the injection site may also result in solubility changes that may affect the absorption of the drug. 
Therefore, many drug products have their pH adjusted with either HCL or NaOH in part to help 
control the solubility of the active ingredient and subsequent absorption profile (increasing or 
decreasing the time to absorption). 
Passive diffusion. The rate of passage of a drug through a biological membrane by 
passive diffusion is affected by several physicochemical factors such as the concentration 
gradient, partition coefficient, degree of ionization, macromolecular binding, and osmolality of 
the drug product. 
(a) Concentration gradient. The rate at which a drug injected into the extravascular 
space crosses a semi-permeable membrane by passive diffusion is described by Fick’s Law, 
expressed as: 
 
where: 
 = The amount of transfer of the drug per unit of time, 
( )1 2DA C CQ
t h
−∂
=
∂
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D = the diffusion constant 
A = the surface area that is available for diffusion 
C1 = concentration of the diffusing pharmaceutical in the extracellular fluid compartment 
C2 = concentration of the diffusing pharmaceutical in the intracellular fluid compartment 
h = thickness of the membrane 
 The magnitude of the diffusion constant is influenced by the physicochemical properties 
of the drug molecule and the characteristics of the membrane. Once the drug unidirectionally 
passes through the biological membrane, it is immediately distributed by the circulation (or 
lymph). For example, in the case of intramuscularly-administered pharmaceuticals, C1 is always 
much greater than C2, establishing a “sink” condition and effectively reducing Fick’s equation to: 
 
(b) Partition coefficient. The partition coefficient is the ratio of concentrations of a 
compound in the two phases of a mixture of two immiscible solvents at equilibrium. Hence these 
coefficients are a measure of differential solubility of the compound between two solvents (one 
water, the other hydrophobic). Therefore, the partition coefficient is a measures of how 
hydrophilic ("water loving") or hydrophobic ("water fearing") a chemical substance is. 
Hydrophobic drugs with high partition coefficients are preferentially distributed to hydrophobic 
compartments such as lipid bilayers of cells while hydrophilic drugs (low partition coefficients) 
preferentially are found in hydrophilic compartments such as blood serum. As an example, in the 
case of intramuscular or subcutaneous absorption, drugs with the higher partition coefficient will 
be absorbed by passive diffusion and distributed faster than water-soluble drugs with a low 
partition coefficient. 
1DCQ
t h
∂
=
∂
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(c) Degree of ionization. Ionization has a profound effect on the absorption of drugs. The 
degree of ionization of an acid or base is determined by an ionization constant, pKa and the pH 
of the drug product. Virtually all drug-like molecules are weak acids or bases. This means that 
they contain at least one site that can reversibly disassociate or associate a proton (a hydrogen 
ion) to form a negatively charged anion or a positively charged cation. Molecules that 
disassociate protons are acids, and those that associate protons are bases. The reversibility, 
means that a sample is always in an equilibrium with some fraction protonated and the rest 
deprotonated: 
 
 By varying the availability of protons (i.e. the acidity of the drug product) the balance of 
the equilibrium can be shifted. This provides a measure of the ease of proton disassociation of a 
site in a compound, the disassociation (or ionization) constant pKa, defined by the equation: 
 
Alternatively, the pKa of a site can be thought of as the pH at which the protonated and 
deprotonated fractions are equal. If the pH is higher than the pKa, the site is mostly 
deprotonated, and if the pH is lower than the pKa, the site is mostly protonated. Therefore, the 
degree of disassociation of a compound at physiologic pH affects the amount of partitionable 
nonionized weak acid or weak base species available for absorption from the injectable dosage 
form. 
(d) Macromolecular (or protein) binding. All biologic fluids contain macromolecules as 
proteins that have an affinity for certain drugs. In general, these proteins are usually too large to 
pass through a membrane by filtration or passive diffusion. Therefore, when a drug becomes 
 or HA H A HB H B+ − + +⇔ + ⇔ +
( )log protonated deprotonatedpKa pH= +
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complexed with a protein (such as albumin), its effective free or “diffusible” form becomes 
lowered, reducing the rate of passive diffusion. Protein binding has a significant effect on passive 
diffusion when the drug is bound by more than 90% because the desorption rate from the drug-
protein complex will be slower than the diffusion rate (in most circumstances) of the drug 
through biological membranes. 
(e) Osmolality. Most parenteral products for intramuscular or subcutaneous 
administration are formulated to be isoosmotic with tissue fluid in order to reduce the possibility 
of irritation that can result if osmotic differences between tissue fluid (or red blood cells) and the 
injectable product are great. When an injection solution is hypoosmotic, it contains fewer solute 
particles than the tissue fluid where it is injected; therefore, when injected into the muscle, the 
solution would cause tissue fluid to move away from the injection site/depot, resulting in an 
increase in the rate of passive diffusion. The converse is true for hyperosmotic pharmaceutical 
preparations. 
(f) Volume of injection. As described above, for the unidirectional flow of a drug given 
by Fick’s equation, when the volume of a pharmaceutical solution decreases, the diffusion rate 
should, in theory, increase. An increase in the injection volume within a relatively confined area 
(such as muscle or subcutaneous tissue) results in the lowering of the tissue surface area-to-
volume ratio, decreasing the passive diffusion (since it is proportional to surface area). 
(g) Physical type of dosage form. The type of dosage form also affects the rate of drug 
release and absorption of the active drug product. For example, aqueous solutions have a much 
faster release profile than aqueous suspensions, which are faster than an emulsion (Aulton, 
2002). 
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Physiologic Factors 
 There are many physiologic influences that have a profound influence on the absorption 
of an injectable drug product. Blood volume, capillary hydrostatic pressure, and osmotic pressure 
all play a role in the ability of a drug to ultimately reach its target site. In addition, body 
temperature, patient age, and the disease state of tissue have been shown to modify the kinetics 
of drug absorption.  
 Furthermore, different anatomical sites are supplied with differences in the vascular 
netwrok, resulting in blood flow changes that may influence drug absorption. The quantitative 
blood supply to various organs and tissues of the body vary according to their functional 
requirements. For example, Binder et al. found that the intramuscular absorption of insulin was 
correlated to regional blood flow in the same individual (Binder et al., 1969). Because muscle 
can require up to 10 times the amount of blood during exercise, blood vessels supplying skeletal 
muscle are richly supplied with capillaries. It is for this reason that the rate of intramuscular 
absorption of some drugs closely approximates that of even intravenous administration. 
Anatomical Factors 
Factors unique to muscle tissue. Muscle tissue provides a drug transport environment in 
which dynamic muscle mechanical motion and loading through contraction (from, for example, 
exercise) may be a predominant influence on the systemic exposure of locally delivered agents. 
These motions and loads, which are shaped by both structure and function of the muscle, can 
present significant and variable physical influences on aqueous drug transport by means of their 
effect on modulating the extracellular space or fluid distribution (Sreter, 1963). 
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 The continuous network of force-transmitting and connective perimysial and endomysial 
collagen fibers between myofibers can hinder interstitial diffusion in a strain-dependent manner. 
Dynamic physical effects such as intramuscular pressure, fluid redistribution, and structural 
deformations during mechanical function can also alter transport kinetics (Gajdosik, 2001). 
Cyclic strain may modify the accessible space, interstitial permeability, and transport kinetics for 
drug absorption intramuscularly. When the cyclic strain of muscles causes the drug to be 
exposed to larger anatomical volumes for absorption, spatial and temporal concentration 
gradients may result that increase the diffusional driving force. This can be caused by myofiber 
deformation, displacement, and thinning due to conservation of volume during elongation that 
increase tissue porosity. Interstitial permeability may increase due to alignment of collagen fibers 
in their dense interstitial networks that form the endomysium and perimysium during stretch, 
which reduces the permeability of a soluble drug (Purslow, 1989). Such changes may result in a 
greater time-averaged porosity and permeability that increases penetration. 
 Whereas local intramuscular delivery minimizes systemic losses and enables efficient 
administration of drugs to target tissues, it is clear that ultimate drug distribution and 
pharmacologic effects are, in large part, determined by target tissue pharmacokinetics, 
physiology, anatomy, and mechanical influences (Wu and Edelman, 2008). Transvascular 
transport of pharmaceuticals usually occurs at the level of continuous capillaries that are 
intermingled among the skeletal muscle tissue (Figure 1) (Becker, Woodley, & Baxter, 2009; 
Netter, 2006). 
  13 
 
1. Capillary in cross section  
2. Skeletal muscle like that which would be found in the Vastus Lateralis Region 
3. Endothelial cell nuclei 
 
Figure 1: Skeletal Muscle Tissue 
 
Following absorption into the capillaries (Figure 2), the pharmaceutical product then moves into 
venules, then into the veins that reach the central circulation. 
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Figure 2: Cross-Section of Typical Continuous Capillary 
 
Factors unique to subcutaneous tissue. Subcutaneous injections pierce the epidermal 
and dermal layers of the skin and deliver the drug into the loose subcutaneous tissue that includes 
adipocytes (fat cells) (Figure 3). Such injectable products are typically prepared as aqueous 
solutions or as suspensions. Following injection, drugs enter the capillaries or lymphatic system 
from the interstitial spaces by diffusion or filtration (Ansel, Allen, & Popovich, 2004). 
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Figure 3: Adipose Tissue in the Subcutaneous Compartment 
 
 The structural characteristics in the interstitial spaces of the subcutaneous compartment 
are similar to the muscle compartment, consisting of a fibrous collagen framework (Figure 4) 
supporting a gel phase made up of glycosaminoglycans, salts, and plasma-derived proteins. The 
glycosaminoglycans are polyanionic polysaccharides that are fully charged at physiological pH 
and are bound covalently to a protein backbone to form proteoglycans which are immobilized in 
the interstitium, with the exception of hyaluronan. Hyaluronan is not immobilized and may be 
removed from the interstitium via the lymph in a flow-dependent manner (Lebel, Smith, Risberg, 
Gerdin, & Laurent, 1988; Lebel, Smith, Risberg, Laurent, & Gerdin, 1989; Pou, Roselli, Parker, 
& Clanton, 1993). 
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Figure 4: Subcutaneous Tissue Matrix Components 
 
 Absorption of drugs from the subcutaneous tissue is influenced, in large part, by the same 
factors that determine the rate and extent of absorption from intramuscular sites; however, the 
vascularity of subcutaneous tissue is less than that of muscle tissue and the additional 
extracellular matrix components of the interstitial architecture pose unique challenges to the 
administration of drugs subcutaneously. For example, decreased blood flow in the subcutaneous 
tissue, especially in diseased states, may lead to slower absorption as compared to intramuscular 
administration (Wilkinson, 2001). Older age may also lead to changes in absorption of drugs 
from the subcutaneous tissue compartment. One example of this includes the fact that older 
individuals are prone to hypothermia which may lead to SC vasoconstriction earlier and to a 
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greater extent as compared to muscle tissue (Inouye, 2004). Furthermore, diffusion of 
macromolecules within the interstitium may be physically retarded by the fibrous collagen 
network and the gel structure of the proteoglycans as well as by electrostatic interaction with 
charged components of the interstitial architecture (Porter & Charman, 2000). 
 Another substantial difference that characterizes the subcutaneous tissue compartment as 
compared to the intramuscular compartment is the availability of the lymphatic system to aid in 
the absorption of drugs. The blood capillaries supplying the subcutaneous tissue are generally 
continuous and are characterized by tight interendothelial junctions and an uninterrupted 
basement membrane. These blood capillaries are relatively permeable to the exchange of small, 
lipophilic molecules, and by virtue of capillary pores, some hydrophilic compounds. In contrast, 
the endothelium of blood vessels constitutes a significant barrier to the transfer of large, 
hydrophilic molecules such as proteins. Since the capillary endothelial barrier is relatively poorly 
permeable to large hydrophilic macromolecules, many proteins may be primarily cleared from 
the interstitium via the lymph. It is still unknown what causes the driving force for 
pharmaceutical transfer from the interstitium to the initial lymphatics, but some authors postulate 
it may be due to the potential energy difference in the fluid phase between the interstitium and 
lymphatics taking the form of a chemical gradient, with associated osmotic or oncotic pressure 
gradients, or a hydrostatic pressure differential (Casley-Smith Jr., 1982). 
Mechanical Administration Factors 
 Achieving the desired clinical outcome following administration by injection depends on 
several mechanical administration factors. This includes utilizing a consistent administration 
technique, choosing the correct needle length and gauge for needle-based systems, ensuring that 
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the fluid jet penetrates into the correct tissue compartment (for needleless systems), and 
understanding the kinematics of injection that may be introduced by various injectable drug 
delivery technologies. 
 Studies have demonstrated substantial variability in techniques of administration for 
drugs injected subcutaneously or intramuscularly. For example, Katsma and Smith (1997) 
studied syringe and needle motion during simulated intramuscular injections into a skin pad 
model by 30 novices (students) and 29 experienced healthcare providers (nurses). The 
kinematics of injection, including the variables of vertical and horizontal needle displacement, 
depth of injection, peak and contact velocity, angle at skin contact, path of injection width, and 
angle at completion of injection were assessed using video motion analysis (Figure 5).   
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Figure 5: Analysis of Injection Kinematics 
 
 The results demonstrated substantial differences in several of the aforementioned 
variables, including vertical needle displacement, peak velocity, path of injection width, and 
angle at skin contact within and between the two groups that would have led to patients receiving 
subcutaneous versus intramuscular injections in practice (Katsma & Smith, 1997). The findings 
between the two groups are important in light of the fact that many injectable drugs are 
administered by novices in the out-of-hospital setting versus being historically administered by 
trained healthcare providers in a hospital or other medical setting. 
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 One potential reason for the mechanical administration variability is the lack of 
standardized training. For example, healthcare professionals throughout medical professional 
schools in America are taught two different ways of administering IM injections. The first, 
widely used in the United States, requires bunching the thigh muscle at the injection site to 
increase muscle mass and to minimize the chance of striking bone (Bergeson, Singer, & Kaplan, 
1982). The second, recommended by the World Health Organization (WHO), suggests stretching 
the skin flat between the finger and thumb, and pushing the needle down at a 90 degree angle 
through the skin (World Health Organization, 1984). Furthermore, there are limited opportunities 
for both student and registered nurses to perform injections in practice, and as such, knowledge 
and skills deteriorate over time (Hemsworth, 2000). Finally, existing practice variability may be 
compounded by new delivery technologies, such as pre-filled syringe devices, pen, or auto-
injector systems that may require new techniques. Indeed, a literature review in the Nursing 
Times perhaps provides the best summary of the challenges regarding proper injection technique 
training by stating “few articles appear to re-examine the evidence for intramuscular injection 
technique; they often repeat opinions and anecdotes with little supporting evidence. A literature 
review of Medline, Cinahl and Cochrane databases found little evidence on injection theory and 
no evidence for aspiration of the syringe plunger. Studies have been undertaken on steps such as 
site selection and needle depth but have not always been rigorous comparative studies; this 
indicates the need for further research” (Malkin, 2008). 
 With the advent of a variety of injectable delivery technologies, a keen understanding of 
the physics of injection must be understood as a part of any drug/device development program. 
Schramm-Baxter and colleagues assessed needle-free jet injection dynamics into human skin 
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utilizing a commercially available, spring-driven injector system, Vitajet 3 (Bioject Inc.; 
Portland, OR). Further, injection kinematics for a needle-free system was provided by a 
derivation of Poiseuille’s law: 
 
and 
P0 = power of the fluid jet 
ρ = density of the Injectable 
D0 = exit diameter 
µ0 = exit velocity 
An = cross-Sectional Area of the Needle 
t = duration of Injection 
Q = amount of Fluid Injection 
 The authors summarize that the power of an injection fluid stream and resultant 
penetration depth and associated dispersion into the tissue depends mainly on exit diameter (the 
diameter of the needle or needle-free orifice) and injection velocity. This equation may be 
applied to any delivery technology with some substantial force acting on a piston to expel an 
injectable medicament through an orifice (whether from a needle with lumen of “x” diameter or 
nozzle in a needle-free jet injector), as is the case with many pen and auto-injector delivery 
systems currently available or in development. The application of physics, including Poiseuille’s 
equation, to an understanding of absorption dynamics affecting bioavailability that may be 
introduced by spring, gas or other “powered” delivery systems warrants further investigation that 
is beyond the scope of this research project. 
0 0 0
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Delivery System Factors  
 Previous studies have demonstrated differences in the bioavailability of an injectable 
drug product between different pharmaceutical delivery technologies (Bennett, Nichols, 
Rosenblum, & Condry, 1998; Brearly, Priestley, Leighton-Scott, & Christen, 2007; Simons, Gu, 
Simons, 2001). For example, in the study by Bennett and colleagues that investigated midazolam 
administered by a conventional syringe and needle compared to a jet injection system, it was 
found that the jet injector reached peak midazolam plasma concentrations over 30% faster with a 
significantly greater overall peak level (Bennett, et al., 1998). Similar studies with insulin have 
demonstrated substantial pharmacokinetic differences between different delivery systems 
(Kerum, Profozic, Granic, & Skrabalo, 1987; Halle, Lambert, Lindmayer, Menassa, Coutu, 
Moghrabi, Legendre, Legault, & Lalumiere, 1986; Taylor, Home, & Alberti, 1981). 
 More importantly, there have been reports of adverse or sub-optimal outcomes as a result 
of choosing the wrong delivery system for the desired clinical response. One example of this 
may be seen with the drug peramivir which was being developed for seasonal flu by 
Pharmaceuticals, Inc. where in a 2007 press release they stated “peramivir for seasonal flu failed 
to meet the primary endpoint in the mid-stage trial because too-short needles failed to deliver the 
drug to the muscle in all of the patients (Biocryst, 2007). As a result of this release, shares of the 
company fell more than 30% providing an example of the economic implications that can arise 
from a company not fully appreciating the potential impact of injection dynamics prior to 
conducting a large clinical trial to support drug development. 
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Models to Assess the Dispersion of Drug Administered by Intramuscular 
or Subcutaneous Routes 
Introduction 
 Although injectable drug delivery is one of the most common administration routes, there 
is little knowledge about what happens to formulations following injection into the tissue. As 
previously discussed, pharmaceutical companies have conventionally focused on developing 
injectable products without consideration for dynamics that may introduce pharmacotherapeutic 
variability at the point the drug is introduced into the target tissue. Recognizing the need for 
direction on assessing these and other variables, the FDA recently issued a draft Guidance for 
Industry entitled “Technical Considerations for Pen, Jet, and Related Injectors Intended for Use 
with Drugs and Biological Products.” Within this guidance, there is a subsection of Performance 
Testing: Injector and Drug/Biological Product Considerations that discusses assessment of depth 
and route of injections. The sections states, “testing should demonstrate that the depth of needle 
penetration and/or dispersion of the injectate are consistent. The model chosen for testing should 
simulate human skin and any specific tissue layers as closely as possible. The application should 
include an explanation to justify the model chosen for testing” (Food and Drug Administration, 
2009). In order to understand models that have been previously developed to investigate 
injectable pharmaceutical dispersion in accordance with this guidance, a literature review was 
conducted. 
Methods 
 Pubmed (Medline), ISI Web of Science, SCIRUS and Google Scholar were screened by 
title and abstract to identify literature for potential relevance. This search was originally 
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conducted in 2008 and was updated in September 2011. Keywords searched included injectable 
dispersion, intramuscular dispersion, intramuscular injection dispersion, subcutaneous 
dispersion, intramuscular injection deposition, injection absorption dynamics, intramuscular 
visualization, and subcutaneous visualization. The complete text was retrieved, and using 
specific inclusion and exclusion criteria, as described in Figure 6, articles were selected for 
consideration. 
Results 
Article selection. Table 1 provides a summary of studies meeting the aforementioned 
search criteria characterized by technique utilized to assess injection dynamics, the route of 
 
Table 1: Summary of Literature Review Results for Models to Assess Dynamics Associated 
with Injectable Drug Delivery 
Author Technique Injection 
In-Vitro or 
In-Vivo 
Species/ 
Model 
Delivery 
system 
Cash CJ, et al. Ultrasound ID and 
SQ 
Both Porcine 
& 
Human 
(n=1) 
Needle-free 
injector 
Donnelly, et al. Radiolabeled 
ALA & Dye 
ID In-vitro Porcine 
skin 
& 
Hydrogel 
SQ-Pen 
Madhu B., et al. MRI SQ In-vivo Porcine 
& Rat 
Needle & 
Syringe 
Schramm-Baxter, et al. Radiolabeled 
mannitol & 
Dye 
 
ID In-vitro Cadaveric Vitajet 3 
(needleless) 
Wagner S., et al. Fluorescent 
Dye 
 
SQ In-vitro Porcine INJEX 
Fishman S., et al. Fluoroscopy/ 
Electro-
myographic 
Guidance 
IM In-vivo Human Needle & 
Syringe 
ID = intradermal, SQ = subcutaneous, IM =  intramuscular 
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administration, whether the study was in-vitro or in-vivo, the species or model chosen, and the 
delivery system utilized. 
Thirteen articles met the inclusion/exclusion criteria, of which, six provide unique 
approaches to assess the dispersion of injectables (Figure 6) (Cash, Berman, Treece, Gee, & 
Prager, 2004; Donnelly, Morrow, McCarron, Garland, & Woolfson, 2007; Fishman, Caneris, 
Bandman, Audette, Borsook, 1998; Madhu, Elmroth, Lundgren, Abrahamsson, & Soussi, 2002; 
Schramm-Baxter & Mitragotri; Wagner, Dues, Sawitzky, Frey, & Christ, 2004). 
 
 
Figure 6: Literature Search Methodology 
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Analysis. The majority of the studies utilized in-vitro approaches to assess injections 
administered intradermally or subcutaneously. Models included injections into gels 
(polyacrylamide or hydrogel), animal models (e.g., porcine) or cadaveric skin/tissue using 
fluoroscopy, MRI, ultrasound, radiolabeled mannitol, or colorimetric dyes to examine the fate of 
the injectate (Bremseth & Pass, 2001; Bennett, Mundell, & Monheim, 1971; Brujan, Nahen, 
Schmidt, & Vogel, 2001; Fishman, et al., 1998; Madhu, et al., 2002; Schramm-Baxter, et al., 
2004a; Schramm-Baxter, & Mitragotri, 2002; Schramm-Baxter & Mitragotri, 2004b; Smith, 
Hurdle, Locketz, & Wisniewski, 2006; Thow, Coulthard, & Home, 1992; Wagner, et al. 2004; 
Wendell, Hemond, Hogan, Taberner, & Hunter, 2006; Cash, et al. 2004). Most models were 
developed to assess the dynamics of jet injectors versus needle-based systems. Donnelly et al. 
studied the influence of solution viscosity and injection protocol on distribution patterns of jet 
injection with its application to photodynamic therapy targeting deep or nodular skin tumors. For 
this investigation they utilized two models. First, a hydrogel was developed by cross-linking 
sodium tetraborate decahydrate with hydroxyl groups on polyvinyl alcohol (PVA) molecules. 
Following mixing, the PVA-borate was then heated for complete homogeneous gel formation at 
80 degrees C for 2 hours, then cooled at room temperature for 48 hours. Injections used 
methylene blue with PVA prepared at different viscosities. For the next model, the investigators 
used full thickness neonate porcine skin from stillborn piglets that were injected with a PVA 
solution containing a photosensitizer, tripropyleneglycol monomethyl ether (TMP). A factorial 
experimental design was then employed such that the effect of five viscosities, three injection 
volumes, and three standoff distances could be simultaneously evaluated. The dispersion pattern 
was quantified using a digital micrometer assessing the total depth of jet penetration (Lt), the 
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maximum width of the penetration pattern formed (Lw), and the depth at which the maximum 
width occurred (Lm) (Figure 7) (Donnelly, et al., 2007).  
 
Figure 7: Measured Penetration Parameters of PVA Solutions containing MB in PVA-STB 
Hydrogels. 
 
A result of the dispersion in porcine skin may be found in Figure 8 below. The investigators were 
unable to correlate the hydrogel findings with the porcine model for any of the parameters 
studied. 
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Figure 8: Dispersion in Porcine Skin 
 
 In another study, human dorsal abdominal skin was procured through the National 
Disease Research Interchange and was frozen at −70 °C until the time of experiments. Jet 
penetration into human skin was quantified using radiolabeled mannitol and jet dispersion was 
assessed using a colorimetric dye, sulforhodamine B (SRB). The authors noted, “the 
experimental setup was previously validated to represent in-vivo jet injections.” However, the 
“in-vivo” correlation for this study was done in a porcine model instead of a human model. The 
authors of this study validated the concern noting, “porcine skin is a good model of human skin 
for testing diffusive permeability; however, this similarity may not extend to jet delivery, where 
the mechanical properties of skin might be important” (Schramm-Baxter & Mitragotri, 2004a). 
 Only one study could be located that attempted to correlate dispersion of an injectable 
with the bioavailability of the drug. This study was located following the formal literature review 
as described above and included an animal model that measured intradermal fluid conductivity 
by infusing mice with human serum albumin with or without the co-administration of an 
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investigational enzyme, recombinant human hyaluronidase. This recombinant hyaluronidase is 
being developed as a "spreading agent" to enhance the drug delivery of local anesthesia, contrast 
agents, and for subcutaneous fluid replacement (also called hypodermoclysis). The model 
assessed the dispersion characteristics and pharmacokinetics of anti-TNF-alpha antibody and 
PEGylated interferon. 
 Flow rates were determined by measuring the time required to inject a known volume of 
the substance. Intradermal drug dispersion was assessed by co-injecting fluoresceinated dextran 
and the hyaluronidase at various doses. Images of the injection site were recorded and the area of 
dispersion was quantified using the fluorescent signal as an indicator. Pharmacokinetic 
parameters of radiolabeled biotherapeutics alone (anti-TNF-alpha antibody and PEGylated 
interferon) or co-administered with the hyaluronidase were analyzed following intravenous and 
intradermal injection into the rats. The reversibility of the effects of hyaluronidase was assessed 
by injecting hyaluronidase intradermally followed by trypan blue dye injection at the same site 
from 0.5 to 48 hours later and quantifying the area of dispersion. 
 The researchers found that drugs co-injected with hyaluronidase intradermally were more 
effectively dispersed, with up to a 20-fold increase in hydraulic conductivity (p<0.05) and 
reduced tissue distortion at the injection site as compared to the drugs injected without the 
hyaluronidase. This was accompanied by a significantly increased systemic bioavailability of co-
administered biotherapeutics (116% vs. 64%, p=0.002, for PEGylated interferon) and faster time 
to maximal blood concentration (Tmax of 8 hours vs. 24 hours, for anti-TNF-alpha monoclonal 
antibody), demonstrating pharmacokinetics approaching those obtained by intravenous dosing of 
the biotherapeutics (Haller, Bookbinder, Keller, Hofer, Radi, Lim, & Frost, 2006). 
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 Authors in several studies note that the opaqueness and composite structure of the skin 
makes it difficult or nearly impossible to visualize dispersion within or below the skin in real 
time (Donnelly, et al., 2007; Schramm-Baxter, Katrenick, & Mitragotri, 2004; Schramm-Baxter 
& Mitragotri, 2004). Although the development of an approach that would be able to 
characterize dispersion in real-time seems difficult at best, a component could include a 
radiographic imaging technique that allows for direct visualization of a radiolabeled injectate or 
imaging agent. This agent would also allow for characterization of systemic exposure 
measurements following administration over time using traditional bioanalytical techniques. 
 Two studies were located that utilized imaging techniques to characterize profiles of an 
injectate, one using ultrasound technology and the other with magnetic resonance imaging (MRI) 
(Cash, et al., 2004; Madhu, et al., 2002). This is surprising given the fact that radioimaging 
technologies have been incorporated into pharmaceutical research of pulmonary delivered 
systems for years (Dolovich, 2001; Newman, Pitcairn, Hirst, & Rankin, 2003; Fleming & 
Conway JH, 2001; Hasani, Agnew, & Toms, et al., 1999; Fleming, Quint, & Bolt, et al., 2006). 
The study by Cash and colleagues incorporated two- and three-dimensional ultrasound in the 
development of a needle-free injection system in order to differentiate and quantify the amount 
of injectate that arrives into the dermis or subcutaneous tissue. For this study, the researchers 
conducted two studies, one in-vitro and another in-vivo. The in-vitro approach used fresh pig loin 
for a serious of injections with a jet injection device (Weston Medical jet injector). The loin was 
scanned using a Daisus ultrasound machine at 16 and 22 megahertz (Mhz) frequencies, 
confirming the injectate location with electronic calipers and dissection.  They then injected 
0.15mL and 0.5mL of the injectate into the abdominal wall of humans where 2-D images were 
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converted to 3-D images using processing software that allowed them to assess the position of 
the injectate in relation to the layer of skin penetrated. In-vitro, investigators were able to 
differentiate between the dermis and SQ tissues with the ultrasound device casting a strong 
acoustic shadow that showed an arc diameter clearly beneath the dermis. Upon dissection, 
injectate location was verified. However, the in-vivo experiment was unable to demonstrate a 
clear injection beneath the dermis (Figure 9). 
 
Left: in-vitro intradermal pig loin injection dissection showing injectate into dermis 
Right: ultrasound following in-vivo intradermal human abdomen injection 
 
Figure 9: Intradermal Injections in Pig Loin (Left) and Human Abdomen (Right) 
 
The strengths of this study include the fact the ultrasound technology is non-invasive and easy to 
use in studying a variety of injectable techniques and delivery systems. Weaknesses include the 
lack of information provided on the injectate used, number of subjects that could provide a 
measure of reproducibility, and the in-vivo results not being able to clearly define the location of 
the injectate. Thus, the practical applicability of this method to researchers or industry may be 
limited (Cash, et al., 2004). 
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 Madhu and colleagues investigated the use of MRI for studying various subcutaneous 
formulations in-vivo without the use of typical marker substances or contrast enhancing agents 
that are normally associated with MRI research. Vehicles assessed included a variety of 
formulations typically incorporated into controlled release pharmaceutical products including 
oils, a lipid emulsion, water solutions of cyclodextrin, normal saline, and block co-polymers 
(poloxamers) that were visualized in-vitro (in a beaker) and in-vivo (pig flesh and the fatty chest 
wall of rats) by a 1H-MRI technique. Poloxamers are surfactants that can be used to increase the 
water solubility of hydrophobic, oily substances or otherwise increase the miscibility of two 
substances with different hydrophobicities, hence their use in controlled release pharmaceutical 
preparations. The in-vitro studies were conducted to assess visibility prior to the in-vivo 
experiments by injecting 0.5mL of each vehicle into a beaker followed by MRI scanning. Next, 
0.5ml of each vehicle was injected into the SQ tissue of pig flesh. Finally, 0.5ml of select 
vehicles were injected into the SQ region of the chest wall (due to its thick distribution) and rats 
were placed-belly down into the scanner and assessed over several time points (up to over 20 
hours). The pattern area of the vehicle was demarcated and measured through imaging software 
and the area was then multiplied by the MRI slice thickness to obtain the volume of the vehicle. 
Volumes were added to determine the total volume of injectate per unit time. 
 The authors found significant variability between what could be detected in-vitro as 
compared to the injections in the pig flesh and rat chest wall. The only vehicle that demonstrated 
consistent qualitative and quantitative detectability among all of the models were the block co-
polymers. Specifically, Poloxamer 407 dissolved in water for injection were clearly present in 
the beaker and pig flesh and displayed the highest contrast in the rat chest wall (Figure 10). As 
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depicted in the below figure volume expansion occurred from the original injection, likely due to 
osmotic properties of the drug. In other words, expansion may have been a function of the higher 
osmotic pressure and diffusion rate of the vehicle. 
 
V6 = Poloxamer 407 and 188 (18 and 10% respectively) dissolved in water for injection 
V11 = Poloxamer 407 (16%) dissolved in water for injection 
 
Figure 10: Poloxamer Detectability in Rat Chest Wall following MRI Scanning 
  
 The strengths of this MRI approach includes the ability to measure extended-release 
pharmaceutical preparations in-vitro first to assess detectability, followed by in-vivo 
confirmation. Other parameters such as formulation concentration, different volumes of 
injection, and different injection site locations may be further studied using this technique. 
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However, because block co-polymers are typically used with extended release pharmaceutical 
preparations coupled with the inability of MRI to distinguish the water based vehicles in-vivo in 
this study, applicability of this approach to conventional, non-controlled release products may 
also be limited (Madhu, B., et al., 2002). 
Conclusions 
 Although some approaches have been used to assess dispersion in-vitro, there is a dearth 
of research that has been conducted to correlate any in-vitro approach with what would be 
expected to occur in-vivo in humans. Additionally, there are few approaches that have been 
suggested to investigate the dispersion of pharmaceuticals using available radioimaging 
technology and, of those reported, the practical application to pharmaceutical research using 
injectable delivery systems remains to be explored. Some of the in-vitro approaches presented 
provide useful information for the development of techniques to assess dispersion in-vivo using 
radiographic imaging technology. For example, the same measurements that were conducted in-
vitro in hydrogels could be applied in-vivo using such measurement parameters as the total depth 
of injection penetration, the maximum width of the penetration pattern formed, the depth at 
which the maximum width occurs. 
 There is a significant need for new approaches to assess the dispersion dynamics 
associated with non-intravenously administered injectable products. These dynamics may have 
an impact on the bioavailability and systemic exposure profiles of these drugs, and therefore, 
may ultimately impact safety and efficacy. An approach that allows for the qualitative and 
quantitative dispersion assessment of an injectable at the moment of tissue deposition coupled 
with an assessment of exposure metrics following systemic absorption could provide substantial 
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information to researchers when developing new injection technologies. Such an approach would 
also afford the ability to assess a variety of injection dynamics as presented earlier in this 
chapter. Ultimately, incorporating quantitative in-vivo measurements that characterize the release 
of an injectable depot from the extravascular compartment into the systemic compartment could 
be correlated with an in-vitro approach. This potential in-vitro, in-vivo correlation approach 
could shorten the development time for injectable pharmaceutical products, initially developed in 
a vial and syringe format to be administered by healthcare providers, that are subsequently 
transitioned into delivery technologies designed for consumer use by providing a surrogate for 
in-vivo bioavailability studies.
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CHAPTER 3. PILOT STUDY TO ASSESS THE DISCRIMINATORY CAPACITY AND 
SAFETY OF COMPUTED TOMOGRAPHY SCANNING AS WELL AS THE 
USABILITY OF IOHEXOL AS AN INJECTABLE STANDARD FOR  
THE INVESTIGATION OF DISPERSION CHARACTERISTICS BY  
PARENTERAL ADMINISTRATION SYSTEMS 
 
Background and Objectives 
 The primary objective of this pilot study was to evaluate the safety and usability of 
Computed Tomography (CT) scanning along with iohexol, a non-ionic, radiocontrast imaging 
injectable agent. This information provided the foundation for the development of an approach 
for assessing dynamics of dispersion that may be introduced by injectable delivery technologies. 
Selection of Radiographic Imaging Approach  
As reported in Chapter 2, there are few studies that discuss the assessment of 
pharmaceutical dispersion through the use of radiographic imaging technology. In developing an 
approach for assessing dispersion of an injectable using available imaging techniques, overall 
imaging requirements should be matched to the appropriate imaging technology. An imaging 
system should be able to assess, qualitatively and quantitatively, a wide variety of variables or 
dynamics associated with the tissue bioavailability of a drug following administration by 
different delivery technologies. Ideally, the imaging technique should allow researchers to 
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1) view/discriminate accurately where an injectable depot is located in the tissue compartment 
immediately following an injection and 2) subsequently, upon evaluation of the radiographic 
images, allow for the application of techniques to measure quantitative dispersion characteristics 
such as location of dispersion, depth of penetration, and width of penetration. Furthermore, the 
ability to detect changes in location and certain parameters over time would be important when 
trying to correlate tissue compartment elimination with the absorption of a pharmaceutical 
product into the systemic circulation. Other imaging requirements for assessing dispersion 
characteristics include the need for excellent resolution in multiple imaging planes as well as the 
ability to apply imaging settings to multiple research subjects. Finally, any approach, and its 
constituent imaging technology component, should be able to be validated against intended 
requirements. This includes at a minimum, that ability to test attributes of specificity, accuracy, 
precision, and reproducibility. Given that most radiographic imaging technologies were 
developed for clinical/medical use, any imaging technology should be relatively readily available 
for research and should not be cost prohibitive. 
  Studies that have incorporated traditional medical imaging approaches have preliminarily 
assessed MRI and ultrasound technology (Cash, et al., 2004; Madhu, et al., 2002). Although 
ultrasound technology can provide images in real time and is relatively inexpensive, the 
technology has been shown to be unable to provide clear resolution for an injectate administered 
below the dermis due to the inability to detect a focal acoustic impedance signal (Cash, et al., 
2004). Magnetic resonance imaging has demonstrated promise as a noninvasive, non-ionizing 
radiation producing technology that can distinguish certain controlled release preparations in 
animal models and, through the use of marker substances such as gadolinium, could prove useful 
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for certain investigations of injectable delivery systems (Madhu, et al., 2002). However, MRI is 
costly and requires a substantial amount of time to acquire an image (usually over 20 minutes per 
scan) limiting the ability to investigate early dispersion characteristics. 
 One overlooked imaging approach that may meet the aforementioned requirements is 
modern multi-slice computed tomography scanning incorporating a non-ionic, radiocontrast 
agent as a model injectable. Computed tomography scanning has been available since the early 
seventies (Beckmann, 2006). This imaging technology incorporates the use of an x-ray source, 
imaging sensor and computer processing that generates cross-sectional slices, or tomograms, of a 
test component or anatomical structure. Pixels of each slice are displayed according to a measure 
of tissue attenuation that translates into relative radiodensity. Once a scan has been acquired, the 
radiodensity data must be processed using reconstruction software that produces a series of 
cross-sectional images for viewing on a monitor. CT scanning technology has evolved drastically 
over the last several decades moving from single technology to spiral CT in the early 90’s 
allowing for the acquisition of imaging data without misregistering anatomical details, to 
multislice CT systems (MSCT) the can simultaneous acquire data from multiple slices per x-ray 
rotation (Crawford & King, 1990). This provides considerable improvement towards isotropic 
three-dimensional imaging. In fact, modern MSCT scanners can acquire 64 slices per rotation 
with an isotropic resolution in the submillimeter range. These latest generation of scanners are 
extremely fast, able to conduct a “whole body” MSCT scan with a 1,500 mm scan range in under 
25 seconds (Kohl, 2005). Additionally, due to the fast acquisition time, tissue changes may be 
examined in rapid succession at any desired time point. Modern technology has also allowed for 
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the optimization and minimization of radiation exposure to a patient. The safety of computed 
tomography is discussed in greater detail below. 
 Radiographic contrast media are utilized clinically in CT scanning to improve the 
visibility of internal body structures in various imaging techniques. Commonly used agents 
include iodine due to its relatively positive safety profile and its water solubility. Iodine may be 
bound in an organic compound or ionic compound. Typically, organic compounds have fewer 
side effects as they do not dissociate into component molecules. The iodine concentration 
determines the radiopacity and subsequent ability to assess changes in tissue radiography on CT.  
Most non-ionic, radiocontrast media are injected intravascularly for angiographic or venographic 
imaging studies. However, iodinated media has been approved for imaging of almost every 
human organ and body cavity including enhancement of computed tomography images for the 
liver, pancreas, brain, spine, kidneys, pelvis, abdominal cavity, and retroperitoneal space. As 
iodine is regulated as a pharmaceutical, is manufactured as a sterile injectable, and shares many 
properties of other small volume parenterals, it may be an ideal agent to study as an injectable 
when developing an approach to assess dispersion characteristics from injectable delivery 
technologies. Iodine is considered to be a safe contrast agent. It has been used for many years 
without serious side effects. The most common side effect of iodine is a warm or "flushed" 
sensation during the actual injection of the iodine, followed sometimes by a metallic taste in the 
mouth that usually lasts for less than a minute. Iodinated contrast may lead to allergic reactions, 
including some severe; however, this is very rare and newer agents have been developed to 
reduce this risk. The safety of non-ionic contrast media is discussed in greater detail below. 
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 Finally, the use of radiographic tomographic imaging techniques coupled to an imaging 
agent or radiotracer is not new in pharmaceutical research involving evaluating parameters 
associated with different delivery/inhaler technologies. For example, in the inhaled drug/device 
combination product development arena, imaging approaches that involve radiation including 
single-photon emission computed tomography (SPECT) with a gamma-emitting radioisotope 
have been used for years to investigate and quantify lung deposition parameters (Fleming & 
Conway, 2001). However, as previously presented, dynamics introduced by injectable delivery 
technologies have been underappreciated and have led to a dearth of imaging technology 
applications in the injectable development arena. 
Safety 
Computed tomography. The safety of computed tomography has recently been brought 
to the forefront of public attention through articles presenting the dangers of radiation exposure 
and associated increase in cancer risk (Gutherie, 2008; LaPook, 2009). The articles discuss the 
challenges with our healthcare system leading to “defensive medicine” and the ordering of 
multiple, unnecessary CT scans in as many as a third of all CT scans. In addition, many 
radiologic technicians are not adjusting the settings of newer scanners to allow for reduced 
radiation exposure. One study demonstrated radiation doses from the identical CT procedure 
varying up to 13-fold among patients at the same institution (Smith-Bindman, Lipson, & Marcus, 
et al., 2009). 
 The radiation dose for a particular study depends on multiple factors: volume scanned, 
patient build, number and type of scan sequences, and desired resolution and image quality. In 
addition, two CT scanning parameters that can be adjusted easily and that have a profound effect 
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on radiation dose are tube current modulation and adjusting the pitch (movement of the 
patient/subject table through the scanner), thus limiting exposure time. Given the ability of new 
multislice scanners to provide a narrow scan field with radiation optimization features, it was 
hypothesized that computed tomography scanning of a narrow area in an extremity could limit 
radiation exposure and result in an associated risk/benefit profile that would be acceptable for 
research purposes. Hence the desire to test this through a pilot cadaveric study.   
Non-ionic radiocontrast media. Most of adverse effects from non-ionic radiocontrast 
media occur soon after administration and are usually self-limiting and of short duration. 
However, some adverse effects may be delayed and may be of a long-lasting nature. Most 
reactions are usually of mild to moderate severity, occurring in less than 5% of patients when 
administered in the vein. Serious, life-threatening and fatal reactions, mostly of cardiovascular 
origin, have been associated with the intravenous administration of iodine-containing contrast 
media. These are rare, occurring in less than <0.3% of administrations. The injection of contrast 
media is frequently associated with the sensation of warmth and pain, especially in peripheral 
angiography; pain and warmth are less frequent and less severe with certain contrast media 
products, such as iohexol compared to others. There are other side effects that are reported, but 
are also rare, usually occurring in less than 0.5% of patient administrations (Omnipaque®, 2008). 
Although non-ionic contrast media is not specifically indicated for direct visualization of 
tissue by subcutaneous or intramuscular administration, the agent has been administered for such 
purposes in clinical settings off-label. In one study, conducted by Fishman and colleagues, 
eleven patients who had symptoms of gluteal pain radiating down the affected leg with one or 
more associated signs of piriformis muscle related irritation of the sciatic nerve, underwent an 
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injection procedure that involved a tri-iodinated agent, iopamidol (Isovue), administered for 
anatomic verification combined with fluoroscopy and electromyographic guidance (Fishman, et 
al., 1998). Of the 17 injections that were performed in 11 subjects, the injection of the non-ionic 
contrast agent was well tolerated with no adverse events reported. During procedures that require 
contrast media administration, it is not uncommon for the iodine to be displaced into the 
extravascular tissue, including muscle and subcutaneous tissue. This usually occurs 
iatrogenically by a healthcare provider puncturing through the vessel following catheter insertion 
for administration of the dye or through the use of power injectors set at levels that are too high 
for some fragile vessels. Several studies have demonstrated that extravasation of non-ionic 
contrast media into the subcutaneous or intramuscular tissue usually results in minimal clinical 
significance (Jacobs, Birnbaum, & Langlotz, 1998; Sistrom, Gay, & Peffley, 1991; Wang, 
Cohan, Ellis, Adusumill, & Dunnick, 2007). For example, in one study, of the 442 adults who 
experienced extravasation from non-ionic contrast media, 97.7% (432) had minimal or no 
adverse effects, nine had moderate adverse effects, and one had a severe complication (75 mL of 
contrast material extravasated into the hand, causing compartment syndrome). Only one 
moderate or severe complication in an adult resulted from an extravasation of less than 50 mL. 
Extravasated volumes ranged from 3 to 150 mL and symptoms usually consisted of swelling 
and/or pain. The authors concluded that extravasation of nonionic iodinated contrast medium 
results only rarely in moderate or severe adverse effects, and these usually occur only when large 
volumes of contrast medium are involved (Wang, et al., 2007). 
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Methods 
Computed Tomography Scanning and Dosimetry  
A cadaveric lower extremity was obtained, with permission, from the Virginia 
Commonwealth University (VCU) Department of Anatomy. The extremity was procured from a 
male human cadaver of approximately 68 years of age. CT scanning took place in the Radiology 
Department of the VCU Medical Center using the Somatom Sensation®, 64-slice CT scanner. 
The scanner provides high-speed, high-resolution sub-millimeter volume scanning (up to 
87mm/s). An initial scan of the thigh region from approximately 3 inches below the pubis 
symphysis to approximately 2 inches above the patella (approximately 13 cm total scan length of 
the extremity) was conducted to localize the injection area as well as to determine the effective 
radiation dose human subjects would receive in the planned, follow-on in-vivo study. The scans 
were conducted by an experienced computed tomography radiology technician followed by 
dosimetry evaluation by two Radiological Physicists at the VCU Office of Radiation Safety 
utilizing the ImPACT CT dosimetry tool (ImPACT, London, UK). 
 Effective dose estimates the total amount of radiation absorbed by tissues, calculated as 
the weighted sum of the dose to irradiated organs and tissues (Payne, 2005). It is expressed in 
sievert (Sv) or millisievert (mSv) units (previously expressed as roentgen equivalent man (rem) 
units. Tissue weighting factors allow CT radiation doses to be calculated and adjusted in light of 
tissue-specific vulnerabilities, which minimizes the risks to subjects. Table 2 provides typical 
effective dose values for CT imaging examinations. 
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Table 2: Effective Dose Values for CT Imaging Examinations 
Computed Tomography Examination Typical Effective Dose (mSv) 
Chest 5-7 
Head 1-2 
Abdomen and Pelvis 8-11 
Coronary Artery Angiogram 9-12 
Colon 6-11 
 
 The imPACT CT dosimetry tool includes software that incorporates complex Monte 
Carlo simulations to calculate effective dose involving the radiation beam, target scan volume, 
gantry motion and the tissue weighting factor values that reflect target organs’ varying 
radiosensitivities. In other words, the calculated radiation dose delivered to each organ volume is 
multiplied by the relevant tissue weighting factors and the sum of these products is the effective 
dose. A sample screenshot from this software is located in Figure 11. 
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Figure 11: ImPACT CT Sample Dosimetry Calculator 
 
Radiocontrast Media (RCM) Injections and Image Acquisition  
Four 1mL injections occurred in the vastus lateralis region of the cadaveric thigh using 
iohexol (a readily available, tri-iodinated, non-ionic, radiocontrast media) at a concentration of 
300mgI/mL. Injections included the use of a 5/8” 25 gauge, subcutaneous needle attached to a 1 
milliliter (mL) pre-filled syringe (PFS), and a 1” 23 gauge intramuscular (IM) needle attached to 
a PFS (2 injections). Images were then loaded into the Main VCU imaging database and 
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analyzed to determine the discriminatory capacity of the scanner to visualize the RCM, confirm 
the estimated radiation exposure, and verify that usable quantitative measurements could be 
achieved from this imaging approach. 
Quantitative Analysis of Computed Tomography Images  
Computed Tomography scans were processed utilizing iSite Picture Archiving and 
Communications System (iSite PACS, Philips Koninklijke Electronics, ver. 3.6.52) software.  
Images were enhanced using the Laplacian Method to increase the visibility of edges in each 
image slice. Measurements of maximum depth of dispersion (MDd) were completed utilizing a 
ruler tool in millimeter units by selecting the point on the skin surface (epidermal region) and 
measuring to the deepest detectable level of iohexol contrast media for a given axial image slice. 
Measurements of maximum width of dispersion (MWd) were completed utilizing the ruler tool 
by selecting the axial image slice with the widest tissue dispersion of iohexol. Finally, 
measurements of the depth at maximum width of dispersion (DMWd) were completed utilizing 
the ruler tool to measure the depth at the axial image slice with the widest tissue dispersion of 
iohexol at each time point by selecting the point on the skin surface (epidermal region) and 
measuring to the deepest detectable level of iohexol contrast media. These measurements were 
independently verified by a Radiologist to ensure inter-rater reliability of the measurements. 
Results 
Dosimetry  
For this pilot study, critical CT scanner settings to maximize image resolution while 
minimizing radiation exposure were chosen through consultation with VCU radiologists and 
radiology physicists. These included selecting a tube-current of 70 milliamps (mA) and peak 
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kilovoltage (kVp) of 80. Each single 1cm scan slice produced effective radiation dose readings 
of 0.0024 mSv. The scan area was approximately 13 cm, providing an estimated per scan 
effective dose of 0.031 mSv of radiation. These dose results were viewed as very positive as one 
goal of this pilot was to determine how many scans could be conducted in the in-vivo study to 
assess changes in dispersion patterns over time while limiting radiation to a level that has been 
comparable to other research projects. Based upon this data, subjects could receive up to 20 
scans without being exposed to more than 1 mSv of radiation, which is less than one-tenth of a 
typical single abdominal CT scan. 
Discriminatory Capacity 
Prior to injection with the iohexol, a scan of the cadaveric thigh was conducted to assess 
the discriminatory capacity of the proposed scan settings. Tissue discrimination was distinct for 
skin, subcutaneous tissue, quadriceps muscle groups, femur, and the bone marrow cavity (Figure 
12). Upon administration, iohexol could also be viewed in multiple image planes (Figure 13). 
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Figure 12: Baseline Scan of Cadaveric Thigh (Near Axial Plane) 
 
 
Left to right: Oblique, near axial, and axial image planes 
Figure 13: Iohexol Administration into Cadaveric Thigh – Multiple Image Planes 
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Discrimination between intramuscular and subcutaneous injection was obtainable (Figures 14 
and 15).  
 
Figure 14: Intramuscular versus Subcutaneous Dispersion of Iohexol in a Cadaveric Thigh 
(Oblique Plane) 
 
Intramuscular 
Subcutaneous 
Femur 
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Figure 15: Intramuscular Administration of Iohexol in the Cadaveric Thigh (Near Axial 
Plane) 
 
Parameters including location, pattern, total depth of dispersion, height of dispersion, width of 
RCM dispersion, and depth of dispersion to maximum width were distinct and measureable 
(Figure 16).  
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Light blue = maximum width of dispersion (33.15mm) , Dark blue = maximum depth of dispersion (13.59 mm),  
Red = height of dispersion (4.30 mm), Green = Depth of dispersion to maximum width (12.21 mm) 
 
Figure 16: Quantitative Measurement of Iohexol Dispersion 
 
In addition, imaging software was able to reconstruct in three-dimensions, the iohexol 
administered and provide a measurement of volume administered (Figure 17 and 18). These 
images can subsequently be animated to provide a fluid perspective on injection location. 
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Figure 17: Three-Dimensional Reconstruction of Iohexol Injection in Cadaveric Thigh 
 
 
Figure 18: Iohexol Injectate Reconstructed Utilizing Imaging Software allowing for 
Volume Measurement 
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Discussion and Conclusion 
 This pilot study sought to assess Computed Tomography scanning and a tri-iodinated 
contrast media pharmaceutical as a useable and safe approach for assessing dispersion dynamics 
that may be introduced by injectable delivery technologies, including pen, jet (needle-free) or 
auto injectors, and pre-filled syringes. The calculated effective radiation dose was well within 
desired safety limits per the VCU radiation safety professional team. This allows for follow-up 
in-vivo study planning to include multiple scanning time points that will be able to characterize 
dispersion immediately following injection and over time. As such, the total radiation exposure 
for the next human study will be no more than approximately 0.5 to 1 millisieverts (mSv), which 
is less than the average person receives from background radiation in three to five years. The 
average person in the U.S. receives an effective dose of about 3 mSv per year from naturally 
occurring radioactive materials and cosmic radiation from outer space. 
 The use of the 64-slice CT scanner afforded remarkable tissue detail both pre and post-
iohexol administration. The ability to discriminate the borders of the injectate clearly, assess 
location of dispersion and, most importantly, measure parameters to characterize the dispersion 
is promising given the previous limited success with other imaging technologies when trying to 
assess dispersion characteristics. Furthermore, because these measurements can be made and the 
effective radiation dose is minute, allowing for the ability to scan a subject’s thigh over time 
following dispersion, an assessment of rate of loss or elimination of iohexol from the 
extravascular compartment to the systemic circulation may theoretically be accomplished. This 
rate may be compared to typical systemic, intravascular exposure parameters using an assay for 
iohexol. As such, it is possible to evaluate not only where this particular drug goes following 
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administration by different delivery technologies, but also to what extent it is deposited and 
dispersed within the extravascular tissue followed by the extent of absorption and elimination 
from the vascular compartment. In summary, computed tomography, utilizing iohexol as an 
injectable standard, is a potentially safe and viable method for assessing dispersion dynamics 
associated with injectable delivery technologies and should be investigated further in humans.
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CHAPTER 4. A RANDOMIZED, SINGLE-BLIND, TWO-TREATMENT, TWO-
PERIOD, TWO-SEQUENCE STUDY TO ASSESS COMPUTED TOMOGRAPHY 
AND THE BIOAVAILABILITY OF IOHEXOL ADMINISTERED 
SUBCUTANEOUSLY BY TWO DELIVERY SYSTEMS IN HEALTHY,  
HUMAN VOLUNTEERS  
 
Introduction and Overview 
 This study consisted of two components. The first component included a comparison of 
in-vivo injection dispersion characteristics from an auto-injector versus pre-filled syringe 
delivery system, administered subcutaneously (depending on subject body habitus), using a non-
ionic radiocontrast media, iohexol (Omnipaque®) and computed tomography (CT) scanning. The 
second component involved a comparison of the bioavailability of iohexol delivered by an auto-
injector delivery system and iohexol delivered by a pre-filled syringe delivery system. Both of 
these components were assessed by conducting a randomized, single-dose, cross-over study. 
 The Study occurred at the Clinical Research Center (CRSU) and Radiology Department 
at the Virginia Commonwealth University Health System. Administration of both treatment 
regimens (Auto-injector with Iohexol and Pre-filled Syringe with Iohexol) occurred in the 
anterolateral thigh of each subject using the same needle length and needle gauge. The systemic 
exposure metrics of iohexol were determined by plasma and urine sampling. Injectable 
dispersion characteristics were assessed using iohexol and CT scanning administered in the
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thigh. Safety was assessed by adverse events (AEs), clinical laboratory tests, vital signs, and 
physical examinations. 
 Twelve eligible subjects were enrolled in the study, and randomized to one of two 
treatment sequences as shown in Table 3 below.  
Table 3: Overview of Study Design 
Treatment 
Sequence 
Number of 
Subjects Period 1 Period 2 
1 Up to 6 Tx A (RCM PFS SC) 
Tx B 
(RCM Auto SC) 
2 Up to 6 Tx B (RCM Auto SC) 
Tx A 
(RCM PFS SC) 
Subjects were dosed on Day 1 in each study period. 
RCM = Radiocontrast Media (Iohexol), Auto = Auto-injector 
PFS = Pre-filled Syringe, SC = Subcutaneous 
 
In each of the treatment periods, subjects received either a subcutaneous injection of iohexol 
administered using an auto-injector in the mid-anterolateral region of the thigh (Autoject® 2, 
Owen Mumford, Ltd.), or an injection of iohexol administered using a pre-filled syringe (Terumo 
Medical Corporation) and needle in the mid-anterolateral region of the thigh. Prior to 
administration, subjects received a CT scan of the thigh region to be injected as well as the 
collection of baseline plasma and urine samples. Following administration, additional CT scans 
occurred to provide an assessment of delivery location and plasma samples were collected to 
assess the bioavailability of iohexol. There was a washout period of at least 7 days between 
treatment periods. 
Ethics 
Institutional and Radiation Safety Review Boards  
The clinical study protocol, any amendments, subject information sheets, written 
informed consent forms (ICFs), and all other relevant study documentation were reviewed and 
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approved by the responsible Institutional Review Board (IRB; Virginia Commonwealth 
University, 800 East Leigh Street, PO Box 980568, Richmond, VA 23298) as well as the VCU 
Center for Clinical and Translation Research Protocol Review Committee (Clinical Research 
Services Unit, North Hospital, 8th Floor, 1300 East Marshall Street, PO Box 980155, Richmond, 
VA 23298). The IRB assigned protocol identification code HM13424 to this investigation. 
Additionally, radiation dosimetry results from the cadaveric study described in Chapter 3 as well 
as the protocol for computed tomography scanning were reviewed and approved by a Radiation 
Safety Review Officer (Office of Environmental Health and Safety- Radiation Safety Section, 
1101 E. Marshall St. PO Box 980112, Richmond, VA 23298). A copy of the IRB and Radiation 
approval forms are provided in Appendix A. 
Ethical Conduct of the Study 
This study was designed and monitored in accordance with procedures which comply 
with the ethical principles of Good Clinical Practices and in accordance with the Declaration of 
Helsinki. 
Subject Information and Consent  
All subjects were informed of the nature and purpose of the study, and their written 
informed consent was obtained prior to the pre-study screening procedures conducted within 30 
days prior to the first dosing day. A sample of the written ICF is provided in Appendix B.1. 
Informed consent was also verified independently by at least two study investigators and/or 
study nurses prior to entry into the study utilizing the process documentation form provided in 
Appendix B.2. 
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Investigators and Study Administrative Structure 
Principal Investigator (PI) 
William R. Garnett, Pharm.D. 
VCU School of Pharmacy 
Sub-Investigator  
William H. Barr, Pharm.D., Ph.D. 
VCU School of Pharmacy 
Assistant Research Coordinator 
Annmarie Panchem 
VCU School of Pharmacy 
Project Manager and Student Investigator 
Eric S. Edwards, BS 
VCU School of Pharmacy 
Clinical Research Unit 
Lead Study Nurse: Lou Usry, R.N. 
Virginia Commonwealth University (VCU) Clinical Research Services Unit (CRSU) at the VCU 
Health System (VCUHS) 
Richmond, VA 
Medical Monitor: 
John N. Clore, M.D., M.S. 
Virginia Commonwealth University CRSU at the VCUHS 
Richmond, VA 
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Computed Tomography Services 
Radiology Coordinator: Megan Quinn, Radiology Oversight: Jonathan Ha, M.D. 
VCUHS Department of Radiology 
Richmond, VA 
Central Laboratory Facilities 
Clinical Laboratory Tests: 
Coordinator: Millicent Smith 
VCUHS Clinical Pathology Research Services (CPRS) 
Richmond, VA 
Bioanalytical Laboratory: 
Analytical Services Coordinator: Matthew Halquist 
VCU Bioanalytical Core Laboratory Service Center 
Richmond, VA 
Study Materials and Management 
VCU Medical Center Investigational Drug Service 
Department of Pharmacy Services 
Richmond, VA 
 All persons involved at the clinical site were qualified to perform their roles. The 
curricula vitae of the Principal Investigators and Medically Responsible Investigator are 
provided in Appendix C. This research project was supported in-part by award Number 
UL1RR031990 from the National Center for Research Resources. The content described in this 
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investigation is solely the responsibility of the author and does not necessarily represent the 
official views of the National Center for Research Resources of the National Institutes of Health. 
Study Aims 
Aim 1 
 To evaluate Computed Tomography (CT) as an approach for investigating sources of 
variability in injectable delivery systems and to assess the dispersion of an injectate beneath the 
dermis over time with its relative bioavailability using iohexol, a type of radiocontrast media 
(RCM) as the injectable standard. 
Aim 2 
 To assess the discriminatory capacity of CT for predicting bioavailability by investigating 
the inter-individual and intra-individual variability in injectable dispersion using two distinct 
injectable delivery systems. 
Investigational Plan 
Overall Study Design and Plan Description 
 This study was a randomized, single dose, single-blind, 2-treatment, 2-period, 2-sequence 
crossover study to document the tissue bioavailability and systemic exposure of iohexol 
delivered by a pre-filled syringe and a commercially available auto-injector delivery system. 
Twelve eligible subjects were planned for enrollment and randomization to one of two treatment 
sequences pre-dose on Day 1 of Period 1, according to a randomization schedule prepared by the 
VCU Health System Investigational Drug Service before the start of the study. Subjects were 
randomized to a treatment sequence; AP or PA, as previously described in Table 3. 
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Interim analysis.  In order to assess whether the approach provided useable data, an 
interim analysis was planned following at least two subjects completing the full study protocol. 
This interim analysis resulted in minor changes in plasma sampling times as well as CT scanning 
time points as described in the Interim Analysis results section. 
Treatment sequences. During Screening (Day -30 to Day -1), subjects signed informed 
consent forms and underwent procedures to determine eligibility. Eligible subjects reported to 
the CRSU on Day 1 (for all treatment periods), the day of dose administration, and underwent 
pre-dose procedures. On Day 1 of each treatment period, subjects received a single injection of 
investigational product in the thigh, administered by the same, trained study nurse. Subjects were 
discharged from the CRSU after the post-dose blood sample was collected (Periods 1 and 2). 
Subjects remained at the CRSU overnight after dosing during any period at the discretion of the 
Investigator. There was a wash-out period of at least 7 days between treatment periods. 
 The systemic exposure of iohexol delivered by either the pre-filled syringe or auto-
injector was determined by plasma concentrations collected through the post-dose sampling time. 
Intensive sampling was obtained during the first hour post-dose to fully characterize the early 
exposure profile after product administration. All CT scans occurred within this first hour in 
order to evaluate early dispersion characteristics. Due to study logistic limitations, CT scanning 
beyond the first hour was unobtainable. Safety was assessed by clinical laboratory tests, physical 
examinations, monitoring of vital signs and monitoring of adverse events (AEs). Refer to Table 4 
for a study flowchart with the schedule of assessments. 
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Table 4: Study Schedule of Assessments 
Evaluation Screening Day -30 to Day -1 
Treatment Period 1 Treatment Period 2 
Day 1 pre-dosea Day 1 treatment Day 1 pre-dose Day 1 treatment 
Informed consent X     
Eligibility Criteria X X  X  
Medical history X     
Urine pregnancy test b X X  X  
Physical examination X     
Clinical laboratory tests 
(Serum Chemistry and Hematology) 
X     
Vital signs X X X (at discharge) X X (at discharge) 
Study treatment including iohexol administration 
and CT Scanning 
  X  X 
Blood samples for systemic exposure analysis    X  X 
Urine samples for systemic exposure analysis d   X  X 
Monitor/record AEs and concomitant medications e  X X X X 
a Admission to clinical site prior to dosing, b All women, regardless of childbearing potential, c Vital signs and ECGs were collected within 60 minutes 
pre-dose d Subjects were asked to provide urine samples in a specimen container, e  Included the review of medications taken since Screening as well as 
any change of health status since Screening. 
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Discussion of Study Design 
 A 2-period, 2-sequence crossover design with the Auto-injector administering iohexol 
once and pre-filled syringe administering iohexol once in a random sequence was selected to 
allow for comparisons of the systemic exposure and dispersion profiles of iohexol administered 
using both delivery systems between subjects and within subjects. All subjects were required to 
fast for a minimum of 4 hours before dosing (to mitigate, for example, food-related effects that 
may influence the absorption behavior of iohexol). A washout period of at least 7 days was 
considered sufficient to prevent carryover effects of the two delivery systems based upon what 
was known regarding the pharmacokinetics of iohexol at the time of the study. Subjects were 
blinded to study treatment to minimize bias based on subjective expectations. For example, a 
subject being able to view the delivery system prior to administration may have resulted in 
variations in anxiety that could affect the absorption of iohexol (e.g. an endogenous epinephrine 
response resulting in vasoconstriction at the injection site due to anxiety). Routine safety 
assessments (AE monitoring, vital signs, 12-lead ECGs, 2-lead cardiac telemetry, physical 
examinations, clinical laboratory tests and concomitant medication monitoring) were performed 
per usual measurements in a bioavailability study of this nature by study personnel. Serial blood 
sampling from pre-dose up to 10 hours post-dose and urine sampling from pre-dose to 24 hours 
post-dose was considered sufficient to determine iohexol systemic exposure profiles following 
an injection using either delivery system. 
Selection and Recruitment of Study Population 
 Twelve healthy, adult, male or female volunteers who met all of the entry requirements 
were planned for enrollment in the study. Subjects were recruited using approved fliers on the 
academic and medical campuses of Virginia Commonwealth University. At the completion of 
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each treatment period, subjects were offered $150.00 for their participation. If a subject 
completed both treatment periods, they received an additional $100.00 for a total compensation 
of $400.00 for full participation in the study. 
Inclusion Criteria  
For inclusion into the trial, subjects were required to fulfill all of the following criteria: 
1. Healthy adult male and female subjects between 21 and 55 years (inclusive) 
2. Ability to give written informed consent to participate in the study 
3. Body mass index (BMI) between 18 and 30 kg/m², inclusive, and a weight of ≥ 50 kg   
Exclusion Criteria 
Any of the following was regarded as a criterion for exclusion from the trial: 
1. Unable to read 
2. Known allergies to radiocontrast media 
3. Not fluent in English 
4. Female subjects who were trying to conceive, were pregnant, or were lactating 
5. Positive urine pregnancy test prior to each drug administration for all women, 
regardless of childbearing potential 
6. A history of clinically significant pulmonary, immunologic, psychiatric, or 
cardiovascular disease or any other condition which, in the opinion of the Medical 
Investigator, would jeopardize the safety of the subject or impact the validity of the 
study results 
7. Currently (in the last 7 days) taking any prescription or non-prescription medicines 
(excluding oral contraceptives), vitamins, dietary or herbal supplements 
8. Previous history of abuse or recent use of alcohol or illicit drugs 
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9. Subjects who donated blood within 30 days or plasma within 14 days of the first 
study dosing 
10. Participation in a clinical trial within 30 days prior to study initiation 
Exclusions were meant to ensure the population studied was able to understand the procedures 
and risks associated with the study, to ensure that all subjects were healthy volunteers, and were 
not placed at unnecessary risks based upon the research proposal. This included ensuring 
subjects had not donated blood since blood samples will be drawn, were not pregnant to ensure 
no potential harm to a fetus, and had no history of being allergic to the investigational products. 
Removal of Subjects from Therapy or Assessment 
 Subjects were informed that they had the right to withdraw from the study at any time for 
any reason without prejudice to their medical care. Subjects were withdrawn from the study for 
any of the following reasons: 
1. Subject request 
2. Subject was unwilling or unable to comply with the protocol 
3. Medical reason, at the discretion of the investigator and/or the Medical Monitor 
 The reasons for discontinuation of the investigational product and/or subject withdrawal 
were recorded if any subject were to withdraw from the study. The PI was to notify the Medical 
Monitor immediately when a subject was discontinued/withdrawn due to an AE. All subjects 
who were withdrawn from the study should have completed the tests and evaluations scheduled 
for the last study day at the time of withdrawal. In the case of subject withdrawal from the study, 
due to the nature of this investigation, additional subjects were not to be enrolled to complete the 
study. 
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Pharmaceutical Product Administration 
Treatments Administered 
During each treatment period subjects received either a single, subcutaneous injection of 
iohexol (150 mgI/mL) or iohexol (300 mgI/mL)  administered using the pre-filled syringe or 
auto-injector delivery system as described below. 
Identity of Investigational Pharmaceutical Product 
 As discussed in Chapters 2 and 3, radiographic contrast media are utilized clinically in 
CT scanning to improve the visibility of internal body structures in various imaging techniques.  
Because of its success in providing direct visualization of dispersion in the cadaveric study and 
due to the availability of a modifiable assay that has previously been used at VCU for another 
investigation, iohexol (Omnipaque®, General Electric Company- Healthcare Division) was 
chosen as the pharmaceutical product for this investigation.  Iohexol (Omnipaque) is a tri-
iodinated, low osmolar, safe and effective, nonionic, water-soluble contrast medium that is well 
established, with U.S. clinical experience since 1985. Worldwide, more than 100 million doses 
of iohexol have been administered. This radiocontrast media agent is approved for use in adults 
and children and is indicated for a broad range of intravascular diagnostic procedures such as 
coronary angiography, spinal cord imaging, and body cavity procedures including shoulder and 
knee joints. 
Clinical pharmacology and pharmacokinetics of Omnipaque (Iohexol). Following 
intravascular injection, iohexol is distributed in the extracellular fluid compartment and is 
excreted unchanged by glomerular filtration. It will opacify those vessels in the path of flow of 
the contrast medium permitting radiographic visualization of the internal structures until 
significant hemodilution occurs. Approximately 90% or more of the injected dose is excreted 
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within the first 24 hours, with the peak urine concentrations occurring in the first hour after 
administration. Plasma and urine iohexol levels from 500 mgI/kg to 1500 mgI/kg does not 
significantly alter the clearance of the drug. The following pharmacokinetic values were 
observed following intravenous administration of iohexol (between 500 mgI/kg to 1500 mgI/kg) 
to 16 adult human subjects: renal clearance—120 (86-162) mL/min; total body clearance—131 
(98-165) mL/min; and volume of distribution—165 (108-219) mL/kg (Omnipaque, 2008). 
 Renal accumulation is sufficiently rapid that the period of maximal opacification of the 
renal passages may begin as early as 1 minute after intravenous injection. Urograms become 
apparent in about 1 to 3 minutes with optimal contrast occurring between 5 to 15 minutes. In 
nephropathic conditions, particularly when excretory capacity has been altered, the rate of 
excretion may vary unpredictably, and opacification may be delayed after injection. Severe renal 
impairment may result in a lack of diagnostic opacification of the collecting system and, 
depending on the degree of renal impairment, prolonged plasma iohexol levels may be 
anticipated. In these patients, as well as in infants with immature kidneys, the route of excretion 
through the gallbladder and into the small intestine may increase. Iohexol displays a low affinity 
for serum or plasma proteins and is poorly bound to serum albumin. No significant metabolism, 
deiodination or biotransformation occurs. Animal studies indicate that iohexol does not cross an 
intact blood-brain barrier to any significant extent following intravascular administration 
(Omnipaque (Iohexol) Prescribing Information. General Electric Company. 2008). 
 Omnipaque enhances computed tomographic imaging through augmentation of 
radiographic efficiency. The degree of density enhancement is directly related to the iodine 
content in an administered dose; peak iodine blood levels occur immediately following rapid 
intravenous injection. Blood levels fall rapidly within 5 to 10 minutes and the vascular 
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compartment half-life is approximately 20 minutes (Olsson, Aulie, Sceen, & Andrew, 1983). 
This can be accounted for by the dilution in the vascular and extravascular fluid compartments 
which causes an initial sharp fall in plasma concentration. Equilibration with the extracellular 
compartments is reached in about ten minutes; thereafter, the decline becomes exponential. The 
pharmacokinetics of iohexol in both normal and diseased tissue (such as tumors) has been shown 
to be variable. 
 Contrast enhancement appears to be greatest immediately after bolus administration (15 
seconds to 120 seconds). Thus, greatest enhancement may be detected by a series of consecutive 
two-to-three second scans performed within 30 to 90 seconds after injection i.e. dynamic 
computed tomographic imaging. Utilization of a continuous scanning technique i.e. dynamic CT 
scanning, may improve enhancement and diagnostic assessment of tumor and other lesions such 
as abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst 
may be distinguished from a vascularized solid lesion when pre-contrast and enhanced scans are 
compared; the non-perfused mass shows unchanged x-ray absorption (CT number). The 
physicochemical properties of the drug may be found in Table 5 below. 
 
Table 5: Physicochemical Properties of Iohexol 300 
mg iodine/ml 300 
Viscosity (cps)  
     at 20°C 11.8 
     at 37°C 6.3 
Osmometrics at 37°C  
   Osmolality (mOsm/kg) 672 
Specific Gravity (g/mL) 1.345 
pH 7 ± 0.5 
Molecular Formula C19H26I3N3O9 
Molecular Weight 821.14 (iodine content 46.36%) 
Melting Point 174-180o 
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Iohexol is designated chemically as N,N´ - Bis(2,3-dihydroxypropyl)-5-[N-(2,3-
dihydroxypropyl)-acetamido]-2,4,6-triiodoisophthalamide. 
 
 
Figure 19: Structural Formula of Iohexol 
 
 Each milliliter of iohexol solution contains 1.21 mg of tromethamine and 0.1 mg of 
edetate calcium disodium with the pH adjusted between 6.8 and 7.7 with hydrochloric acid. All 
solutions are sterilized by autoclaving and contain no preservatives (Omnipaque, 2006). 
Identity of Investigational Delivery Systems 
There are a wide-array of commercially available auto-injectors; however, most come 
pre-filled with a pharmaceutical product preventing easy access to the drug container closure 
system for modification or filling with a custom injectable, such as a contrast media agent. In 
order to limit the source of variability being assessed at the point of injection to device-related 
factors only (e.g. force/mechanics of injection), an FDA-approved auto-injector was chosen that 
allowed for the insertion of a standard pre-filled syringe into the delivery system. This allowed 
for the comparison of a manual delivery technique using a pre-filled syringe device to an 
automatic injection using an auto-injector without the introduction of additional variables that 
could lead to challenges in assessing usability. 
The VCU Health Center Investigational Drug Service obtained and dispensed all study 
materials, including the syringes pre-filled with iohexol by the Drug Service staff per standard 
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operating procedures, with the exception of the auto-injector, which was provided by the study 
investigators. All supplies of investigational product were stored at room temperature. Until 
dispensed to nursing personnel for dosing procedures, investigational product was stored in a 
secure area, accessible to authorized persons only. Accountability for investigational product was 
the responsibility of the PI.   
Auto-injector selection. All subjects were dosed with the Autoject® 2 (Owen Mumford, 
Ltd., Lot: JMD2009-1). This auto-injector system is a re-usable automatic injection device 
designed to incorporate a wide-array of plastic and glass fixed-needle syringes. The product is 
indicated for the subcutaneous administration of insulin and a variety of other injectables (Figure 
19). It also includes an adjustable depth setting mechanism. This depth setting mechanism was 
adjusted to ensure the exposed needle length mimicked the exposed needle length of the pre-
filled syringe to be administered manually. 
 
Figure 20: Autoject® 2 Delivery System 
 
Pre-filled syringe delivery system selection. A 1mL 23 gauge x ½” fixed-needle 
syringe (Terumo Sursaver™, Terumo Medical Corporation, Lot MM1936-09) was chosen for 
this investigation based upon its ability to be used with the auto-injector delivery system (Figure 
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20). The syringe was pre-filled with either 0.5mL or 1.0ml iohexol (300mgI/mL) by the VCUHS 
Investigational Drug Service. 
 
Figure 21: Terumo Sursaver Syringe Example 
 
Method of Assigning Subjects to Treatment Groups 
Enrolled subjects were allocated to one of 2 treatment sequences according to a computer 
generated randomization schedule prepared by the VCU Health Center Investigations Drug 
Service prior to the start of the study. The randomization schedule included 3-digit subject 
numbers. Once a randomization number was allocated to one subject, it could not be re-assigned 
to another subject. The randomization schedule is located in Appendix D. 
Selection of Dose and Regimen in the Study 
 In this crossover-design study, in each treatment period, subjects received either a single 
SC injection of 300 mg (1.0 mL) iohexol or injection of 150 mg (0.5 mL) iohexol using the auto-
injector or a single SC injection of 300 mg (1.0 mL) iohexol or 150 mg (0.5 mL) iohexol 
administered using the pre-filled syringe in the mid-anterolateral thigh region (i.e., the measured 
midpoint between the upper border of the patella [knee cap] and the inguinal fold [crease] at top 
of thigh). All injections occurred no less than 1 and no more than 2 inches from the previous 
injection site. This was accomplished by marking the injection site and measuring with a ruler 
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from the marked location. The larger dose of 300 mg (1.0 mL) was only utilized in this study if 
the planned interim analysis demonstrated the 150 mg dose to be insufficient in direct 
visualization by computed tomography or the plasma concentration analysis fell below the limit 
of quantitation for the chosen analytical method. Water was allowed and encouraged ad libitum 
during the study. Subjects were required to fast for 4 hours after dosing. Standard meals were 
provided at approximately 4 hours after administration of the investigational product. During 
housing, meal plans were identical for all treatment periods. 
Blinding 
This was a single-blind study; subjects were blind to their own injections and to the 
injections received by other subjects. Subjects were also blinded from seeing which delivery 
system (auto-injector or pre-filled syringe) was being administered during their own injections. 
To ensure proper blinding, a screen was placed on top of the subject's mid section to prevent 
viewing of the injection. It was not possible to blind the nurse administering the drug as injection 
systems were visibly different.  
Prior and Concomitant Therapy 
 Concomitant medications were reviewed on Day 1 of each Treatment Period. This 
included the review of medications taken since screening to ensure inclusion/exclusion criteria 
had been met for the study. 
Treatment Compliance 
Trained CRSU personnel administered the investigational product.  The same individual 
at the CRSU administered all injections to all subjects. The date and time of the injection as well 
as the location were recorded for each subject at each treatment period on the Subject Flow 
Sheets (See Appendix E.1a – interim flowsheet and Appendix E.1b – final flowsheet). If an 
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injection system malfunctioned or was accidentally activated prior to injection of the subject, a 
description of the incident was to be recorded, and a new device was to be obtained from the 
pharmacy. Finally, subjects were under the direct supervision of the CRSU staff during the 
treatment periods to ensure compliance with the treatment regimen. 
 
Computed Tomography, Systemic Exposure and Safety Variables Assessed 
Appropriateness of Measurements 
 The safety measures used during this study are standard accepted methods of monitoring 
the safety of subjects during an investigative clinical trial and took into account the research-
based use of computed tomography scanning, pharmacologic properties of iohexol being studied, 
as well as the locations of study activities. All safety assessments were carried out according to 
the standard operating procedures (SOPs) of the CRSU. The systemic exposure variables that 
were utilized were appropriate to characterize the plasma concentration-time profiles for iohexol 
injection administered by the auto-injector and pre-filled syringe. Parameters obtained from 
Computed Tomography scanning included the qualitative variable of location of injection as well 
as novel quantitative measures that were consistent with those that were appreciated through the 
cadaveric pilot study work conducted as described in Chapter 3. 
Iohexol Concentration Measurements 
Iohexol assay. An HPLC-UV method was utilized for the determination of iohexol in 
human plasma and urine as described by Farthing et al. (Farthing, D., Sica, Larus, Ghosh, 
Farthing, C., Vranian, & Gehr, 2005). This method incorporating iohexol was originally 
developed for assessment of Glomerular Filtration Rate (GFR) from medications marketed for 
patients with cardiovascular disease. Although the method was used for investigations involving 
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the intravenous administration of iohexol, the results indicated that it was possible to achieve 
detection at levels as low as 2.5 µg/mL, which the investigators felt could be sufficient for the 
analysis of iohexol administered subcutaneously. 
Chemicals used. Iohexol (Omnipaque) was purchased from United States Pharmacopeia 
(USP, Rockville, MD, USA) (South Plainfield, NJ, USA). Trifluoroacetic acid was reagent 
grade, methanol and acetonitrile were HPLC grade and all were purchased from VWR (Radnor, 
PA, USA). 
Equipment and mobile phase. The HPLC equipment consisted of a Waters 2695 
Separations Module Alliance (Waters Corporation, Milford, MA, USA). The analytical column 
used was a Supelco Discovery C18, 250mm x 4mm i.d., 5µm packing, 180 Å (Supelco, 
Bellefonte, PA, USA). The mobile phase consisted of aqueous trifluoroacetic acid (0.1% TFA in 
deionized water (pH 2.2), v/v) and methanol gradient. An injection volume of 10 µL of the 
prepared plasma sample and 20 µL of the prepared urine sample was accomplished using the 
Waters 2695 Separations Module Alliance. Component detection was achieved using the Waters 
2487 dual wavelength absorbance detector Waters Corporation, Milford, MA, USA with an 
absorbance wavelength of 254nm. Data acquisition and component computations were 
performed using Empower Pro software Waters Corporation, Milford, MA, USA. 
Sample preparation. Plasma samples were thawed and prepared by pipetting 250 µL of 
plasma and 250 µL of 0.1% TFA in deionized water into a polypropylene bullet centrifuge tube. 
Plasma proteins were precipitated by vortexing for 15 s. The samples were centrifuged at 13,000 
rpm for 10 min. The clear supernatant was transferred to a 0.2 µm Nanosep MF filter (Pall 
Corporation, Port Washington, NY, USA) and centrifuged for 1 minute at 13,000 rpm. The 
filtered supernatants were transferred to glass HPLC autosampler vials. Urine samples were 
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prepared by pipetting 20 µL of urine and 980 µL of deionized water directly into the glass 
autosampler vial and vortexing for 10 s. For urine and plasma sample analysis, 10 and 20 µL 
were injected into the HPLC system, respectively. 
Linearity, limit of quantitation and detection, accuracy, precision and recovery. The 
plasma method was linear throughout the concentration range 2.5 -100 µg/mL (mean correlation 
coefficient of 0.9947, n=9). The iohexol isomers are separated under a lower column temperature 
(~20) however, by increasing the column temperature to 40 °C the isomers will co-elute for 
improved sensitivity (Farthing et al., 2005). Both isomers (labeled I2 and iohexol) were 
monitored during quantification. Accuracy and precision for the method was determined by 
evaluation of replicate prepared control samples. The method demonstrated good accuracy and 
precision for both plasma and urine samples. Precision and accuracy was assessed for both 
matrices and found to be acceptable (±15%) according to FDA bioanalytical guidelines (FDA, 
2001). The quality control precision and accuracy results as well as the back-calculated values 
for the calibration curve standards may be found in Appendix F. 
Chromatography. The method demonstrated good plasma chromatographic selectivity 
with no endogenous interference at the retention time of approximately 6.14 min. A sample 
chromatogram may be found in Appendix G. Urine chromatograms displayed good detector 
response and adequate baseline resolution from the endogenous urine substances. 
Plasma sampling procedure. Plasma samples for the first two subjects were drawn at 
pre-dose, 10, 20, 30, 40, 50 minutes and 1, 2, 3, 5, and 7 hrs. Following the interim analysis as 
previously described, the sample schedule was modified and approved by the IRB to drawing 
times at pre-dose, 15, 30, 40 minutes and 1, 1.5, 2, 4, 6, 8 and 10 hrs post-dose. Subjects were 
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asked to provide urine samples in a specimen container. Urine samples were collected at pre-
dose, 0-2, 2-3, 3-4, 4-6, 6-8, and 8-24 hours post-dose intervals. 
 An in-dwelling catheter for multiple blood draws was inserted into the subject and cared 
for according to the CRSU SOPs. In the event that the catheter did not function properly, a 
needle was used to collect blood samples and was recorded if required. All blood samples (1  × 
10 mL) were collected in Heparin/Lithium Vacutainers. 
 The blood sample was immediately transported to the laboratory for processing following 
sample collection. Sample processing initiated within 60 minutes of blood collection and 
consisted of separating the plasma by centrifugation at ~3000 rotations per minute (rpm) × 10 
minutes at 4°C and transferring equal aliquots of plasma to 2 clearly labeled polypropylene 
tubes. One tube was considered the primary sample, and the other tube was considered the back-
up  sample. Both the primary and back-up plasma samples were immediately stored in a non-
defrosting -20°C freezer. The plasma samples were analyzed for concentrations of iohexol using 
the high performance liquid chromatography method (HPLC) as described above. 
 The following systemic exposure parameters were estimated from the plasma and urine 
iohexol concentrations: 
- Cmax: maximum plasma or urine concentration 
- Tmax: time to maximum plasma or urine concentration 
- AUC(0-t): area under the concentration-time curve from baseline to the last measurable 
concentration 
- AUC(0-∞): area under the plasma concentration-time curve from baseline extrapolated to 
infinity 
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- AUC(partial): area under the plasma concentration-time curve from baseline extrapolated 
to select sample time points prior to the last measurable concentration 
- AUC(Tmax): area under the plasma concentration-time curve from baseline extrapolated 
to select to the time of maximum plasma concentration 
- λz: elimination rate constant 
- T½: terminal elimination half-life 
Computed Tomography (CT) Parameter Measurements 
 All subjects received CT scanning in the VCU Health System Radiology Department 
using the Somatom Sensation®, 64-slice CT scanner. An initial scan of the thigh region from 
approximately 3 inches below the pubis symphysis to approximately 2 inches above the patella 
(approximately 13 cm total scan length of the extremity) was conducted to localize the injection 
area and to provide baseline measurements prior to dosing with iohexol. CT image collection 
time points included 0.5, 5, 10, 15 and 20 minutes for the first two subjects and 0.5 10, and 20 
minutes for the subsequent 10 subjects following the interim analysis results. More detail for this 
IRB-approved protocol amendment may be found in the Interim Analysis section below. 
 Subject CT scans were processed utilizing iSite Picture Archiving and Communications 
System (iSite PACS, Philips Koninklijke Electronics, ver. 3.6.52) software. Images were 
enhanced using the Laplacian Method to increase the visibility of edges in each image slice. The 
following parameters were measured for each subject, at each scanning time point, for each 
period from the computed tomography images and associated iSite PACS: 
- location of Injection 
- maximum depth of dispersion (MDd)  
- maximum width of dispersion (MWd)  
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- depth at maximum width of dispersion (DMWd)  
In addition, the iSite PACS includes a tool for measuring radiodensity. This tool measures 
radiodensity in Hounsfield Units (HU), which represents a line transformation from linear 
attenuation coefficient measurements into one where water is assigned a value of zero and air is 
assigned a value of -1,000. The linear attenuation coefficient is the probability that an X-ray 
photon will interact with the material it is traversing per unit path length travelled. If mw, ma, 
and m are the linear attenuation coefficients of water, air and a substance of interest, the HU of 
the substance of interest is: 
 
Thus, a change of one Hounsfield unit (HU) corresponds to 0.1% of the attenuation coefficient 
difference between water and air, or approximately 0.1% of the attenuation coefficient of water 
since the attenuation coefficient of air is nearly zero. This allows for radiodensity in this study to 
provide a measure of iohexol elimination from the injection site in the extravascular tissue 
compartment. The change in radiodensity over time at the injection site can subsequently provide 
an estimate of the iohexol loss rate from the extravascular compartment into the systemic 
circulation. 
Safety Variables 
 Safety was assessed by clinical laboratory tests, physical examinations, urine pregnancy 
testing, 12-lead ECG at screening, monitoring of vital signs, and monitoring of AEs and 
concomitant medications. 
Adverse events. Subjects were queried regularly on all study days using non-leading 
questions, such as “How do you feel?” In addition, all AEs reported spontaneously during the 
course of the study were recorded. Adverse event description details included start date and time, 
( ) ( )1000HU m mw mw ma= − −
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stop date and time, severity, relationship to investigational product, action taken, outcome and 
whether it was serious. The severity of AEs was rated as mild, moderate, severe or life 
threatening. Relationship to investigational product was indicated as none, unlikely, possible, 
probable, or definite. Outcome was recorded as resolved, ongoing, death or unknown. 
 Action taken regarding an AE was recorded and indicated as none, investigational 
product withheld permanently, medication given, or other. Details of any medication given were 
recorded and included: medication name, start date and time, stop date and time, dose, route, 
frequency, reason and whether it was ongoing at the end of the study. Details of 'other' were 
specified. A sample Adverse Event Form is located in Appendix E.2. 
Clinical laboratory tests.  Blood samples for clinical laboratory testing (hematology, 
chemistry) were obtained at Screening. Following blood and urine collection, samples were 
delivered to the VCUHS Clinical Pathology Research Services (CPRS) for analysis. 
Hematology. The following hematology parameters were assessed: Hematocrit, hemoglobin, 
white blood cell (WBC) count, differential white blood cell count, red blood cell (RBC) count, 
and platelets. 
Chemistry. The following clinical chemistry parameters were assessed: Alkaline phosphatase, 
aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine, 
glucose, blood urea nitrogen (BUN), sodium, potassium, chloride, calcium, anion gap, total 
protein, albumin, and globulin.  
Additional clinical laboratory tests. At screening and prior to each treatment (CT Scan), urine 
was collected from female subjects for urine pregnancy testing using QuickVue One-Step hCG 
urine testing (Quidel Corporation). 
   
 80 
 Vital signs. Vital signs were assessed at Screening and at the following time points on each 
treatment day (Day 1 of each treatment period): within 60 minutes of dosing (pre-dose) and at 
approximately 6 hours post-dose. The following vital signs were measured: 
- supine blood pressure (mmHg); 
- heart rate (beats per minute [bmp]); 
- oral temperature (°C); 
- respiratory rate (breaths per minute). 
Vital signs were performed according to the applicable CRSU SOPs. Supine blood pressure 
recordings were made after the study subject had been recumbent and at rest for ≥ 5 minutes. A 
sample Screening Form displaying vital sign measurements may be found in Appendix E.3. 
12-Lead Electrocardiograms. Standard 12-lead ECGs were performed at Screening by 
CRSU study nurses. Electrocardiograms were performed after the subject had been resting 
supine for ≥ 5 minutes. Electrocardiograms were also evaluated by a qualified physician for the 
presence of abnormalities (qualitative assessment). The physician assessed each ECG as normal, 
abnormal/not clinically significant (NCS), or abnormal/clinically significant (CS). 
 Physical examinations.  Each subject received a complete physical exam at Screening. 
The physical examination included an assessment of general appearance and a review of systems 
(skin, eyes/ears/nose throat, head/neck/thyroid, lymphatic, lungs/chest, cardiovascular, abdomen, 
genitourinary, extremities, neurological and musculoskeletal). Additionally, the Screening exam 
included the following measurements: weight (kg), height (cm), thigh circumference (cm) and a 
calculation of body mass index (kg/m2). Thigh circumference and skin-fold thickness were 
measured at the mid-point of the anterior (front) surface of the thigh, midway between the patella 
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(knee cap) and inguinal fold (crease at top of thigh) using a standard skin-fold caliper. A sample 
Physical Exam Form may be found in Appendix E.4. 
Medical history. A review of each subjects medical history, including a history of 
cardiovascular, gastrointestinal, hepatic, endocrine, genitourinary, hematological, neurological, 
musculoskeletal, respiratory, immunological, neoplastic, dermatological, psychiatric, head and 
neck disorders, medications, allergies, HIV, surgical and traumatic history. A sample Medical 
History Form may be found in Appendix E.5. Personal habits were also assessed at screening. A 
sample Personal Habits Questionnaire may be found in Appendix E.6. 
Data Quality Assurance 
 Data collection processes and procedures were reviewed and validated to ensure 
completeness, accuracy, reliability, and consistency. The student investigator cooperated with the 
Principal Investigator for the periodic review of source documents to ensure the accuracy and 
completeness of the data capture system. Electronic CT image scanning consistency checks and 
manual review of the source documents were used to identify errors or inconsistencies. 
Study Monitoring and Auditing 
 In order to ensure the accuracy, consistency, completeness, and reliability of the data as 
well as include an independent review of adverse events, a Data Safety and Monitoring Board 
(DSMB) was assembled. This multidisciplinary group consisted of a biostatistician, radiologist, 
and physician who, collectively, had experience with the professional conduct and monitoring of 
clinical studies. The DSMB was responsible for safeguarding the interests of study participants, 
assessing the safety of the intervention during the study, and for monitoring the overall conduct 
of the clinical study. The DSMB team also provided advisory assistance to the study 
investigators. The investigators were responsible for promptly reviewing the DSMB 
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recommendations, to decide whether to continue or terminate the study, and to determine 
whether amendments to the protocol or changes in study conduct were required. At specific 
study intervals, the DSMB met with the student investigator to review any protocol changes, 
information pertaining to subject screening and withdrawal, eligibility violations (if any), 
baseline demographics of subjects, and any safety signals following dosing that required 
intervention. In addition to the DSMB oversight, the Medical Monitor was in constant 
communication with the investigators at regular intervals during the study.  
Summary of Treatment Period Flow 
 In summary, during each of the treatment periods, subjects reported to the CRSU to 
check-in and begin pre-study procedures which included confirmation of a 4-hour fast, obtaining 
vital signs within 60 minutes prior to dosing, review exclusion criteria, obtaining a urine 
pregnancy test (for females), and placement of a saline lock for blood draws. Subjects were 
transported to the Radiology Department from the CRSU 30 minutes prior to their scheduled 
scan time. CT scanning, blood draws, and urine collection occurred according to the sampling 
schedule and were tracked by the study flowsheets as found in Appendix E.1. Following the final 
plasma draw, after an overnight stay, subjects were placed on “pass” and allowed to go home or 
to class with urine containers for collection of urine for the 8-24 hour collection sample point. 
They then returned the urine at 24 hours where they had their vital signs and injection site 
assessed followed by discharge procedures. 
Results 
Disposition of Subjects 
Subject disposition is presented in Figure 22. A review of the Participant Screening Log 
indicates that 19 volunteers underwent screening visits. Five subjects failed screening, either 
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because they withdrew consent or due to medical history, BMI, abnormal clinical laboratory 
tests, abnormal vital signs, abnormal ECGs, or other. Fourteen subjects were originally enrolled 
(randomized), 2 subjects were kept as reserves for the study, and 12 subjects completed the 
study. Eleven adverse events were reported. All were mild and resolved spontaneously as 
described in the Safety Evaluation section below. 
  
N = number of subjects; A= Auto-injector; P = Pre-filled Syringe 
Figure 22: Disposition of Subjects 
Enrolled 
N = 14 
Treatment Sequence 
AP 
N = 6 
Treatment Sequence 
PA 
N = 6 
Completed 
N = 6 
Completed 
N = 6 
Adverse Event (5) 
Protocol Deviation (0) 
Placed in Reserve Pool (1) 
Adverse Event (6) 
Protocol Deviation (0) 
Placed in Reserve Pool (1) 
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Demographic and Other Baseline Characteristics 
Demographic characteristics. Demographic variables are summarized by treatment 
sequence for the interim and post-interim subject populations in Tables 6 and 7, respectively. 
Descriptive statistics for the continuous and categorical variables by treatment sequence for all 
enrolled study subjects combined may be found in Appendices H.1 and H.2, respectively. 
Subjects in each treatment sequence were well matched for most all continuous and categorical 
variables with the exception of gender. Because of early enrollment challenges and the timing 
associated with scheduling the first two study subjects, the interim subject population included 
two males. This resulted in 60% of the subjects being female in the post-interim subject 
population. While there were slight differences between the treatment sequences in race, these 
differences were not expected to affect the study results or analyses.  
 
Table 6: Summary of Demographic Variables by Treatment Sequence (Interim Analysis 
Population) 
 
Demographic Variable 
Treatment Sequence 
AP 
N=1 
PA 
N=1 
Overall 
N=2 
Continuous Variables: mean (SD)    
Age (years) 44 47 45.5 (1.73) 
Height (cm) 177.5 186.0 181.75 (4.91) 
Weight (kg) 79.2 90.0 84.6 (6.24) 
Body mass index (kg/m²) 25.13 26.01 25.57 (0.51) 
Thigh circumference (cm) 57.5 57.5 57.5 (0) 
Categorical Variables: n (%)    
Race: Black or African American 1 (100.0) 1 (100.0) 2 (100.0) 
Race: Asian 0 (0) 0 (0) 0 (0) 
Race: White 0 (0) 0 (0) 0 (0) 
Race: American Indian or Alaska Native 0 (0) 0 (0) 0 (0) 
Gender: Female 0 (0) 0 (0) 0 (0) 
Gender: Male 1 (100.0) 1 (100.0) 2 (100) 
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Table 7: Summary of Demographics Variables by Treatment Sequence (Post-Interim 
Analysis Population) 
 
Demographic Variable 
Treatment Sequence 
AP 
N=5 
PA 
N=5 
Overall 
N=10 
Continuous Variables: mean (SD)    
Age (years) 23.8 (1.03) 30.2 (12.15) 27 (8.81) 
Height (cm) 174.36 (8.59) 170.52 (10.79) 172.44 (9.63) 
Weight (kg) 68.04 (7.51) 64.08 (9.26) 66.06 (8.41) 
Body mass index (kg/m²) 22.35 (1.52) 21.90 (0.64) 22.13 (1.18) 
Thigh circumference (cm) 45.16 (12.74) 50.56 (1.54) 47.86 (9.50) 
Categorical Variables: n (%)    
Race: Black or African American 1 (20) 1 (20.0) 2 (20.0) 
Race: Asian 1 (20.0) 0 (0) 1 (10.0) 
Race: White 3 (60.0) 4 (80.0) 7 (70.0) 
Race: American Indian or Alaska Native 0 (0) 0 (0) 0 (0) 
Gender: Female 3 (60.0) 3 (60.0) 6 (60.0) 
Gender: Male 2 (40.0) 2 (40.0) 4 (40.0) 
 
Other baseline characteristics. None of the subjects enrolled had a clinically significant 
medical history or findings on screening physical examinations that would exclude them from 
participation in the study. 
Interim Analysis 
 The first two subjects, (Subject # 306 and 307) underwent full study protocols as 
originally approved by the IRB, VCU Center for Clinical and Translation Research Protocol 
Review Committee, and Radiation Safety Committee. Both were African-American males, ages 
44 and 47, respectively. These subjects received 150mg of iohexol 300 (0.5 mL at 300 mgI/mL) 
using the pre-filled syringe and auto-injector. Blood was drawn at pre-dose, 10, 20, 30, 40, 50 
minutes and 1, 2, 3, 5, and 7 hrs post-dose. Urine samples were collected at pre-dose, 0-2, 2-3, 3-
4, 4-6, 6-8, and 8-24 hours post-dose intervals. CT scans occurred at baseline, 0.5, 5, 10, 15 and 
20 minutes. 
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Systemic exposure interim-analysis results. Plasma concentration data by sampling 
time point may be found in Table 8. Urine concentration by sampling time point may be found in 
Table 9 and the resultant urine concentration-time profile is shown in Figure 24. Each subject 
had quantifiable data with either the pre-filled syringe (subject 306) or auto-injector (subject 
307); however, as depicted in the below Table 8 and as shown in the plasma concentration-time 
profile located in Figure 23, the systemic exposure data obtained was below the limit of 
quantitation for the majority of early plasma sampling time points, preventing further non-
compartmental analysis from being conducted with the plasma data. Based upon this 
information, the student investigator in consultation with the principle investigator, DSMB and 
bioanalytical team, made the decision to move to the 300 mg dose and to adjust the plasma 
sampling schedule in order to improve the likelihood for measureable values with the remaining 
subjects. 
Table 8: Plasma Concentrations Obtained for Interim Analysis (First Two Subjects) 
Time 
(Minutes) 
306-auto 
(ug/mL) 
307-pfs 
(ug/mL) 
306-pfs 
(ug/mL) 
307-auto 
(ug/mL) 
0 BLQ BLQ BLQ BLQ 
3 BLQ BLQ BLQ BLQ 
7 BLQ BLQ BLQ BLQ 
12 BLQ BLQ BLQ BLQ 
20 BLQ BLQ BLQ BLQ 
40 BLQ BLQ 5.4780 BLQ 
60 BLQ 3.0440 8.0500 3.5520 
120 BLQ 3.1050 13.0870 11.0940 
240 BLQ BLQ 10.2110 10.6780 
360 BLQ BLQ 7.8890 9.5520 
480 BLQ BLQ 4.7700 6.5990 
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Table 9: Urine Concentration Obtained for Interim Analysis (First Two Subjects) 
Time 
(Hours) 
306-auto 
(ug/mL) 
307-pfs 
(ug/mL) 
306-pfs 
(ug/mL) 
307-auto 
(ug/mL) 
0 0 0 0 0 
2 BLQ 69.66 315.75 289.50 
4 381.34 121.07 1203.61 624.30 
6 341.51 379.11 1713.31 1421.97 
24 76.37 72.49 946.89 1395.40 
 
 
Figure 23: Plasma Concentration – Time Profile for Interim Analysis (First Two Subjects) 
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Figure 24: Urine Concentration – Time Profile for Interim Analysis (First Two Subjects) 
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using the PFS as compared to the auto-injector within each subject (Figures 25 - 28). 
Discrimination between intramuscular and subcutaneous injection was obtainable and 
quantitative measurements including location, pattern, maximum depth of dispersion (MDd), 
maximum width of dispersion (MWd), and depth at maximum width of dispersion (DMWd) 
could be assessed (Table 10).  A sample depth at maximum width reading demonstrating the 
iSite PACS ruler function is provided in Figure 29. Additionally, radiodensity could be measured 
effectively using the software. Summary statistics are provided in Table 11 and an example of 
the radiodensity measurements over time are displayed in Figure 30.   
 Dispersion patterns were similar over time between subjects (Figures 31- 35).  The 
quantitative measurements of dispersion seemed to suggest a consistent increase in the width of 
dispersion among all subjects over time, especially at the later time points (Table 10). Given this, 
it was recommended that the CT scanning time points should be changed from baseline, 0.5, 5, 
10, 15 minutes to baseline, 0.5, 10  and 20 minutes for the remaining subjects. 
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Table 10: Dispersion Parameters for Interim Subject Population 
Dispersion 
Parameter (mm) 
306 – Auto 306 – PFS 307 – Auto 307 - PFS 
Baseline Skin to 
Muscle Thickness 
2.1 2.2 9.0 9.1 
MDd (0.5 min) 19.8 14.2 13.1 16.3 
MDd (2 min) 19.6 14.1 13.3 16.8 
MDd (5 min) 19.0 14.0 13.5 16.5 
MDd (10 min) 19.4 14.2 13.6 17.2 
MDd (15 min) 19.4 13.5 12.8 17.7 
MWd (0.5 min) 14.2 16.8 25.3 12.3 
MWd (2 min) 14.4 17.3 25.5 12.5 
MWd (5 min) 14.7 17.8 26.0 12.7 
MWd (10 min) 15.1 18.4 26.6 12.9 
MWd (15 min) 16.1 19.5 26.9 13.8 
DMWd (0.5 min) 17.7 10.9 15.3 15.0 
DMWd (2 min) 18.0 10.8 15.5 14.9 
DMWd (5 min) 18.0 11.1 16.2 15.3 
DMWd (10 min) 18.2 11.7 15.8 16.2 
DMWd (15 min) 18.5 12.0 15.6 16.9 
 
Table 11: Radiodensity Parameters for Interim Subject Population 
Radiodensity 
Parameter (HU) 
306 – Auto 306 – PFS 307 – Auto 307 - PFS 
Radiodensity at 0.5 
min 
2821.57 2815.81 2927.72 2733.72 
Radiodensity at 2 
min 
2648.82 2755.25 3071.00 2726.35 
Radiodensity at 5 
min 
2610.03 2746.60 3068.09 2747.90 
Radiodensity at 10 
min 
2601.07 2466.42 2873.33 2192.95 
Radiodensity at 15 
min 
2420.84 2150.62 2529.32 1739.53 
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Figure 25: Subject 307 Iohexol by PFS into Thigh at 10 min (Axial Plane) 
 
 
Figure 26: Subject 307 Iohexol by Auto-injector into Thigh at 10 min (Axial Plane) 
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Figure 27: Subject 306 Iohexol by PFS into Thigh at 10 min (Axial Plane) 
 
 
Figure 28: Subject 306 Iohexol by Auto-injector into Thigh at 10 min (Axial Plane) 
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Figure 29: Example of DMWd Measurement using Ruler Tool in iSite PACs 
 
 
Figure 30: Example of Radiodensity Measurement using iSite PACs 
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From Left to Right: 0.5min, 2min, 5min, 10min and 15min CT scans showing very little change in dispersion pattern 
Figure 31: Subject 307 CT Scan - PFS Iohexol Dispersion in the Vastus Region of the Thigh over Time (Axial Plane) 
 
 
From Left to Right: 0.5min, 2min, 5min, 10min and 15min CT scans showing very little change in dispersion pattern 
Figure 32: Subject 307 CT Scan - Auto-injector Iohexol Dispersion in the Vastus Region of the Thigh over Time (Axial Plane) 
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From Left to Right: 0.5min, 2min, 5min, 10min and 15min CT scans showing very little change in dispersion pattern 
Figure 33: Subject 306 CT Scan - PFS Iohexol Dispersion in the Vastus Region of the Thigh over Time 
 
 
From Left to Right: 0.5min, 2min, 5min, 10min and 15min CT scans showing very little change in dispersion pattern 
Figure 34: Subject 306 CT Scan  -  Auto-injector Iohexol Dispersion in the Vastus Region of the Thigh over Time 
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Figure 35: Representative Radiodensity Changes over Time (Axial Plane) 
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Interim Safety Results 
 The injection of iohexol by both delivery systems was well tolerated. No subjects 
experienced a single adverse event in either treatment period. 
Interim Analysis Conclusions 
 The administration of iohexol (150 mgI/mL) in the first two subjects resulted in plasma 
and urine concentrations that were lower than anticipated, especially at the early sampling time 
points. However, the ability to obtain measureable iohexol concentrations to complete a 
sufficient non-compartmental analysis with the higher, 300 mgI/mL dose, and a new sampling 
schedule was deemed to be achievable by the study team. Computed tomography scanning 
resulted in images that provided excellent discrimination between intramuscular and 
subcutaneous injections and the ability to measure the desired quantitative parameters, including 
both dispersion and radiodensity measurements. Iohexol administration by either delivery system 
was well tolerated with no reported adverse events. Therefore, given the data obtained from this 
interim analysis along with the aforementioned proposed protocol changes, the investigators 
chose to proceed with the remaining 10 subjects.   
Systemic Exposure Evaluation for Post-Interim Subject Population 
Data sets analyzed. Twelve subjects were initially enrolled into the study. As previously 
discussed, the first two subjects finished both periods and were included in the interim analysis. 
Following this analysis, the protocol was modified to allow for a change in sampling time as well 
as an increase in the dose of iohexol administered (150 mg in 0.5mL to 300 mg in 1.0 mL). The 
systemic exposure population was defined as all subjects who had an evaluable plasma iohexol 
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concentration following protocol revision. Therefore, 10 subjects were included in the remaining 
data set. 
Systemic exposure parameters. Concentration-time data of iohexol administered by the 
two delivery systems were examined using non-compartmental analysis assuming uniform 
weighting, extravascular input and linear interpolation with WinNonLin software (version 5.1; 
Pharsight Corporation, Mountain View, CA, USA). Missing concentration data values after time 
zero up to the first quantifiable concentration were set to "0”. Missing values between 
concentrations or at the end of the profile were set to "missing."  
 The terminal rate constant, lambda z (λz), was determined from the slope of the terminal 
log-linear portion of the plasma-concentration-time curve, and the terminal half-life (T1/2) was 
calculated as ln(2)/λz. Lambda z (λz) was calculated using at least three points, generally 
optimizing the correlation coefficient and r-squared (r2) measure, while attempting to avoid the 
use of Cmax. In some instances this was not possible. The goodness of fit statistic for the terminal 
elimination phase, with and without adjusting for the number of points used in the estimation of 
λz (r2 and adjusted r2, respectively) and the percentage of AUC0-∞  that was due to extrapolation 
from Tlast to infinity was assessed to determine the T1/2 and λz values. Subjects 309, 311, 312, 
315, and 317 for the auto-injector and 304, 311, 314, 315, and 317 for the pre-filled syringe 
treatment groups were included in the analysis of T1/2  and λz (See Table 12 for summary 
statistics). Details regarding the range of data points selected for the λz analysis by subject may 
be found in Appendix I. 
 Maximum plasma and urine concentrations (Cmax) and time to maximum concentration 
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(Tmax) were determined by direct observation of the data. The area under the concentration-time 
curve to the last non-zero plasma concentration that was above the lower limit of quantification 
was calculated as AUC0-t. The area under the concentration-time curve extrapolated to infinity 
(AUC0-∞) was calculated as AUC0-t + (Clast/λz). To assess early exposure of iohexol after 
administration, partial area under the concentration-time curve was determined at various early 
exposure time points (AUCpartial = AUC0-30, AUC0-40, AUC0-60, and AUC0-Tmax). Means and 
standard deviations for the parameters were also obtained using the descriptive statistics tool in 
WinNonlin version 5.1. Further analysis using linear mixed-effect modeling was conducted 
using JMP Software (version 8.0; SAS Institute, Inc., Cary, NC, USA). 
Systemic exposure analysis and results. Mean (± SD) observed Iohexol plasma 
concentration-time data by treatment are displayed graphically in Figure 36 (linear scale) and 
Figure 37 (semi-log scale). Observed iohexol plasma pharmacokinetic parameters are 
summarized descriptively in Table 12. Mean (± SD) observed Iohexol urine concentration-time 
data by treatment are displayed graphically in Figure 38 (linear scale) and Figure 39 (semi-log 
scale). Observed iohexol urine exposure parameters are summarized descriptively in Table 13. 
Individual subject plasma concentration-time profiles, including the graphical display of λz and 
associated goodness of fit measurements, may be found in Appendix J. The non-compartmental 
analyses output files may be found in Appendix K. 
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Figure 36: Mean ± SD Plasma Iohexol Concentration – Time Profiles by Delivery System 
(Observed) – Linear Scale 
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Figure 37: Mean ± SD Plasma Iohexol Concentration – Time Profiles by Delivery System 
(Observed) – Semi-log Scale 
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Figure 38: Mean ± SD Urine Iohexol Concentration – Time Profiles by Delivery System 
(Observed) – Linear Scale 
 
 
Figure 39: Mean ± SD Urine Iohexol Concentration – Time Profiles by Delivery System 
(Observed) – Semi-log Scale 
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Table 12: Summary of Iohexol Plasma Systemic Exposure Parameters 
Treatment 
Group Statistic 
Cmax 
(µg/mL) 
Tmax 
(min) 
T ½ 
(min)* 
Lambda z 
(1/min)* 
AUC0-t 
(µg.min/mL) 
AUC0-∞ 
(µg.min/mL) 
Pre-filled n 10 10 5 5 10 9 
Syringe Mean 16.395 147.0 139.132 0.00532 4852.788 6365.609 
 SD 5.087 65.5 38.944 0.00150 1360.513 1463.046 
 Median 15.560 120.0 127.840 0.00540 5065.710 6159.300 
 Min 9.170 90.0 92.820 0.00360 2493.170 3477.390 
 Max 26.370 240.0 192.510 0.00750 7181.580 8744.200 
 CV (%) 31.03 44.56 27.99 28.18 28.04 22.98 
        
Auto- N 10 10 5 5 10 9 
Injector Mean 17.037 120.0 142.954 0.00486 4555.656 5788.618 
 SD 6.871 44.7 8.858 0.000321 2127.979 2338.269 
 Median 15.950 120.0 141.930 0.00490 4804.670 5959.100 
 Min 7.267 90.0 130.440 0.00450 2095.780 2715.540 
 Max 29.800 240.0 152.800 0.00530 7980.810 8560.270 
 CV (%) 40.33 37.27 6.20 6.60 46.71 40.39 
* Note: Analysis completed with subset of population 
 
Table 13: Summary of Iohexol Urine Systemic Exposure Parameters 
Treatment 
Group Statistic 
Cmax 
(µg/mL) 
Tmax 
(hrs) 
AUC0-t 
(µg.hr/mL) 
Pre-filled Syringe n 10 10 10 
 Mean 2122.4 4.7 14895.12 
 SD 1057.5 2.5 9352.06 
 Median 1902.0 3.0 12581.50 
 Min 714.8 2.0 5597.65 
 Max 4386.0 8.0 34357.20 
 CV (%) 49.83 53.12 62.79 
     
Auto-injector N 10 10 10 
 Mean 2305.7 4.3 11315.09 
 SD 1564.2 2.2 4906.74 
 Median 1761.5 3.0 11147.70 
 Min 717.3 3.0 3227.75 
 Max 5714.0 8.0 19347.10 
 CV (%) 67.84 50.30 43.36 
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 Iohexol plasma peak (Cmax) and total (AUC 0-t) exposure were similar whether 
administered by pre-filled syringe or auto-injector. Mean Cmax values were approximately 16.4 
µg/mL and 17.0 µg/mL for the PFS and auto-injector groups, respectively. Mean AUC 0-t values 
were 4852.79 and 4555.66 µg.min/mL for the PFS and auto-injector groups, respectively (Table 
12). The between-subject variability in these parameters was high (CV% ranged from 
approximately 28 to 47%). Iohexol peak plasma exposure took more time than anticipated; 
median Tmax was 120 minutes and ranged from approximately 90 to 240 minutes for both 
products. Plasma Tmax values were highly variable as suggested by the broad range of observed 
values and by CV% values of 45% and 37% for the pre-filled syringe and auto-injector products, 
respectively. Mean plasma T1/2  was similar in both treatment groups occurring at approximately 
140 minutes (139 minutes for the PFS and 143 minutes for the auto-injector). Lambda z (λz) was 
also similar for both treatments (0.005 hr-1) suggesting a similar rate of elimination from the 
systemic circulation. Finally, because more than 20% of the plasma AUC0-∞ estimates were 
extrapolated for many of the subjects in both treatment groups, no conclusions could be drawn 
associated with this parameter. 
 Iohexol urine peak (Cmax) and total (AUC 0-t) exposure as well as time to maximum 
exposure (Tmax ) were similar whether administered by pre-filled syringe or auto-injector and 
highly variable (the between-subject variability was over 40% for all parameters) (See Table 13). 
The urine concentration-time profiles were similar by treatment group exhibiting two peaks that 
were approximately 3 hours apart. 
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Mixed model assessment of systemic exposure parameters. Linear mixed-effects models 
were used to test for differences in mean plasma Cmax, Tmax, AUC0-t, and AUC0-∞ between the 
Auto-Injector and PFS treatment groupings after controlling for period and sequence effects as 
well as the covariates of age, sex, and thigh circumference. The models included a random 
subject effect to account for within subject variations. Additionally, the models included fixed 
effects for treatment, period, and sequence as well as the aforementioned covariates. Each of 
these covariates were included in the model in order to determine what effects each, or any may 
have on the response parameters (Cmax, Tmax, AUC0-t, and AUC00-∞). Using these models, the 
mean responses (Cmax, Tmax, AUC0-t, and AUC00-∞) were estimated for each group (Table 14) and 
the differences in the means were compared statistically between the groups using a significance 
level of α = 0.05 (Table 15). 
Plasma Cmax and Tmax.  The mixed-effects model accounted for 94.9% (r2 adjusted = 
91.0%) of the variations in Cmax and 52.6% (r2 adjusted = 18.2 %) of the variations in Tmax. 
There was no evidence of a significant treatment effect on either Cmax (p = 0.5021) or Tmax (p = 
0.2914). There were no significant effects of any of the covariates on either Cmax or Tmax with the 
exception of a significant period effect on Cmax (p = 0.0025), with mean Cmax significantly lower 
in the first period than the second (12.52 µg/mL vs. 16.49 µg/mL). It is unclear what may have 
led to this difference. One possibility could be subjects having less anxiety during the second 
period; therefore, there may have been less endogenous, epinephrine-induced vasoconstriction 
that could slow absorption in the second period leading to greater overall absorption. The least 
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squares mean Cmax and Tmax estimated from the model are summarized by treatment group in 
Table 14 and the difference between groups is summarized in Table 15. 
Extent of exposure (AUC0-t and AUC0-∞).  The mixed-effects model accounted for 
87.8% (r2 adjusted = 79.0%) of the variations in AUC0-t and 71.3% (r2 adjusted = 45.8%) of the 
variations in AUC0-∞. There was no evidence of significant treatment effects (AUC0-t, p = 
0.4799; AUC0-∞, p = 0.2932) or other model covariates on either AUC0-t or AUC0-∞ with the 
exception of a significant period effect on AUC0-t (p = 0.0010). The mean AUC was significantly 
lower in the first period than the second (2992.25 µg.min/mL vs. 4959.03 µg.min/mL for AUC0-t. 
There were no substantial changes in the results when comparing the untransformed data to the 
log transformed data. Mean AUC0-t and AUC0-∞ are summarized by treatment group in Table 14 
and the difference between groups is summarized in Table 15. 
 
Table 14: (Adjusted) Mean Response Measures by Treatment Group 
 Auto-injector Pre-filled Syringe 
Response Mean SE 95% CI Mean SE 95% CI 
Cmax (µg/mL) 14.83 2.88 (5.92, 23.74) 14.19 2.88 (5.28, 23.10) 
Tmax (min) 
126.27 27.90 (51.61, 200.92) 122.53 27.90 (78.61, 227.92) 
AUC0-t 
(µg.min/mL) 
3792.07 721.94 (1673.24, 5910.90) 4089.20 721.94 (1970.37, 6208.03) 
AUC0-∞ 
(µg.min/mL) 
5273.56 750.32 (3410.27, 7136.84) 6085.31 746.67 (4173.44, 7997.17) 
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Table 15: (Adjusted) Mean Differences in Response Measures between Treatment Groups 
 
Response Difference SE 95% CI  
Cmax (µg/mL) 0.64 0.91 (-1.47, 2.75)  
Tmax (min) 27.00 23.91 (-28.13, 82.13)  
AUC0-t  (µg.min/mL) 297.13 401.04 (-627.66, 1221.93)  
AUC0-∞  (µg.min/mL) 811.75 715.06 (-874.35, 2497.85)  
† Indicates statistically significant at α = 0.05 
Systemic exposure analysis of early exposure. In order to assess early plasma exposure 
parameters of iohexol, a partial AUC analysis was conducted at various time points (30, 40 and 
60 minutes) as well as up to Tmax for each treatment group. In addition, a calculation of 
Cmax/AUC0-t was conducted as a measurement of absorption rate. Although the rate of absorption 
(using Cmax/AUC0-t) was similar between treatment groups (approx. 0.004 min-1) there was a 
difference in the extent of early systemic exposure, with the mean AUC difference between 
treatment groups increasing over time up until 60 minutes post-dose (Table 16). This difference 
was not apparent by the time the maximum plasma concentration, Tmax ,was reached as mean 
AUC0-tmax was similar for the PFS (1281.06 µg.min/mL) and auto-injector (1110.32 µg.min/mL) 
groups. Although the between-subject variability was high for these early exposure parameters 
up until 60 minutes post-dose (CV% ranging from approximately 55% to 82%), these results 
suggest the delivery system may have had an effect on the extent of early exposure to iohexol 
(see mixed-effects model analysis below). 
The time prior to the time point corresponding to the first measurable (non-zero) 
concentration was calculated as Tlag. Similar Tlag data were obtained relative to the pre-filled 
syringe (mean 27.5 min) and auto-injector (22.5 min) products; however, the between-subject 
variability in these parameters was high (CV% ranged from approximately 59% to 82%) limiting 
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the ability to draw definitive comparative conclusions regarding the average time for removal 
from the extravascular tissue “compartment” to the systemic circulation.
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Table 16: Summary of Iohexol Plasma Early Exposure Parameters 
Treatment 
Group Statistic 
Tlag 
(min) 
Cmax /AUC0-t 
(min-1) 
AUC(0-30min) 
(µg.min/mL) 
AUC(0-40min) 
(µg.min/mL) 
AUC(0-60min) 
(µg.min/mL) 
AUC(0-Tmax) 
(µg.min/mL) 
Pre-filled n 8 10 6 8 9 10 
Syringe Mean 27.5 0.00355 63.427 108.539 266.410 1281.058 
 SD 16.3 0.00137 38.184 71.627 149.138 612.214 
 Median 22.5 0.00302 46.895 114.250 295.080 1323.940 
 Min 15.0 0.00237 23.850 16.200 49.340 584.360 
 Max 60.0 0.00716 115.350 208.440 500.110 2475.950 
 CV (%) 59.12 38.66 60.20 65.99 55.98 47.79 
        
Auto-injector n 6 10 9 9 9 10 
 Mean 22.5 0.00405 89.986 173.801 413.271 1110.323 
 SD 18.34 0.00135 73.939 118.359 236.291 371.503 
 Median 15.0 0.00369 44.870 116.460 341.180 1109.200 
 Min 15.0 0.00255 30.740 75.590 165.840 541.800 
 Max 60.0 0.00718 226.430 395.530 865.830 1728.930 
 CV (%) 81.65 33.29 82.17 68.10 57.18 33.46 
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Mixed model assessment of early exposure parameters. Mixed-effects models were also 
used to test for differences in untransformed and log transformed mean early exposure parameter 
data (AUC0-30, AUC0-40, AUC0-60, and AUC0-Tmax) between the Auto-Injector and PFS delivery 
systems after controlling for the covariates of period, sequence effects, age, sex, and thigh 
circumference. The models included a random subject effect to account for within subject 
variations and fixed effects for treatment, period, and sequence as well as the aforementioned 
covariates. Each of these covariates were included in the model in order to determine what 
effects each, or any may have on the response parameters (AUC0-30, AUC0-40, AUC0-60, and 
AUC0-Tmax) by treatment group. Using these models, the mean responses (AUC0-30, AUC0-40, 
AUC0-60, and AUC0-Tmax) were estimated for each group (Table 17) and the differences in the 
means were compared statistically between the groups using a significance level of α = 0.05 
(Table 18). 
AUC0-30, AUC0-40, and AUC0-60.  The mixed-effects model accounted for the vast majority 
(greater than 93%) of the variations in AUC0-30, AUC0-40 and AUC0-60  (AUC0-30 r2 adjusted = 
83.7%, AUC0-40 r2 adjusted = 85.8%, AUC0-60 r2 adjusted = 92.0%). There was no evidence of a 
significant treatment effect on AUC0-30 (p = 0.0630); however, there were significant treatment 
effects on AUC0-40 and AUC0-60 (p = 0.0347 and p = 0.0113, respectively). The mean response 
for the Auto-injector treatment group was significantly higher than for the PFS treatment group 
(AUC0-40 difference = 73.27, 95% CI = 7.81, 138.73; AUC0-60 difference = 126.63, 95% CI = 
40.60, 212.66) (Table 18). 
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 There were also significant period effects for each of these early exposure parameters 
with mean AUC0-30, AUC0-40, and AUC0-60 significantly lower in the first period than the second 
(p = 0.0144, p = 0.0167, p = 0.0049, respectively ). There were not significant effects of any of 
the other covariates on AUC0-30, AUC0-40, or AUC0-60. There were no substantial changes in the 
results when comparing the untransformed data to the log transformed data. 
AUC0-Tmax. The mixed-effects model accounted for only 12.6% (r2 adjusted = -0.51%) of 
the variations in AUC0-Tmax. There was no evidence of significant treatment effects (AUC0-Tmax 
(p = 0.5078) or other model covariates on AUC0-Tmax. There were no substantial changes in the 
results when comparing the untransformed data to the log transformed data. 
 
 Table 17: (Adjusted) Mean Response Measures by Treatment Group 
 Auto-injector Pre-filled Syringe 
Response Mean SE 95% CI Mean SE 95% CI 
AUC0-30 
(µg.min/mL) 
46.29 35.88 (-99.89, 192.48) 3.50 38.77 (-124.78, 131.79) 
AUC0-40 
(µg.min/mL) 
136.16 58.12 (-51.71, 324.03) 62.89 58.75 (-123.75, 249.53) 
AUC0-60 
(µg.min/mL) 
324.09 107.89 (-11.23, 659.41) 197.46 107.02 (-140.72, 535.64) 
AUC0-Tmax 
(µg.min/mL) 
898.42 196.55 (434.06, 1362.79) 1069.16 196.55 (604.80, 1533.52) 
 
Table 18: (Adjusted) Mean Differences in Response Measures 
Response Difference SE 95% CI  
AUC0-30  (µg.min/mL)) 42.79 16.87 (-3.68, 89.26)  
AUC0-40  (µg.min/mL) 73.27 25.52 (7.81, 138.73) † 
AUC0-60 (µg.min/mL) 126.63 35.24 (40.60, 212.66) † 
AUC0-Tmax  (µg.min/mL) 170.74 246.30 (-397.23, 738.70)  
† Indicates statistically significant at α = 0.05 
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Computed Tomography Scanning Analysis for Post-Interim Subject Population 
Data sets analyzed. Twelve subjects were initially enrolled into the study. As discussed 
in the Computed Tomography (CT) Scanning Parameter Measurements section, following the 
interim analysis, the protocol was modified to allow for a change in computed tomography 
scanning time points from 0.5, 5, 10, 15 and 20 minutes for the first two interim analysis subjects 
to 0.5 10, and 20 minutes for the subsequent 10 subjects. The CT scanning population was 
defined as all subjects who had an evaluable computed tomography scan following protocol 
revision. Therefore, 10 subjects were included in the remaining CT scanning data set. 
Computed tomography parameters. Subject Computed Tomography scans were 
processed utilizing iSite Picture Archiving and Communications System (iSite PACS, Philips 
Koninklijke Electronics, ver. 3.6.52) software. Images were enhanced using the Laplacian 
Method to increase the visibility of edges in each image slice. Determination of location of 
iohexol injection was made by direct CT scan observation. Measurements of maximum depth of 
dispersion (MDd) were completed utilizing a ruler tool in millimeter units by selecting the point 
on the skin surface (epidermal region) and measuring to the deepest detectable level of iohexol 
contrast media for a given axial image slice. Measurements of maximum width of dispersion 
(MWd) were completed utilizing the ruler tool by selecting the axial image slice with the widest 
tissue dispersion of iohexol. Finally, measurements of the depth at maximum width of dispersion 
(DMWd) were completed utilizing the ruler tool to measure the depth at the axial image slice 
with the widest tissue dispersion of iohexol at each time point by selecting the point on the skin 
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surface (epidermal region) and measuring to the deepest detectable level of iohexol contrast 
media. 
 Means and standard deviations for the parameters of total depth of dispersion, width of 
RCM dispersion, and depth of dispersion to maximum width were obtained using the descriptive 
statistics tool in JMP Software (version 8.0; SAS Institute, Inc., Cary, NC, USA). Further 
analysis using mixed-effect modeling was also conducted using the JMP Software. 
 In order to assess the rate and extent of disappearance or loss of Iohexol from the 
extravascular compartment over time, a radiodensity measurement was calculated utilizing the 
radiodensity tool iSite PACs software. Each image was assessed for radiodensity at the slice 
corresponding to the depth at maximum width of dispersion (DMWd) at each time point. 
Radiodensity was plotted over time and the rate of iohexol elimination from the extravascular 
tissue (LossTiss) was estimated using the slope from the fit line calculated from the linear 
regression model for each individual subject utilizing the JMP software. 
Computed tomography qualitative analysis.  Tissue discrimination was distinct for 
skin, subcutaneous tissue, quadriceps muscle groups, femur, and the bone marrow cavity. Upon 
administration, iohexol could be viewed in multiple image planes (Figure 40). There was a 
notable difference in the dispersion pattern between male and female subjects, likely due to the 
underlying differences in subcutaneous tissue depth. Representative CT scan images from a male 
versus female subject using the auto-injector delivery system over time may be found in Figures 
41 and 42. 
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Figure 40: Iohexol Dispersion in Axial (Left) and Oblique (Right) Viewing Planes 
 
From left to right: Iohexol dispersion patterns at 30 seconds, 10 minutes, and 20 minutes 
 
 Figure 41: Representative Male Subject Auto-Injector Dispersion Pattern over Time 
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From left to right: Iohexol dispersion patterns at 30 seconds, 10 minutes, and 20 minutes 
 
Figure 42: Representative Female Subject Auto-injector Dispersion Pattern over Time 
 
Additionally, 40% of the subjects had iohexol tissue dispersion that includes interstices 
penetrating the muscle (Figure 43) versus solely remaining in the subcutaneous tissue as 
intended (Figure 44). 
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Figure 43: Iohexol Dispersed in the Subcutaneous and Intramuscular Tissue 
 
Figure 44: Iohexol Dispersed in the Subcutaneous Tissue 
 
 The images could be reconstructed in three dimensions using the imaging software which 
allowed for greater discrimination of the dispersion differences between the delivery systems 
over time.  As seen in Figures 45 and 46, the auto-injector appeared to produce a more widely 
distributed dispersion pattern as compared with the pre-filled syringe alone.  
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Figure 45: Representative Subject A - Dispersion Pattern by Auto-injector (Left) versus 
PFS at 10 minutes (Right) 
 
 
Figure 46: Representative Subject B - Dispersion Pattern by Auto-injector (Left) versus 
PFS at 10 minutes (Right) 
 
Furthermore, the difference in dispersion patterns could be discriminated over time in the three 
dimensions. The auto-injector appeared to have visibly, a greater width of dispersion over time 
as compared to the pre-filled syringe delivery system. A representative subject scan 
demonstrating this is shown in Figures 47 and 48. 
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From left to right: Iohexol dispersion patterns at 30 seconds, 10 minutes, and 20 minutes 
Figure 47: Representative Iohexol Dispersion by Auto-injector Delivery System over Time 
 
 
From left to right: Iohexol dispersion patterns at 30 seconds, 10 minutes, and 20 minutes 
Figure 48: Representative Iohexol Dispersion by PFS Delivery System over Time 
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Computed tomography quantitative analysis and results. Observed iohexol dispersion 
and radiodensity parameters are summarized descriptively in Tables 19 and 20, respectively. 
Mean iohexol dispersion over time was similar for all parameters between the two treatment 
groups. Additionally, the iohexol dispersion measurements were similar at each scanning time 
point whether by auto-injector or PFS with the exception of the Maximum Width of Dispersion 
(MWd) parameters. The MWd increased over time for both treatments (Table 19). 
 Baseline skin to muscle thickness were similar whether administered by pre-filled syringe 
or auto-injector (mean values of approximately 7.97 mm and 8.81 mm for the PFS and auto-
injector groups, respectively, and median of approximately 7.2 mm for both groups). The 
between-subject variability for this parameter was high (CV% ranged from approximately 54 to 
62%) (Table 20). There was no correlation found between mean thigh circumference 
measurements and the mean skin to muscle thickness measurements regardless of delivery 
system. There was also no correlation found between mean skin to muscle thickness and mean 
body mass index measurements.  
 The loss rate of iohexol from the extravascular tissue compartment (Losstiss) was 
substantially greater (more than 2X) with the auto-injector delivery system as compared to the 
PFS (auto-injector mean = 0.585, SD = 0.271; pfs mean = 0.214, SD = 0.252). This suggests a 
more rapid elimination of iohexol from the tissue from the auto-injector as compared to the PFS 
which could help explain the early exposure difference in the systemic circulation previously 
described. The radiodensity of iohexol was similar between the two treatments at the initial 30 
second scan (PFS mean = 2744.32, SD = 346.39; auto-injector mean = 2566.18, SD = 573.19); 
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however, by the 20 minute (600s) scanning time point, there was a large difference between the 
groups (PFS mean = 2519.44, SD = 615.44; auto-injector mean = 1882.69, SD = 617.87).  
Radiodensity decreased for both treatment groups over time suggesting elimination of the 
iohexol from the extravascular tissue compartment into the systemic or possibly lymphatic 
circulation. In addition, the rate of iohexol loss from the extravascular tissue (LossTiss) was much 
greater for the auto-injector as compared to the PFS (auto-injector mean (HU/min) = 0.585, SD = 
0.271; pfs mean (HU/min) = 0.214, SD = 0.252) (Table 20). 
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Table 19: Summary of CT Scanning Dispersion Parameters by Treatment Group 
Treatment 
Group Statistic 
MDd MWd DMWd 
30s 
(mm) 
600s 
(mm) 
1200s 
(mm) 
(30s) 
(mm) 
600s 
(mm) 
1200s 
(mm) 
30s 
(mm) 
600s 
(mm) 
1200s 
(mm) 
Pre-filled  n 10 10 10 10 10 10 10 10 10 
Syringe Mean 10.29 9.60 9.59 28.78 32.44 34.48 9.30 8.81 9.01 
 SD 4.21 3.79 3.61 6.24 5.94 5.63 3.80 3.11 3.31 
 Median 10.35 9.90 10.45 26.55 31.00 33.20 10.15 9.70 9.40 
 Min 4.90 4.40 4.20 21.40 25.60 27.80 4.50 4.60 4.20 
 Max 17.30 14.40 14.30 42.00 43.90 44.30 16.90 13.20 13.40 
 CV (%) 40.88 39.51 37.68 21.69 18.32 16.33 40.90 35.26 36.72 
           
Auto-injector n 10 10 10 10 10 10 10 10 10 
 Mean 10.84 10.50 11.60 29.22 32.68 37.01 9.44 9.28 9.63 
 SD 3.83 4.53 4.74 8.39 7.94 7.58 3.81 3.81 3.30 
 Median 9.90 9.65 10.70 27.85 31.60 34.40 9.25 8.75 9.70 
 Min 7.20 5.50 6.70 19.80 22.60 27.10 5.00 5.30 5.30 
 Max 18.20 19.30 21.20 50.30 50.80 52.90 16.00 17.50 16.60 
 CV (%) 35.32 43.14 40.90 28.70 24.28 20.48 40.36 41.05 34.29 
MDd =  Maximum Depth of Dispersion, MWd = Maximum Width of Dispersion, DMWd = Depth at Maximum Width of Dispersion
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Table 20: Summary of CT Scanning Radiodensity Parameters by Treatment Group 
Treatment 
Group Statistic 
Baseline 
Skin 
to Muscle 
Thickness 
(mm) 
 Radiodensity 
LossTiss 
(HU/min) 
30s 
(HU) 
600s 
(HU) 
1200s 
(HU) 
Pre-filled  n 10 10 10 10 10 
Syringe Mean 7.97 0.214 2744.32 2656.51 2519.44 
 SD 4.33 0.252 346.39 566.63 615.44 
 Median 7.15 0.113 2883.58 2868.32 2818.59 
 Min 2.60 0.015 2070.12 1285.62 1081.05 
 Max 16.10 0.841 3067.95 3047.39 3050.05 
 CV (%) 54.35 117.52 12.62 21.33 24.43 
       
Auto-injector n 10 10 10 10 10 
 Mean 8.81 0.585 2566.18 2293.68 1882.69 
 SD 5.49 0.271 573.19 635.57 617.87 
 Median 7.20 0.588 2853.63 2406.37 1929.57 
 Min 3.20 0.048 1651.05 1120.49 1038.96 
 Max 18.90 1.06 3051.63 3028.98 2990.25 
 CV (%) 62.26 46.27 22.34 27.71 32.82 
LossTiss = Iohexol loss rate from extravascular tissue 
 
Mixed model assessment of computed tomography parameters. Mixed-effects models 
were used to test for differences in the mean changes over time (30s, 600s, 1200s) between the 
delivery systems as well as differences between delivery systems at each individual time point 
with respect to the maximum depth at dispersion (MDd), maximum width of dispersion (MWd), 
depth at maximum width of dispersion (DMWd), and radiodensity after controlling for period 
and sequence effects as well as age, sex,, thigh circumference, and baseline skin to muscle 
thickness. The models included a random subject effect to account for within subject variations. 
Furthermore, the models included fixed effects for treatment, time, treatment by time, period, 
and sequence as well as the aforementioned additional covariates. Each of these covariates were 
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included in the model in order to determine what effects each, or any may have on the response 
parameters (MDd, MWd, DMWd, and radiodensity) by treatment group. Using these models, the 
mean response was estimated at each time point by treatment group and the mean changes over 
time were compared statistically between the groups using the treatment by time interaction 
effect at a significance level of α = 0.05 (Tables 21 and 22). 
 
Table 21: (Adjusted) Mean Dispersion Response Measures by Treatment Group 
  Auto-injector Pre-filled Syringe 
Response Time (s) Mean SE 95% CI Mean SE 95% CI 
MDd 30 10.69 1.00 (8.17, 13.20) 11.35 1.01 (8.72, 13.78) 
(mm) 600 10.35 1.00 (7.83, 12.86) 10.56 1.01 (8.03, 13.09) 
 1200 11.45 1.00 (8.93, 13.96) 10.55 1.01 (8.02, 13.08) 
        
MWd 30 28.96 2.35 (23.98, 33.95) 28.11 2.38 (23.03, 33.18) 
(mm) 600 32.42 2.35 (27.44, 37.41) 31.77 2.38 (26.69, 36.84) 
 1200 36.75 2.35 (31.77, 41.74) 33.81 2.38 (28.73, 39.88) 
        
DMWd 30 9.20 0.69 (7.65, 10.76) 9.85 0.70 (8.27, 11.42) 
(mm) 600 9.04 0.69 (7.49, 10.60) 9.36 0.70 (7.78, 10.93) 
 1200 9.39 0.69 (7.84, 10.95) 9.56 0.70 (7.98, 11.13) 
  
CT maximum depth of dispersion (MDd).  There was not a significant treatment by time 
interaction effect on the maximum dispersion depth (p = 0.3793); that is, the changes in MDd 
over time did not differ significantly between the two treatment groups.  Additionally, there were 
no significant treatment or time effects (that is, the PFS and auto-injector groups were not 
different, irrespective of time, and there were no changes over time irrespective of the delivery 
system utilized).  The adjusted mean MDd is summarized and plotted over time by each 
treatment group in Table 21 and Figure 49, respectively. There was a significant effect of skin to 
muscle thickness on MDd (p < 0.0001). For every one mm increase in subject skin to muscle 
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thickness the maximum depth of dispersion increased by 1.32 mm (SE = 0.23, 95% CI = 0.84, 
1.80). Therefore, the greater the distance between skin and muscle (or the larger the 
subcutaneous tissue layer), the greater the depth of dispersion regardless of treatment group.  No 
other covariates were found to have an effect on MDd. 
 
Figure 49: Adjusted Changes in MDd (mm) over Time (seconds) by Treatment Group 
 
CT maximum width of dispersion (MWd).  There was not a significant treatment by time 
interaction effect on the maximum width of dispersion (MWd) (p = 0.8028); that is, the changes 
in MWd over time did not differ significantly between the two treatment groups. There was not a 
significant treatment effect on MWd (that is, iohexol delivery by PFS or auto-injector were no 
different, irrespective of time); however, there was a significant time effect on MWd (that is, 
there were increases in MWd over time, irrespective of delivery system) (p = 0.0042). The 
adjusted mean MWd is summarized and plotted over time by each treatment group in Table 21 
and Figure 50, respectively. There were no significant effects of any of the other covariates on 
MWd. 
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Figure 50: Adjusted Changes in MWd (mm) over Time (seconds) by Treatment Group 
 
CT depth at maximum width of dispersion (DMWd). There was not a significant 
treatment by time interaction effect on the depth at maximum width of dispersion (DMWd) (p = 
0.8731); that is, the changes in DMWd over time did not differ significantly between the two 
treatment groups. Mean DMWd is summarized and plotted over time by each treatment group in 
Table 21 and Figure 51, respectively. There were no significant treatment or time effects (that is, 
the delivery system groups were not different, irrespective of time, and there were not changes 
over time, irrespective of delivery system). There was a significant effect of skin to muscle 
thickness on DMWd (p < 0.0001). For every one mm increase in subject skin to muscle 
thickness the depth at maximum width of dispersion increased by 0.93 mm (SE = 0.18, 95% CI = 
0.55, 1.31). Therefore, the greater the distance between skin and muscle (or the larger the 
subcutaneous tissue layer), the greater the depth at maximum width of dispersion irrespective of 
treatment group. 
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Figure 51: Adjusted Changes in DMWd (mm) over Time (seconds) by Treatment Group 
 
Radiodensity.  Mean iohexol radiodensity is summarized and plotted over time by each 
delivery system treatment group in Table 22 and Figure 52, respectively. There was not a 
significant treatment by time interaction effect (p = 0.2734); that is, the changes in radiodensity 
over time did not differ significantly between the two treatment groups. There was a significant 
treatment/delivery system effect on the elimination of iohexol as measured by radiodensity (p = 
0.0002); that is, there were significant differences between the delivery system treatment groups, 
regardless of time. Specifically, the Auto-injector treatment group had a significantly lower 
iohexol radiodensity measurement as compared to the PFS treatment group at both the 10 minute 
(600 s) and 20 minute (1200 s) scanning time points (Radiodensity difference at 600s = 469.55, 
95% CI = 55.72, 883.38; Radiodensity difference at 1200s = 743.46, 95% CI = 329.63, 1157.29) 
(Table 23).  There was a significant time effect (p = 0.0095). That is, there were decreases in 
radiofrequency over time, irrespective of treatment group.  No other covariates had an effect on 
radiodensity. 
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Table 22: (Adjusted) Mean Radiodensity Response Measures by Treatment Group 
Treatment Group Time 
(s) 
Mean SE 95% CI 
Auto-injector 30 2565.33 190.78 (2110.30, 3020.37) 
 600 2292.83 190.78 (1837.80, 2747.86) 
 1200 1881.85 190.78 (1426.81, 2336.88) 
     
Pre-filled Syringe 30 2850.20 194.58 (2386.59, 3313.80) 
 600 2762.38 194.58 (2298.77, 3225.98) 
 1200 2625.31 194.58 (2161.70, 3088.92) 
 
 
Figure 52: Adjusted Changes in Radiodensity (HU) over Time (seconds) by Treatment 
Group 
 
Table 23: (Adjusted) Mean Differences (PFS – Auto-injector) in Radiodensity Measures 
 
 Radiodensity (HU)   
Time Difference SE 95% CI p-value  
30 s 284.86 204.87 (-128.97, 698.69) 0.1719  
600 s 469.55 204.87 (55.72, 883.38) 0.0272 † 
1200 s 743.46 204.87 (329.63, 1157.29) 0.0008 † 
† Indicates statistically significant at α = 0.05 
Mixed model assessment of Iohexol loss rate from the extravascular tissue. A Mixed-
effect model was also used to test for differences in the iohexol loss rate from the extravascular 
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tissue compartment (LossTiss) between the Auto-Injector and PFS delivery systems after 
controlling for the covariates of period, sequence effects, age, sex, and thigh circumference. The 
models included a random subject effect to account for within subject variations and fixed effects 
for treatment, period, and sequence as well as the aforementioned covariates. Each of these 
covariates were included in the model in order to determine what effects each, or any may have 
on the loss rate by delivery system treatment group. Using this model, the mean responses were 
estimated for each group and the differences in the means were compared statistically between 
the groups using a significance level of α = 0.05. 
 The mixed-effects model accounted for 71.3% variations in the iohexol extravascular 
tissue loss rate (LossTiss)(r2 adjusted = 50.4%). There was a significant treatment effect on the 
loss rate of iohexol from the extravascular tissue compartment. Mean LossTiss for the Auto-
injector treatment group was significantly higher than the PFS treatment group (auto-injector 
mean LossTiss = 0.562, 95% CI = 0.315, 0.809; PFS mean LossTiss = 0.191, 95% CI = -0.056, 
0.438). The mean difference between treatments was 0.37 HU/min (95% CI = 0.14, 0.60; p = 
0.0058) confirming the elimination of iohexol from the subcutaneous or intramuscular tissue 
occurred significantly faster with the auto-injector as compared to the PFS. None of the other 
covariate, including the physiologic/non device-related covariates of age, sex and thigh 
circumference has an effect on the iohexol extravascular tissue loss rate. 
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Comparison of Tissue Bioavailability and Dispersion Characteristics with the Systemic 
Exposure of Iohexol 
 As discussed in the Analysis of Early Exposure section, there was greater early exposure 
of iohexol into plasma (i.e., systemic circulation) with the auto-injector as compared with the 
pre-filled syringe (See Mixed Effect Model AUC0-40 and AUC0-60 analysis within this earlier 
section). Because the change in radiodensity over time at the injection site can be thought of as a 
measure for the loss rate of iohexol from the extravascular compartment into the systemic 
circulation (LossTiss), one would have anticipated the auto-injector to have a significantly lower 
radiodensity level as compared to the PFS at time points prior to 60 minutes, as was indeed the 
case for the 600s (10 min) and 1200s (20 min) time points as shown in Table 23. 
  As a result of these findings, a local in-vivo(extravascular disappearance), systemic in-
vivo(intravascular appearance) correlation (IV(extra)IV(intra)C) was conducted to assess the rate of iohexol 
loss from the extravascular tissue compartment (LossTiss) relative to the extent of early plasma 
exposure (AUC0-30, AUC0-40 and AUC0-60 and AUC0-Tmax) between the two delivery systems. 
There was a significant positive correlation between the loss rate of iohexol from the 
extravascular tissue compartment (using radiodensity as a measure for the loss of iohexol from 
this compartment) and the extent of early plasma exposures up to 60 minutes (AUC0-30, AUC0-40 
and AUC0-60) with the auto-injector treatment group.  Therefore, higher rates of iohexol 
extravascular elimination, presumably reflecting uptake into the intravascular compartment, were 
correlated with a higher extent of early iohexol plasma exposures when administered by the auto-
injector delivery system. This significant correlation was not present when comparing the loss 
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rate from the extravascular tissue with AUC0-Tmax possibly due to iohexol plasma levels 
equilibrating by the time Cmax was reached. Additionally, there was no correlation found between 
the loss rate of iohexol from the extravascular tissue compartment and the extent of early iohexol 
plasma exposures at any of these early AUC metrics for the PFS treatment group.  This confirms 
that the delivery system had an effect on the disappearance of iohexol from the injection site 
when compared to the appearance of iohexol in the vasculature as measured by the extent of 
early plasma exposure. A summary of the IV(extra)IV(intra)C results and associated levels of 
significance may be found in Table 24. 
 
Table 24: Summary of IV(extra)IV(intra)C Parameters 
 Auto-Injector Pre-filled Syringe 
LossTiss 
by 
AUC0-30 
LossTiss 
by 
AUC0-40 
LossTiss 
by 
AUC0-60 
LossTiss  
by  
AUC0-Tmax 
LossTiss 
by 
AUC0-30 
LossTiss 
by 
AUC0-40 
LossTiss 
by 
AUC0-60 
LossTiss by  
AUC0-Tmax 
r2 (%) 74.6 79.0 83.7 5.8 -3.9 1.0 14.6 -24.6 
Slope  276.92 454.68 961.11 798.41 -48.36 2.50 82.74 -598.19 
p-
value 
0.021 0.011 0.005 0.078 0.441 0.982 0.707 0.494 
Units for AUC = ug.min/mL, Units for LossTiss/Rate of Disappearance = HU/min 
 
Representative linear regression plots for the Auto-injector as compared to the Pre-filled syringe 
may be found in Figures 53 and 54 below. 
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AUC (ug.min/mL), LossTiss/Rate of Disappearance (HU/min) 
Figure 53: Bivariate Fit of AUC0-30 by LossTiss (Left: Auto-injector, Right: PFS) 
  
 
AUC (ug.min/mL), LossTiss/Rate of Disappearance (HU/min) 
Figure 54: Bivariate Fit of AUC0-40 by LossTiss (Left: Auto-injector, Right: PFS) 
 
 Because the extent of early exposure of iohexol was found to be different between the 
auto-injector and PFS delivery systems at the early exposure time points, especially AUC0-40 and 
AUC0-60, and because the radiodensity measurements were also found to be different between the 
delivery systems, these differences were evaluated further for a relationship.  The radiodensity 
parameter was chosen at 20 minutes to compare with each partial AUC measurement because the 
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AUC time point range was beyond this last, 20 minute, CT scanning time point. Therefore, the 
difference in radiodensity at 20 minutes was compared with the differences between the early 
exposure parameters, AUC0-30, AUC0-40 and AUC0-60 and AUC0-Tmax.  
 There was a significant positive correlation between the difference in radiodensity at 20 
min and the difference in AUC0-30 values between the delivery systems; that is larger differences 
in radiodensity between the auto-injector and PFS at 20 minutes were associated with larger 
differences in AUC0-30 between the delivery systems (r2 = 86.5%, p = 0.0261).  This was also the 
case with AUC0-60 and AUC0-Tmax (AUC0-60  r2 = 73.2%, p = 0.0389; AUC0-Tmax r2 = 73.2%, p = 
0.0389) and was borderline significant for AUC0-40  (r2 = 75.3%, p = 0.0507).  
 In summary, the differences in radiodensity at the 20 minute time point between the PFS 
and auto-injector had a positive correlation with most all of the early exposure measurement 
differences between the delivery systems. Iohexol delivery by the auto-injector had a significant, 
positive IV(extra)IV(intra)C which was not present when iohexol was administered by the pre-filled 
syringe. This difference may be due to the extravascular loss rate itself which was significantly 
higher for the auto-injector as compared to the PFS. Because the only difference between the 
treatment groups in this study was the nature of the delivery system, providing either a manual 
injection (PFS) or automated injection (auto-injector) of the iohexol, these findings suggest 
device-related factors such as the kinematics of injection (including associated fluid dynamics 
and injection force) may have had an effect on the resultant systemic exposure behavior of the 
drug. 
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Safety Evaluation 
 The safety population was defined as all subjects who received at least one dose of 
iohexol. Ten subjects were included in the safety population. A summary of TAEs is presented in 
Table 25.  There were no deaths or TEAEs. Iohexol delivery by either the pre-filled syringe or 
auto-injector was well tolerated by all subjects with only mild, injection site-related adverse 
events reported. Subjects experienced more mild adverse events with the auto-injector (8 events 
in 6 subjects) as compared to the pre-filled syringe (3 events in 3 subjects). A summary of events 
by treatment group and event classification/description may be found in Table 26. All events 
resolved spontaneously prior to study discharge. 
 
Table 25: Summary of TEAEs by Delivery System 
 Treatment Group 
Pre-filled Syringe 
N = 10 
n (%) e 
Auto-injector 
N = 10 
n (%) e 
All TEAEs 3 (30.0) 3 6 (60.0) 8 
'Related' TEAEs 3 (30.0) 3 6 (60.0) 8 
Mild TEAEs 3 (30.0) 3 6 (60.0) 8 
Moderate TEAEs 0 0 
Severe TEAEs 0 0 
Deaths 0 0 
Serious TEAEs 0 0 
TEAEs leading to Withdrawal 0 0 
N = number of subjects; n = number of subjects with treatment emergent adverse event; e = number of separate 
events; % = percentage of subjects experiencing event (n/N X 100); TEAE = treatment emergent adverse event; 
“related” = definite, probable, possible 
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Table 26: Number of Subjects Experiencing Treatment Emergent Adverse Events and 
Percentage of Subjects per Exposure (i.e. injection) by Treatment Group and Event 
Description 
 
Event Description 
 
Treatment Group 
Pre-filled Syringe 
n (%) 
Auto-injector 
n (%) 
General Injection Site Reactions 3 (30.0) 8 (80.0) 
Injection Site Discomfort 0 (0.0) 1 (10.0) 
Injection Site Swelling 0 (0.0) 1 (10.0) 
Injection Site Bleeding 0 (0.0) 2 (20.0) 
Injection Site Induration 1 (10.0) 1 (10.0) 
Injection Site Pain 2 (20.0) 1 (10.0) 
Injection Site Paraesthesia 0 (0.0) 1 (10.0) 
Injection Site Burning 0 (0.0) 1 (10.0) 
n = number of subjects with treatment emergent adverse event; % = percentage of subjects experiencing event (n/N 
X 100) 
 
Conclusion 
 The primary objective of this randomized, single-dose, crossover study was to assess the 
ability of a radioimaging approach combined with an analysis of systemic exposure 
measurements to serve as a novel approach for investigating sources of variability that may be 
introduced by injectable delivery systems. This was accomplished by comparing qualitative and 
quantitative in-vivo injection dispersion parameters from computed tomography (CT) scanning 
with systemic exposure metrics following administration of a non-ionic radiocontrast media, 
iohexol (Omnipaque®).  The discriminatory capacity of the approach was assessed by comparing 
iohexol administered subcutaneously by an auto-injector delivery system versus a pre-filled 
syringe delivery system. 
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 Twelve subjects were randomized to one of two possible treatment sequences (Auto-
injector first, pre-filled syringe second or pre-filled syringe first, auto-injector second) to 
determine the order in which they would receive the iohexol in Periods 1 or 2. The first two 
subjects were included in an interim analysis set to evaluate the usability of the iohexol assay as 
well as the Computed Tomography images. The final analysis was conducted with the remaining 
ten subjects, after adjusting the iohexol dose, plasma sampling schedule and CT scanning 
schedule. None of the subjects had pre-existing conditions that prohibited them from 
participation and all met the inclusion/exclusion criteria.  
 Serial blood sampling was performed relative to dosing in each study period, and the 
systemic exposure parameters were calculated from each subject’s plasma iohexol concentration-
time profiles. Computed tomography scanning was also performed relative to dosing and the CT 
qualitative and quantitative parameters were assessed through non-compartmental analysis from 
each subject’s radioimaging series. Iohexol peak (Cmax) and total (AUC0-t, AUC0-∞) exposure 
were similar whether administered by pre-filled syringe or auto-injector. However, partial area 
data (AUC0-40, AUC0-60) relative to the auto-injector and pre-filled syringe were significantly 
different, suggesting early exposure differences between the two delivery systems. Additionally, 
although the dispersion measurements obtained were also similar whether administered by pre-
filled syringe or auto-injector, changes in radiodensity over time, as a measure of the loss of 
iohexol from the extravascular tissue compartment into the systemic circulation, were 
significantly different between the two delivery systems.  
   
136 
 Finally, a local in-vivo(extravascular disappearance), systemic in-vivo(intravascular appearance) correlation 
(IV(extra)IV(intra)C) was conducted to assess the rate of iohexol loss from the extravascular tissue 
compartment (LossTiss) relative to the extent of early plasma exposure (AUC0-30, AUC0-40 and 
AUC0-60 and AUC0-Tmax) between the two delivery systems. There was a significant positive 
correlation between the loss rate of iohexol from the extravascular compartment and the extent of 
early plasma exposure with the auto-injector treatment group. This was not present with the pre-
filled syringe treatment group. Therefore, higher rates of iohexol extravascular elimination, 
presumably reflecting uptake into the intravascular compartment, were correlated with a higher 
extent of early iohexol plasma exposures when administered by the auto-injector delivery 
system.  
 These data show that changes in the manner that an injectable is administered may have 
an impact on the systemic exposure of a drug as a result of changes in the behavior of the drug in 
the tissue. Iohexol administration by either delivery system was well tolerated with minimal 
adverse events being solely related to injection site reactions that resolved spontaneously without 
intervention. This study provided early data that CT scanning with an analysis of systemic 
exposure metrics using iohexol as an injectable standard may be used to assess sources of 
variability from different injectable delivery systems. 
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CHAPTER 5. DISCUSSION AND FUTURE RESEARCH 
 
Discussion 
 This dissertation seeks to provide an initial, novel approach for understanding what 
occurs at the moment of injectable drug delivery deposition into the tissue along with an 
assessment of systemic exposure, as well as the relationship between these two events. The 
radioimaging approach utilized in this study, computed tomography scanning, coupled with a 
non-ionic contrast media, provided a unique method for the evaluation of tissue dispersion 
characteristics. This included an assessment of the injectate location and the ability to quantify 
depth and width of penetration. Furthermore, this approach allowed for the detection of changes 
in these parameters over time. This is important when trying to correlate tissue compartment 
elimination of an injectable with the absorption of the injectate into the systemic circulation.  
 Pharmaceutical scientists have focused decades of research and development on the 
manipulation of an injectable formulation itself to impact the systemic exposure and resultant 
pharmacodynamic behavior of a drug; however, there has been very little focus on modifying  
delivery mechanics in order to adjust the desired behavior of a drug. Traditionally, devices for 
injectable delivery have been viewed as “secondary packaging” components for an injectable 
drug/device combination product. The primary goal was to ensure an injectable reached its target 
site. For example, needle-free injectors must demonstrate that the fluid jet force through a micro-
orifice is sufficient to pierce the skin and deposit an injectate beneath. However, little has been 
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done to understand how changes in the kinematics of injection, as driven by changes in device-
related factors, affect injectable formulation characteristics and the resultant drug behavior. This 
is in stark contrast to inhaled drug product development, where scientists have understood the 
need to focus not only on formulation factors, but also on variables related to device engineering 
that can affect drug deposition or dispersion and the resultant systemic compartment behavior in-
vivo for decades. This dissertation research provides a paradigm that may be leveraged to begin 
evaluation of these device-related dynamics in injectable product development. 
 There were several notable findings of this research. First and foremost, if the study 
analysis only included an assessment of the conventional exposure parameters, Cmax, Tmax, 
AUC0-t, and AUC0-∞, the results would have indicated a similar profile between the auto-injector 
and pre-filled syringe. By incorporating the CT measurement of radiodensity as a measure of 
iohexol loss from the extravascular tissue into the systemic circulation, it was clear that there was 
a difference in drug behavior present between the delivery systems. This was confirmed by 
evaluating early exposure parameters closer to the CT scanning time points where these 
radiodensity changes were apparent (CT measurements only occurred up to 20 minutes post 
injection). This evaluation demonstrated a difference in early systemic exposure. The differences 
were likely device-related because the covariates of age, sex and thigh circumference analyzed 
had no effect on the rate of loss of iohexol from the extravascular tissue into the system 
circulation or on the early iohexol plasma exposure parameters (AUCpartial). This is an important 
finding as differences in early systemic exposure may be clinically relevant for certain classes of 
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drugs. Examples include acute-care injectables for life-threatening emergencies such as 
epinephrine for anaphylaxis, glucagon for severe hypoglycemia, and certain benzodiazepines for 
acute repetitive seizures where a greater extent of early exposure may result in therapeutically 
beneficial pharmacodynamic changes independent of the time to maximum plasma concentration 
(Tmax). Alternatively, there are some pharmaceuticals whereby a greater early extent of exposure 
may be harmful to a patient. In this study, iohexol was shown to have a higher early systemic 
exposure with an auto-injector as compared to a PFS method of administration. If the iohexol 
results were translatable to other drugs with similar physicochemical properties indicated for the 
treatment of a life-threatening emergency, the earlier exposure achieved by the auto-injector may 
have been clinically meaningful.  
 It is important to note the radiographic and systemic exposure differences seen with 
iohexol in this study between the auto-injector and the pre-filled syringe are not necessarily 
translatable to other drugs. For example, another contrast media agent with different 
physicochemical properties may behave differently if administered by the same delivery systems 
evaluated in this study. Alternatively, iohexol may behave differently if new variables were 
assessed such as having different individuals administer the injections versus the same 
individual, or even having iohexol being injected using other delivery systems. This is one 
advantage of the approach as it allows for the assessment of tissue dispersion and systemic 
exposure metrics across any number of delivery techniques or systems.   
   
140 
Another notable finding was the difference in dispersion patterns obtained from the 
interim subject population as compared to the post-interim subject population. Specifically, the 
dose of 150 mg delivered in 0.5 mL by the auto-injector during the interim period as compared to 
the 300 mg dose delivered in 1.0 mL by the auto-injector in the post-interim period resulted in a 
noticeably deeper iohexol penetration (Figure 55).  
 
Figure 55: Dispersion by Auto-injector Delivery System at 10 minutes following a 
150mg/0.5mL Iohexol Dose (Left) as compared to a 300 mg/1.0mL Iohexol Dose (Right) 
 
Upon further evaluation of the mechanics surrounding the Autoject 2® delivery system, there was 
a substantial difference discovered in the distance between the loaded spring and the piston, 
when setting a volume of 0.5 mL for delivery as compared to 1.0 mL. The spring load in the 
auto-injector has a certain amount of potential energy that is available to act on the syringe 
resulting in the delivery of the injectate. This potential energy is the same regardless of the 
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position of the piston; however, due to the gap created from setting the piston at a lower level in 
the syringe to allow for a 0.5 mL volume as compared to a 1.0 mL volume, there may be more 
kinetic energy applied during actuation to the 0.5 mL dose. This would result in a greater force 
against the piston and subsequent higher fluid jet force exiting the needle orifice when against 
the injection site. This may explain the substantial difference in the deposition of the iohexol in 
the muscle with the first two subjects (interim population) as compared to the remaining ten 
subjects (post-interim population) where the vast majority of injections were located 
subcutaneously. These mechanical and kinematic, device-related factors, warrant further 
investigation as a result of this finding as there are substantial clinical implications if there is a 
difference in dispersion characteristics that may be solely attributable to the variable of volume 
administered. 
 The local in-vivo(appearance), systemic in-vivo(disappearance) correlation was only applicable to 
the auto-injector as compared to the pre-filled syringe. Because the rate of iohexol tissue loss 
was also significantly greater for the auto-injector as compared to the pre-filled syringe, it is 
presumed that this is the determining factor for achieving the correlation. As such, one would 
expect that the incorporation of another pharmaceutical formulation which had a similar LossTiss 
profile using the same auto-injector, would also result in a positive correlation. 
 This is the first known study describing the systemic exposure of iohexol delivered 
subcutaneously. The pharmacokinetics of iohexol have been previously studied through other 
routes of administration including the intravenous and intrathecal routes. The iohexol product 
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monograph provides a terminal elimination half-life of approximately 12 hours when 
administered intravenously and 4.5 hours following a subarachnoid injection (Omnipaque 
(Iohexol) Prescribing Information. General Electric Company. 2008). This is in contrast to other 
pharmacokinetic studies of iohexol. For example, a study by Olsson and colleagues that injected 
multiple doses of iohexol intravenously resulted in a terminal elimination half-life of between 2 
and 6 hours and peak plasma concentrations of 10 to 50 µg/mL (Olsson et al., 1983). These are 
similar to the values reported in this research study assessing these exposure parameters with 
mean plasma T1/2 occurring at approximately 2 hours and peak plasma concentrations of 2 -30 
µg/mL (mean of approximately 17 ug/mL).  
 For years, pharmaceutical research scientists have been developing parenteral dosage 
forms and have been testing these products in clinical trials with, for the most part, traditional 
pharmacokinetic analyses. A large reason for this has been the regulatory requirements for the 
conduct and execution of clinical studies to support marketing applications. As is the case with 
most pharmaceutical development programs, regardless of the dosage form, the majority of these 
injectable product clinical trials are conducted in controlled settings, with well-trained 
administrators providing injections to subjects that ensure compliance with the desired 
administration regimen and delivery techniques. However, with the relatively recent explosion of 
injectable products being moved out of the healthcare environment administration setting into the 
home environment for administration by laypersons or caregivers, the questions must be asked:  
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• How do we know that the clinical trials completed in the controlled trial setting to 
support marketing applications are characteristic of what occurs in the out-of-
hospital environment?  
• How can we ensure that safety and efficacy results are translatable into a setting 
whereby numerous variables are introduced that weren’t controlled for in the clinical 
trials conducted to support original marketing approval?  
• What is the impact of the additional variables, introduced by device and 
administration-related factors unique to injectable products, on the safety and 
efficacy of a drug product (being that the risk of noncompliance with an 
administration regimen are only amplified by the injectable route versus a 
conventional oral route of administration)?  
These and other similar questions can only be answered by having a complete understanding of 
the mechanics of tissue deposition and dispersion, along with systemic absorption and 
distribution parameters that may be affected by various administration factors introduced by 
injectable drugs and their associated means of delivery.  
  
Future Research Directions 
 This work provides a glimpse into numerous possibilities for investigating sources of 
pharmacokinetic variability that may be introduced by injectable drugs and associated delivery 
systems or mechanisms. As this research was an initial pilot study, further work is required to 
   
144 
validate the approach and to assess its usability on a greater scale. One limitation of this work 
includes the choice of iohexol as the injectable standard. This approach allows a research 
scientist to evaluate the impact of changing certain device and related variables on the behavior 
of drugs identical or similar to the physicochemical properties of iohexol; however, this must be 
proven to be reproducible with drugs other than iohexol in additional studies. One approach 
would be to formulate iohexol to closely match the physicochemical characteristics of another 
compound, followed by conducting a cross-over study with both drugs, assessing the dispersion 
of iohexol and the resultant bioavailability of each, within and between subjects. Another 
limitation of this study was the use of a CT program that was built for clinical assessment and 
diagnosis as compared to being optimized for pharmaceutical research. The image processing 
software requires manual measurements of the dispersion and radiodensity parameters for each 
individual CT slice, resulting in calculations based on the image processing program tools for the 
given slice assessed. Optimizing the software to automatically provide the dispersion and 
radiodensity measurements across the entire series of images for a given subject would reduce 
potential human error, save time, and improve the robustness of the analysis. In addition, due to 
the absence of a dedicated CT scanner for research purposes, scanning times were limited for 
each subject resulting in scanning time points that could not exceed 20 minutes per subject. 
Further research should be conducted with scanning time points further out and more closely 
aligned to the plasma sampling time points. 
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 As there was a difference in the rate of loss of iohexol in this study relative to the 
delivery system chosen for administration, further work needs to be conducted to assess which 
dispersion parameters likely had an effect on this loss rate. Furthermore, because there appeared 
to be a difference in dispersion as a result of changes in device-related factors, such as piston 
placement that determines volume administered, research should be conducted to understand 
which factors (e.g. piston placement, spring force, needle gauge or length) have the greatest 
impact on dispersion and the associated systemic exposure parameters following administration. 
 Similarly, this approach allows scientists to investigate the impact of formulation factors 
(e.g. pH, osmolality, viscosity, molecular weight, partition coefficient, inclusion of an extended 
release vehicle) on dispersion parameters. This study attempted to manipulate one variable, the 
choice of delivery system. It is clear that this approach could be used to investigate other 
administration-related variables such as differences between injection techniques by trained 
nurses, or the differences between healthcare practitioner and layperson administration using an 
identical delivery system. 
 In conclusion, this research resulted in a novel local in-vivo(extravascular disappearance), systemic 
in-vivo(intravascular appearance) correlation approach that could assess a wide variety of dynamics 
associated with injectable drug delivery below the dermis. The work demonstrated the feasibility 
of combining radioimaging approaches with traditional systemic exposure metrics to achieve a 
greater understanding of the in-vivo behavior of injectable drugs and their associated delivery 
systems.  
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Appendix B.1 
Research Subject Information and Consent Form 
 
TITLE: DEVELOPMENT OF A NOVEL MODEL TO ASSESS QUALITATIVE AND 
QUANTITATIVE INJECTABLE DELIVERY DYNAMICS 
 
VCU IRB Protocol # HM13424 
VCU Clinical Research Study # 11EPHD 
 
PRINCIPAL INVESTIGATORS: 
William R. Garnett, Pharm.D. 
School of Pharmacy - Pharmacotherapy & Outcomes Science   
410 N 12th Street   
P.O. Box 980533   
Richmond, VA 23298-0533 
 
William H. Barr, Pharm.D., Ph.D. 
School of Pharmacy - Pharmacotherapy & Outcomes Science   
410 N 12th Street   
P.O. Box 980533 
Richmond, VA 23298-0533
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FOR GENERAL RESEARCH PROBLEMS CONTACT THE STUDENT 
INVESTIGATOR: 
Eric S. Edwards, BS 
School of Pharmacy - Pharmacotherapy & Outcomes Science   
111 Virginia St. Ste. 405 
Richmond, VA 23219 
 
FOR MEDICAL EMERGENCIES CONTACT THE MEDICAL MONITOR: 
John N. Clore, MD 
VCU Medical Center  
Department of Internal Medicine  
Division of Endocrinology  
1200 East Broad Street  
P.O. Box 980155 
Richmond, VA 23298   
This consent form may contain words that you do not understand.  Please ask the study doctor or 
the study staff to explain any words or information that you do not clearly understand.  You may 
take home an unsigned copy of this consent form to think about or discuss with family or friends 
before making your decision. Reading this form and talking to the study doctor or study staff 
may help you decide whether to take part or not.  If you decide to take part in this study, you 
must sign your name at the end of this form.  Nothing can be done for the research study until 
you sign this form. 
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PURPOSE OF THE STUDY 
The purpose of this research study is to make a model that shows where drugs go in your body 
after they are injected under your skin. You are being asked to participate in this study because 
you are a healthy volunteer, meet the study entry requirements, and are interested in being in the 
study. 
Taking part in this study is entirely voluntary. 
 
DESCRIPTION OF THE STUDY  
This study involves receiving injections of a drug typically administered for viewing parts of the 
body using two different injectable delivery systems and receiving a computed tomography scan 
(CT scan) to verify where each of the delivery systems administers the drug. Iohexol is approved 
by the FDA for use in imaging different parts of the body.  The drug is not typically used in the 
way that it will be used in this research and is, therefore, experimental. These drugs will be 
administered into your outer thigh, under the skin using two different delivery systems. One 
delivery system is a standard FDA-approved syringe and needle and the other is an FDA-
approved automatic injector. The automatic injector is indicated for use with the approved 
syringe. 
 
Your participation in this study may last up to 8 weeks. Up to 12 subjects will participate in this 
study.  
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Significant new findings developed during the course of the research that includes adverse 
reactions to the study drug or devices which may relate to your willingness to continue 
participation will be provided to you. 
 
1. OVERVIEW OF PROCEDURES 
If you decide to take part in this study, you will have a Screening Visit to see if you qualify.   
After the Screening Visit, there are 2 study periods, each consisting of 2 days and 1 night where 
you will stay in the clinic.   
 
This is a single-blind study, therefore your study doctor and staff will know exactly whether you 
will be receiving the injection of the study drug by either the syringe and needle or auto-injector 
device. You will be prevented from seeing which delivery system (auto-injector or pre-filled 
syringe) is being used during your injections by placing a screen above your waist that prevents 
viewing of the injection area.   
 
During Study Period 1, you will be randomly assigned (like the flip of a coin) to be given the 
study drug by using either the syringe or the auto-injector during the first period of the study. 
You have an equal chance of being assigned to either of the groups. Using the randomly assigned 
delivery system, the study drug, iohexol, will be given into your outer thigh, followed by a 
computed tomography (CT) scan to verify the location of injection. During Study Period 2, you 
will be given the study drug, iohexol, by using the other delivery system that was not used during 
the first study period. 
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You will not know which study drug delivery device is being used to give you the medicine.  
This is done (blinding) so that a fair evaluation of results may be made. 
 
You will undergo a venous blood draw at least 10 times during each study period.  On the day 
you are given the study drug, you will have a catheter (flexible tube) inserted into a vein to make 
multiple blood collections easier.  The blood will be taken from this tube at different times, 
beginning just before dosing and throughout the course of the study following the CT scanning.  
Blood may have to be taken via needle sticks into your veins. In addition, you will be asked to 
provide a urine sample at least 5 times during each study period.  
 
YOUR ROLE IN THE STUDY 
Taking part in a research study can be an inconvenience to your daily life.  Please consider the 
study time commitments and responsibilities as a research subject when you are deciding to take 
part.  Your responsibilities as a study subject include the following: 
• Tell the truth about your medical history and current conditions. 
• Tell the study doctor if you have been in a research study in the last 30 days or are in 
another research study now. 
• Do not donate blood for at least 30 days before taking study drug, throughout the entire 
study, and for 2 weeks after you receive the study drug. 
• Tell the study doctor about any problems you have during the study. 
• Be willing to fast at certain times during the study and follow meal and liquids 
requirements and restrictions for the study. 
• Do not drink any alcohol for 24 hours before taking the study drug and until after 
collection of the final blood sample of the In-House Study Visit. 
• Do not use tobacco (smoking cigarettes, pipes, cigars, chewing tobacco, nicotine patch, 
or any other nicotine containing products) for at least 24 hours before the Screening Visit 
and throughout the study.  
• Do not take any prescription or non-prescription medicines, vitamins, dietary or herbal 
supplements throughout the study. 
• From the time of your first dose of study medication until at least 2 weeks after 
completing the study, use at least two forms of contraception (e.g., condom plus IUD, 
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condom plus birth control pills, diaphragm with spermicide) if engaging in sexual 
intercourse where you or your partner could become pregnant.  
• Do not take illegal drugs throughout the study.  
• Bring enough money for travel to and from the study site. 
 
Study Period 2 will take place at least 7 days after Visit 1. Therefore, your part in this study is 
expected to last about 4-6 weeks (possible time period from screening visit through the last study 
visit).  There is no final follow-up visit for this study. Up to 12 subjects will take part in this 
study. 
 
WHAT WILL HAPPEN DURING THE STUDY 
Screening Visit      
During the Screening Visit, the following procedures will be done: 
• You will be asked about your medical history and about any medicines you are taking. 
• You will have a physical exam. 
• Your vital signs (heart rate, breathing rate, blood pressure and temperature), height, and 
weight will be measured.  Your blood pressure will be measured in a lying down (supine) 
position. 
• You will have an electrocardiogram (ECG – a tracing of the electrical activity of the 
heart). 
• You will give blood for routine lab tests.  Approximately 1-2 tablespoons of blood will be 
collected. 
• Women will have a urine pregnancy test  
 
If you qualify and wish to continue, Study Period 1 will be scheduled within 7 days after you 
complete this Screening Visit. 
 
In-House Study Visits 
Study Period 1 – Study Day 1 (Admission) 
On this study day, the following procedures will be done: 
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• You will be asked about any changes in your health since the screening visit. 
• You will be asked if you have taken any medicines, including prescription and over-the-
counter medicines, vitamins, and herbal supplements, since the Screening Visit. 
• Your vital signs (heart rate, breathing rate, blood pressure and temperature), height, and 
weight will be measured.  Your blood pressure will be measured in a lying down (supine) 
position. 
• You will be asked if you have used any drugs or alcohol in the last 24 hours. 
• Women will have a pregnancy test. 
 
If you continue to qualify, you will remain at the study site and will wait to receive your dose of 
drug. You will enter the unit at least 3 hours prior to your scheduled dosing time. If you have not 
already done so, you will be asked to fast for 4 hours. 
Study Period 1 – Study Day 1 (Dosing)  
The following procedures will occur after you have fasted: 
• You will be asked how you are feeling. 
• You will have a brief physical exam. 
• You will have a catheter (flexible tube) inserted into a vein to make multiple blood 
collections easier. 
o You will give blood before receiving your injection and 15, 30, 40 minutes and 1, 
1.5, 2, 4, 6, 8 and 10 hrs after dosing (for a total blood collection volume of 
approximately 60 cc or 4 tablespoons), to test for the amount of study drug in 
your blood. 
• You will be asked to provide a urine sample before receiving your injection as well as 0-
2, 2-3, 3-4, 4-6, 6-8 and 8-24 hours after dosing, to test for the amount of study drug in 
your urine. 
• Your vital signs will be measured before dosing.  Your blood pressure will be measured 
in a lying down (supine) position. 
• You will then have a computed tomography (CT) scan of your thighs done below your 
pelvis. 
• You will be given the dose of study drug (iohexol) using the randomly selected delivery 
system.  
• You will then have additional computed tomography (CT) scan of your thighs done 
below your pelvis at 0.5, 10, and 20 minutes following the injection of the drug. You will 
be asked to remain lying in bed or sitting for at least 6 hours after you are given the study 
drug. 
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You will be given a standard meal at least two hours after taking the study drug.  You will also 
be given water or other non-caffeinated beverages to drink after being given the study drug in 
order to ensure adequate urine production for collecting samples of the injected drug in your 
urine. 
 
You will be discharged from the study site after remaining overnight in the unit at least 24 hours 
on Study Day 2, once all procedures are completed and the study doctor has decided you can 
leave. You will be scheduled to return to the study site at least 7 days later to begin Study Period 
2.  
Study Period 2 – Study Day 8 or more (Admission to the Site) 
On this study day, the following procedures will be done: 
• You will be asked about any changes in your health since the screening visit. 
• You will be asked if you have taken any medicines, including prescription and over-the-
counter medicines, vitamins, and herbal supplements, since the Screening Visit. 
• Your vital signs (heart rate, breathing rate, blood pressure and temperature), height, and 
weight will be measured.  Your blood pressure will be measured in a lying down (supine) 
position. 
• You will be asked if you have used any drugs or alcohol in the last 24 hours. 
• Women will have a pregnancy test. 
 
If you continue to qualify, you will remain at the study site and will wait to receive your dose of 
drug. You will enter the unit at least 3 hours prior to your scheduled dosing time. If you have not 
already done so, you will be asked to fast for 4 hours. 
 
Study Period 2 – Study Day 8 or more (Dosing Day & Discharge From Site) 
The following procedures will occur after you have fasted: 
• You will be asked how you are feeling. 
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• You will have a brief physical exam. 
• You will have a catheter (flexible tube) inserted into a vein to make multiple blood 
collections easier. 
o You will give blood before receiving your injection and 15, 30, 40 minutes and 1, 
1.5, 2, 4, 6, 8 and 10 hrs (for a total blood collection volume of approximately 60 
cc or 4 tablespoons), to test for the amount of study drug in your blood. 
• You will be asked to provide a urine sample before receiving your injection as well 0-2, 
2-3, 3-4, 4-6, 6-8 and 8-24 hours after dosing, to test for the amount of study drug in your 
urine. 
• Your vital signs will be measured before dosing.  Your blood pressure will be measured 
in a lying down (supine) position. 
• You will then have a computed tomography (CT) scan of your thighs done below your 
pelvis. 
• You will be given the dose of study drug (iohexol) using the randomly selected delivery 
system.  
• You will then have additional computed tomography (CT) scan of your thighs done 
below your pelvis at 0.5, 10, and 20 minutes following the injection of the drug. You will 
be asked to remain lying in bed or sitting for at least 6 hours after you are given the study 
drug. 
 
You will be given a standard meal at least two hours after taking the study drug.  You will also 
be given water or other non-caffeinated beverages to drink after being given the study drug. You 
will remain in the unit overnight until at least 24 hours following your administration of the 
study drug. 
 
You will be discharged from the clinical unit once all procedures are completed and the study 
doctor has decided you can leave. Your participation in the study will be complete at this point. 
 
RISKS AND DISCOMFORTS 
Adverse reactions following the use of Iohexol are usually transient (not lasting for a long period 
of time), and are usually of mild to moderate severity, occurring in less than 5% of patients when 
administered in the vein.  
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However, serious, life-threatening and fatal reactions, mostly of cardiovascular origin (from the 
heart and blood vessels), have been associated with the administration of iodine-containing 
contrast media, including iohexol. These are rare in occurrence (<0.3%).  
It should be noted that there is limited information on the safety of iohexol when injected into 
muscle or fat tissue beneath the skin. The amount of Iohexol that will be injected is less than a 
quarter of a teaspoon of fluid. 
 
The injection of contrast media is frequently associated with the sensation of warmth and pain, 
especially in studies that look at arteries or veins using contrast media. Pain and warmth are less 
frequent and less severe with iohexol than with many contrast media. 
 
Possible additional side effects associated with the use of iohexol include (by organ system): 
Cardiovascular System:  
• Arrhythmias (irregularity of heart rate)   
• Angina/chest pain 
• Low Blood Pressure  
 
Nervous System:  
• Vertigo (including dizziness and lightheadedness)  
• Pain  
• Vision abnormalities (including blurred vision) 
• Headache 
• Taste changes 
• Rarely: Anxiety, fever, motor and speech problems, convulsions, paresthesia (numbness), 
somnolence (sleepiness), stiff neck, hemiparesis (numbness or inability to control one 
side of your body), syncope (fainting), shivering, transient ischemic attack (mini-stroke), 
cerebral infarction (stroke), and nystagmus (involuntary eye movement) have been 
reported, with an individual incidence of 0.3% or less. 
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Respiratory System:  
• Rarely: Dyspnea (difficulty breathing), rhinitis (inflammation of the nasal passages), 
coughing, and laryngitis (inflammation of the throat), with an individual incidence of 
0.2% or less. 
 
Gastrointestinal System: Nausea and vomiting  
• Others including diarrhea, indigestion, cramp, and dry mouth were reported, with an 
individual incidence of less than 0.1%. 
 
Skin and Appendages:  
• Hives, rashes, itching or other reactions of the skin with an individual incidence of less 
than 0.3%. 
 
As the study procedures and study drugs might injure an unborn child, pregnant women may not 
participate in this study. Women who might become pregnant should use a medically accepted 
form of birth control such as total abstinence, birth control pills, an IUD, diaphragm, 
progesterone injections or implants, or condoms plus a spermicide. Methods of birth control 
other than total abstinence are not 100% effective, and should a woman become pregnant there is 
a risk of injury to an unborn child.  For similar reasons, women who are nursing an infant may 
not participate. 
 
Radiation Risks 
As a participant in this study you will receive radiation exposure that is for research purposes 
only (not for your direct health benefit). Your radiation dose from participating in this study is 
approximately 1.3% of the annual permissible occupational exposure level for radiation workers.  
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The National Council on Radiation Protection and Measurements has set permissible 
occupational radiation exposure limits for many radiologists, technologists, and scientists who 
work with radiation and are exposed nearly every day.  These limits are defined as the dose of 
radiation that, in light of present knowledge, is not expected to cause appreciable bodily injury to 
a person at any time during his/her lifetime.  The risk of this amount of occupational exposure to 
radiation is, thus, considered to be very small.  The radiation dose mentioned is what you receive 
from the research component of this study only and does not include any exposure you may have 
received or will receive in the future from other tests.  
Injection Site Reactions 
You might experience localized reactions that are from the injection or delivery system. Previous 
adverse events associated with the auto-injector included local injection site reactions that were 
mild and temporary, including bleeding, bruising, pain, redness, and swelling.  In addition, 
although the injection is intended to be in your subcutaneous (fat) tissue, there is a possibility 
that the injection may occur in the muscle tissue that may or may not lead to localized reactions. 
Previous studies have demonstrated reactions that do occur with non-ionic contrast media, such 
as iohexol, injected into the subcutaneous (fat) or muscle tissue are localized to the injected area 
and are usually mild and temporary. 
 
Unknown Risks 
You might have side effects or discomforts that are not listed in this form.  Some side effects 
may not be known yet.  New ones could happen to you.  Tell the study doctor or study staff right 
away if you have any problems. 
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BENEFITS TO YOU AND OTHERS 
There is no guarantee that you will receive any medical benefits from being in this study. 
 
This is not a treatment study, and you are not expected to receive any direct medical benefits 
from your participation in the study.  The information from this research study may lead to a 
better understanding of how to give injectable drugs to patients outside of the hospital, which 
may also have an impact on treatments in the future for people with a variety of diseases.  You 
may benefit from the physical exams, ECGs, lab tests, and other study procedures. 
 
COSTS 
There are no costs to you for participating in this study other than the time you spend in the 
study.  This will be about an hour today, two days (including an overnight stay) for Study Period 
1 and two days (including an overnight stay) for Study Period 2. 
 
PAYMENT FOR PARTICIPATION  
At the completion of each treatment period you will receive $150.00. If you complete both 
periods, you will receive an additional $100.00 for a total compensation of $400.00. 
 
ALTERNATIVE TREATMENT 
Since you are a healthy volunteer, your alternative is not to take part in this study. 
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CONFIDENTIALITY  
Potentially identifiable information about you may consist of data abstracted from your medical 
screening log. Data is being collected only for research purposes. Your data will be identified by 
ID numbers, not names, and stored separately from medical records in a locked research area. All 
personal identifying information will be kept in password-protected files and these files will be 
deleted within 6 months from the completion of the study.   
 
Other records including data obtained from the medical history and physical exam will be kept in 
a locked file cabinet. Access to all data will be limited to study personnel.  
 
You should know that research data or (medical information if applicable) about you may be 
reviewed or copied by approved personnel of Virginia Commonwealth University.  Personal 
information about you might be shared with or copied by authorized officials of the Department 
of Health and Human Services (if applicable).   
 
What we find from this study may be presented at meetings or published in papers, but your 
name will never be used in these presentations of papers.   
 
COMPENSATION FOR INJURY 
Virginia Commonwealth University and the VCU Health System have no plan for providing 
long-term care or compensation in the event that you suffer injury as a result of your 
participation in this research study. 
 
   
172 
If you are injured or if you become ill as a result of your participation in this study, contact your 
study doctor immediately.  Your study doctor will arrange for short-term emergency care or 
referral if it is needed. 
 
Fees for such treatment may be billed to you or to appropriate third party insurance.  Your health 
insurance company may or may not pay for treatment of injuries as a result of your participation 
in this study. 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
Your participation in this study is voluntary.  You may decide to not participate in this study.  
Your decision not to take part will not result in a penalty or loss of benefits to which you are 
otherwise entitled.  If you do participate, you may freely withdraw from the study at any time.   
 
Your participation in this study may be stopped at any time by the study doctor without your 
consent. The reasons might include: 
· the study doctor thinks it necessary for your health or safety; 
· you have not followed study instructions; 
· the study has been stopped; or 
· administrative reasons require your withdrawal. 
 
If you stop participating in the study before it is finished, you should complete the final study 
visit so that the study team can assess your health and follow up on any continuing adverse 
events.    
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GETTING ANSWERS TO YOUR QUESTIONS ABOUT THE STUDY 
 
You can ask questions about this consent form or the study before you decide to start the study or 
at any time during the study.   
 
Contact the study doctor or study staff with any questions or concerns.  Their telephone numbers 
are printed on the first page of this form. 
 
If you have questions about your rights as a research subject, you may contact: 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
PO Box 980568 
Richmond, VA  23298 
(804) 827-2157 
You may also contact this number for general questions, concerns or complaints about the 
research. Please call this number if you cannot reach the research team or wish to talk to 
someone else. 
 
Do not sign this consent form unless you have had a chance to ask questions and have had all of 
your questions answered.  Additional information about participation in research studies can be 
found at http://www.research.vcu.edu/irb/volunteers.htm. 
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1. CONSENT 
 
I have been provided with an opportunity to read this consent form carefully.  All of the 
questions that I have about this study have been answered.   
 
By signing this consent form, I have not waived any of the legal rights or benefits, to which I 
otherwise would be entitled.  My signature indicates that I freely consent to participate in this 
research study.  I will receive a copy of the consent form once I have agreed to participate. 
 
________________________________________________ 
Subject Name, printed 
 
________________________________________________  ________________ 
Subject Signature        Date 
 
________________________________________________  ________________ 
Signature of Person Conducting Consent    Date 
 
________________________________________________  ________________ 
Printed Name of Person Conducting Consent   Date 
 
________________________________________________  ________________ 
Witness Signature        Date 
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_________________________________________________ _______________ 
Printed Name of Witness       Date 
 
___________________________________________________ _____________ 
Principal Investigator Signature (if different from above)   Date 
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APPENDIX B.2 
Informed Consent Process Documentation Form 
 
Subject Initials ________________                         Subject Number:_________     
 
Informed Consent Process Documentation 
 
Please INITIAL next by “yes” or “no” on each line as appropriate (if no, you MUST explain 
in the notes section below): 
 
_____ Yes   _____  No  Subject was given a copy of the ICF to read. 
 
_____  Yes  _____  No  Ample time was given to the subject to read and ask questions. 
 
_____  Yes  _____  No  All questions and concerns were addressed prior to signing consent 
form. 
 
_____  Yes  _____  No  A copy of the consent form was provided to the subject. 
 
_____  Yes  _____  No  No study procedures were performed prior to signing of the consent 
form.
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_____  Yes  _____  No  Was an Assent required. 
 
Who was present during the ICF process? 
_________________________________________________ 
 
The details of this research study were discussed with the subject.  The study was explained in 
detail including all the contents of the informed consent document.  The patient/subject was 
encouraged to ask questions.  All questions were answered to the satisfaction of the 
patient/subject. The patient/subject was given adequate time to read the informed consent form 
and the opportunity to discuss it.  The patient demonstrated understanding of the informed 
consent document and indicated that they would like to participate in the study.  The patient 
demonstrated understanding that this is a research study.  The IRB-approved informed consent 
document was signed without alteration by the patient/subject. A copy of the informed consent 
document was placed in the patient/subject record, and a copy was given to the patient/subject.  
No activities specifically related to research were started until after the execution of the consent. 
 
The subject signed informed consent document, approval date:  
 
Yes  OR  NO (circle one)        on _____________________________________________. 
 
___________________________________________                          __________ 
Signature of person that obtained consent                                                 Date 
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Appendix C.1 
 
William H. Barr Curriculum Vitae 
 
Summary of Qualifications (CV) 
WILLIAM BARR, PHARM D, PHD 
Virginia Commonwealth University 
School of Pharmacy-Center For Drug Studies 
MCV West Hospital; Room 12-410 
1200 E. Broad St  
Richmond VA 23298 
Business Phone Number – 804-828-8334 
Fax-804-828-6902 
EDUCATION:  
B.S. Pharmacy (highest honors) - Univ. Calif. (S.F.) – 1960 
Pharm.D. – Univ. Calif. (S.F.) – 1961 
Ph.D. (Pharmaceutical Chemistry) – Univ. Calif. (S.F.) – 1966 
(Pharmacology minor) 
TRAINING:  
Clinical research beginning in 1964, graduate thesis (UCSF)
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Asst/Assoc Professor of Pharmaceutics and Research Asst/Assoc Professor of Pediatrics (clinical 
research in Pediatrics and Clinical Pharmacokinetics), (SUNY @ Buffalo), 1966-1972 
Professor and Chairman, Dept. of Pharmacy and Pharmaceutics, Virginia Commonwealth 
University/Medical College of Virginia, 1972-2001. 
Director, Clinical Research Unit (Center for Drug Studies) for 20 years, (VCU) 1982-present. 
Has been Principal Investigator on over 90 clinical studies (Phase 1) 
 
RELEVANT AFFILIATIONS: Professor, School of Pharmacy, VCU 
Director, Center for Drug Studies, VCU 
 
MAJOR OR RELEVANT PUBLICATIONS:  
Over 150 publications (chapters, papers, and abstracts) relating to biopharmaceutics, clinical 
pharmacokinetics and clinical pharmacology. 
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APPENDIX C.2 
Curriculum Vitae 
 
WILLIAM RUSSELL GARNETT, PHARM.D.                          
 
ADDRESS 
VA Commonwealth University     Telephone:  804-828-8328 
Medical College of Virginia      FAX:  804-828-8359 
410 N. 12th Street, Rm. 334      e-mail:        WRGarnet@VCU.EDU 
Box 980533 
Richmond, VA 23298-0533 (mail)  
 23219 (Fed-Ex) 
BIRTH DATE AND PLACE 
June 2, 1946 
Farmville, VA      
EDUCATION 
Hampden-Sydney College      1964-1966  
Hampden-Sydney VA  
Pre-pharmacy 
Medical College of VA      1966-1969 
Richmond, VA 
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School of Pharmacy  
B.S. Pharmacy   
Philadelphia College of Pharmacy and Science  1971-1973 
Philadelphia, Pennsylvania   
Doctor of Pharmacy 
ACADEMIC POSITIONS 
Instructor in Clinical Pharmacy                 July 1, 1973-June 30, 1976 
University of NC at Chapel Hill 
School of Pharmacy 
Chapel Hill, NC 
VA Commonwealth University 
Medical College of VA  
School of Pharmacy 
Department of Pharmacy  
Richmond, VA   
Assistant Professor        July 1, 1976 - June 30, 1981 
Associate Professor (tenure)       July 1, 1981 - June 30, 1986 
Professor (tenure)        July 1, 1986 - present 
Graduate Faculty        July 1989 - present 
Interim Chairman        April 1998 – 1999 
COMMITTEES - MCV/VCU  
Multiple, including: 
Pharm.D. Admissions Committee - School of Pharmacy, MCV, 1978 - 1986 
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Pharm.D. Promotion Committee - School of Pharmacy, MCV, 1976 - present 
School of Pharmacy B.S. Curriculum Committee, 1982 - 1986 
Graduate Program Committee - 1988 - present 
Interdisciplinary Research Grant Committee, 1998 to present 
Non-Traditional Pharm.D. Program Committee, 1998 to present 
MCV Hospital Pharmacy - Certification of Clinical Competency Committee, 1981-1985 
MCVH Pharmacy and Therapeutics Committee, 1982-1985 
MCV/VCU Institutional Research Committee, 1982-1985 
VCU Promotion and Tenure Appeal Committee - 1990-1993, Chairman 1991-1992 
LICENSURE AS A PHARMACIST 
Commonwealth of VA Licensure #004233 (June 1969) 
SELECT MEMBERSHIPS 
American Society of Hospital Pharmacists 
American Pharmaceutical Association 
Rho Chi Honorary Pharmaceutical Society 
Sigma Zeta Honorary Science Society 
American Association of Colleges of Pharmacy 
VA Pharmaceutical Association 
American Association of Pharmaceutical Sciences 
American College of Clinical Pharmacy 
Phi Kappa Phi Honor Society (inducted as a faculty member) 
RESEARCH ADVISOR - Research Committee for 7 Ph.D. Students 
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HONORS: 
- Alpha Delta Chapter of Phi Delta Chi - Alumni of the Year 
- Selected the Robert Leonard Memorial Lecturer, TX Society of Hospital Pharmacist, 1993 
- Phi Kappa Phi Honor Society (faculty member) 
- Elected Fellow American College of Clinical Pharmacy, 1993 
- American College of Clinical Pharmacy Education Award, 1996 
-         Invited Professor to Tan Tock Seng by Singapore Ministry of Health 8-96 to 9-96 
SELECT PUBLICATIONS IN REFERRED JOURNALS 
- Garnett, William R.: "Diluents for Antineoplastic Drugs," Drug Intelligence and Clinical 
Pharmacy 5:261 (Aug)1971. 
- Garnett, William R. and Snyder, Thomas C.:  "Indomethacin's Value," J. Am. Pharm. Assoc., 
NS13(2):66 (Feb) 1973. - Garnett, William R.; Carter, Barry L.; and Pellock, John 
M.:"Bioavailability of Phenytoin Administered with Antacids," Therapeutic Drug Monitoring, 
Vol. 1, 1979, p. 435-437. 
- Garnett, William R.; Carter, Barry L.; and Pellock, John M.: "Effect of Calcium and Antacids 
on Phenytoin Bioavailability,: Arch Neurol. Vol. 37, (July) 1980, p. 467. 
- Garnett, William R.; Goldberg, Jeffrey A.; and Lowenthal, Werner: "Evaluation of a Systemic 
Approach to Clinical Pharmacy Consultation in a Long Term Care Facility," The Gerontologist. 
Vol. 21 No. 2 (April), 1981, p.151-157. 
- Garnett, William R.; Davis, Larry J.; McKenney, James M.; Steiner, Kenneth C.: "Evaluation 
of the Effect of a Follow-Up Telephone Call on Patient Compliance," Am. J. Hosp. Pharm. Vol. 
38, No. 5,(May), 1981, p.676-679. 
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- Garnett, William R.:  "Sucralfate - An Alternative in Peptic Ulcer Therapy," Clin. Pharm. Vol. 
1, No.4, July-Aug. 1982, 307-314. 
- Garnett, William R.: "Discontinuing Anticonvulsant Medications," Clin. Pharm.  Vol. 3, No. 4, 
Sept. - Sept-Oct., 1984, p. 456-457. 
 - Garnett, William R.:  "Mechanism of Action of Drugs Used in the Treatment of Drug Induced 
Gastritis," Practical Gastroenterology. Vol. X No. 5 Sept/Oct 1986 p.40-44. 
- Garnett, William R.:  "Is The Clinical Scientist an Oxymoron?"  Am J Pharm Ed. Vol. 52, 
Winter 1988, p467-468. 
- Garnett, William R.: "The Final Frontier:  Clinical Pharmacy Practice in Community Pharmacy 
Settings." Am J Pharm Educ. Vol. 53, Fall 1989, p313-314. 
- Garnett William R.:  "Geriatric Pharmacokinetics," FL J Hosp Pharm. Vol. 9, 1989, p23-28. 
- Garnett, William R.: Patient Outcome Management of Acid Related Disorders.  J Am Soc 
Consulting Pharm. 1992. 
- Garnett, William R.: Epilepsy. US Pharmacist. December 1992. 
- Garnett, William R.: Efficacy, safety, and cost issues in managing patients with 
gastroesophageal reflux disease.  Am J Hospital Pharm.  1993; 50(Suppl 1):S11-S18. - Garnett 
William R.: Fluvastatin cost considerations.  Ann Pharmacotherapy.  1994; 28:1111-1112. 
- Garnett William R.: Chronopharmacology: Giving the right drug at the right time.  Clinical 
Trends in Pharmacy Practice.  1994; 8:16-28. 
- Garnett William R.: The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor.  
Clin Cardiol.  1994; 17(Suppl IV):3-10. 
- Garnett William R. and Pellock JM: AFocus on lamotrigine: A new antiepileptic drug for 
patients with partial seizures.  Hosp Formul.  1994; 29:806-812. 
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- Garnett William R.: New opportunities for the treatment of epilepsy. Am. J. Health - Syst 
Pharm. 1995; 52, 88-91. 
- Garnett William R and Pellock JM: ACritical drug appraisal: Lamotrigine - Effective oral add-
on therapy.  P & T.  1995; 20:156-170. 
- Garnett William R.: Drug interactions with the HMG-CoA reductase inhibitors.@  Am J 
Health-Sys Pharm.  1995, 52; 1639-45. 
- Garnett William R.: Lansoprazole.  Ann pharmacotherapy. 1996; 30: 1425-1436 
- Garnett William R: Treatment and prevention of acid-related disorders.  US Pharmacist. 1997; 
22:119-130. 
- Garnett WR, Levy B, McLean AM, et al.  Pharmacokinetic evaluation of twice-daily extended-
release carbamazepine (CBZ and four-times daily immediate release CBZ in patients with 
epilepsy.  Epilepsia.  1998 Mar;39(3): 274 – 9. 
- Garnett WR.  Antiepileptic drug treatment: outcomes and adherence.  Pharmacotherapy.  2000 
Aug;20(8 Pt 2): 191S – 199S. 
- Garnett WR, Yunker NS.  Treatment of Crohn’s disease with infliximab.  Am J Health Syst 
Pharm.  2001;Feb 15;58(4): 307 – 16. 
- Garnett WR.  Clinical implications of drug interactions with coxibs.  Pharmacotherapy. 2001; 
Oct;21(10)1223 -32. 
 
In addition, Dr. W.R. Garnett has been involved in over ten book reviews, authored 50 book 
chapters and published over 45 abstracts, and led over 775 presentations during his academic 
career.
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APPENDIX C.3 
John N. Clore M.S., M.D. Curriculum Vitae 
 
1 BIOGRAPHICAL SKETCH 
 
 
NAME 
Clore, John Newton 
POSITION TITLE 
Professor of Medicine, VCU 
eRA COMMONS USER NAME 
jnclore 
EDUCATION/TRAINING   
INSTITUTION AND LOCATION 
DEGREE 
(if 
applicable) 
MM/YY FIELD OF STUDY 
Virginia Commonwealth University, Richmond 
VA 
 
BS 1976 Biology 
Virginia Commonwealth University, Richmond 
VA 
 
MS 1977 Biology 
Virginia Commonwealth University, Richmond 
VA 
 
MD 1982 Medicine 
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Virginia Commonwealth University, Richmond 
VA 
 
Resident 1982-1985 Internal Medicine 
Virginia Commonwealth University, Richmond 
VA Fellow 1985-1988 
Endocrinology 
 
 
A. Personal Statement 
 
In my role as Program Director of the General Clinical Research center at VCU for more than 15 
years, I have had the opportunity to mentor a number of young investigators who have gone on 
to academic careers focused in clinical research. This role has included instruction in 
methodology as well as critique and assistance in data analysis, manuscript writing and 
submission of grants. Recognition of my abilities as a mentor include my selection as 
Distinguished Mentor in Clinical Science by the School of Medicine at VCU. My particular area 
of clinical and research interest for over 25 years has focused on diabetes mellitus, the focus of 
the present application. I have an active clinical practice which will enhance the candidate’s 
ability to recruit potential research subjects and I will be able to assist the candidate in clinical 
outcomes measures. 
 
B. Positions and Honors. 
Professional Positions: 
Virginia Commonwealth University (VCU) 
1988-1993 Assistant Professor of Medicine 
1993-1998 Associate Professor of Medicine 
1996- Program Director, General Clinical Research Center 
1998- Professor of Medicine 
1998-         Professor of Biochemistry and Molecular Biophysics 
       2007-        Associate Vice President for Clinical Research 
Selected Honors: 
AOA, William Harrison Higgins Award,1985; 
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Young Investigator Award, ADA, 1987 
Clinical Associate Physician Award, NIH, 1987-1990. 
Distinguished Mentor in Clinical Science, 2008 
C. Selected Peer-Reviewed Publications 
1. Clore JN and Blackard WG (1994). Suppression of gluconeogenesis does not deplete liver 
glycogen in patients with NIDDM after a three-day fast. Diabetes 43: 256-262, 1994. 
2. Clore JN, Li J, Gill R, Gupta S, Zuelzer W and Blackard WG. (1998) Skeletal Muscle 
Phosphatidylcholine Fatty Acids and  Insulin Sensitivity in  Normal Man. Am J Physiol 275: 
E665-E670. 
3. Clore JN, Li J, Zuelzer W, Harris P and Rizzo W. (1999) Changes in Skeletal Muscle 
Phosphatidylcholine Fatty Acid Composition Alters Insulin Responsiveness in Normal Man. 
Metabolism 49:232-238. 
4. Clore JN, Stillman J and Sugerman HJ. (2000) Glucose-6-phosphatase flux is increased in 
Type 2 diabetes. Diabetes 49:969-974 
5. Sugerman HJ, Wolfe LG, Sica DA and Clore JN. Diabetes and hypertension in severe obesity 
and effects of gastric bypass-induced weight loss. Annals of Surgery 237:751-758, 2003. 
6. Levy JR,  Clore JN and Stevens W. Dietary n-3 Polyunsaturated Fatty Acids Decrease 
Hepatic Triglycerides,  Hepatology 39:608-616. 2004. 
7. Clore JN, Levy JR and Stillman JS. Acute infusion of saturated but not polyunsaturated fatty 
acids impairs hepatic insulin action in man. Am J Physiol 287:E358-E365, 2004. 
8. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling AK,  Stravitz RT, 
Shiffman ML, Clore JN,  Mills AS. A pilot study of vitamin E versus vitamin E and 
pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 
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2:1107-15, 2004 
9. Shannon, K.A., R.M. Shannon, Clore JN, C. Gennings, B.J. Warren, and J.A. Potteiger. 
Resistance exercise and postprandial lipemia: an investigation into the dose effect of differing 
volumes of acute resistance exercise bouts.  Metabolism: Clinical and Experimental, 54:756-763 
2005 
10. Shannon KA, Shannon RM, Clore JN, Gennings C, Warren BJ, Potteiger JA. Effects of 
acute aerobic exercise  on postprandial lipemia: a comparative investigation of untrained African 
American and Caucasian women. International Journal of Sport Nutrition & Exercise 
Metabolism 18:37-48, 2008 
11. Luebbers PE, Potteiger JA,Warren BJ,Clore JN,Gennings C, Bond DS. Glucose Uptake after 
Resistance  
12.  Shannon KA, Shannon RM, Clore JN, Gennings C, Warren BJ, Potteiger JA. Effects of 
acute aerobic exercise on postprandial lipemia: a comparative investigation of untrained African 
American and Caucasian women. International Journal of Sport Nutrition & Exercise 
Metabolism 18:37-48, 2008 
D. Research Support 
Ongoing Research Support 
1UL1RR031990-01 (Clore JN, PI).       07/01/10-06/30/15 
Institutional Clinical and Translational Science Award 
The VCU CTSA provides broad-based infrastructure support for clinical and translational 
research across the institution. 
Role: Principal Investigator 
 N66001-09-2-2060 (Cifu, PI)       05/01/2009-4/30/2011 
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Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PCS) After Mild 
Traumatic Brain Injury (MTBI): A Randomized, Double-Blinded, Sham-Controlled, Variable 
Dose, Prospective Trial. 
This trial will assess the efficacy of hyperbaric oxygen in veterans with traumatic brain injury. 
Role: Co-investigator,  
Completed Research Support  
Agency: National Center for Research Resources    9/01/06-8/31/07 
Type P20 RR023414 
This Planning Grant for an Institutional Clinical and Translational Science Award supports the 
establishment of a new Center for Translational Science and the development of degree 
programs in clinical and translational research. 
Role: Principal Investigator 
 
Type: U01 DK61731 
“The role of de-novo lipogenesis in non-alcoholic fatty liver disease.” 
The long-term objective of this project is to examine the mechanisms by which fatty liver occurs 
in some but not all individuals with insulin resistance.  
Role: Principal Investigator 
 
Agency: National Institutes of Diabetes, Clore (PI)    6/01/1996-6/30/2001 
Digestive Diseases and Kidney 
Type: RO1 DK43013,  
“Control Mechanisms of Hepatic Glucose Output” 
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The long-term objective of this project is to examine the mechanisms by which hepatic glucose 
production is increased in patients with Type 2 diabetes mellitus. Particular emphasis has been 
placed on the reciprocal relationship between liver glycogen release and gluconeogenesis which 
is stimulated by free fatty acids. 
Role: Principal Investigator
  
  
191 
APPENDIX D 
Randomization Schedule 
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APPENDIX E.1a 
Interim Study Flowsheet 
 
Protocol # 13424  PIs: Garnett, W., Barr, W., & Edwards, E.  
Development of a novel model to assess qualitative & quantitative injectable 
delivery dynamics  
 
□ Study Period 1           □ Study Period 2           Date:__________ Unit Arrival Time:________ 
ID#________________     HT  ______cm  WT  _____ kg         □  Confirm Fasting x4hr:  
Yes____No____ 
□ Review Exclusion Criteria (Study Questionnaire)                 □ Have Pt change/dress 
□ Place Saline lock (Use Catheter Tracking Log)                    □ Quick Vue Urine Pregnancy Test 
(females):________ 
□ 45-60 Minutes prior to Dosing – obtain pre-dose Blood Draw, followed by Pre-dose Urine 
□ VS(within 60 min predosing)Time: _____ BP( supine 5 min)_____\______  HR_______ 
RR_____ Temp ______C 
□ Transport to Radiology 30 minutes prior to Scheduled Dosing Time 
□ Pt. to remain sitting or lying in bed for 6 hours post dosing(Bath Room Privileges Only) 
□ Encourage water and non-caffeinated beverages post dosing
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Time 
 
Rel 
Time 
Actual 
Time 
PK 
Lt 
GrnTT 
4.5ml 
CT 
Scan 
Urine         
2 ml 
Staff 
Initials 
Comments 
Pre-
injection  
  X  X 
TV: 
  
Pre-
injection 
Scan 
   X  
Period 
1 only 
   
Injection 
SubCut 
 (0 min) 
Prefilled syringe or Auto-
injector 
Site: (Right or Left  
Thigh?____________@ 
___________ 
 
 
0-2hr  
TV:_____ 
 
Actual Collection 
Time:__________ 
  
 
   0.5 min 
(30 sec) 
   X   
      2 min    X   
  3 min.   X    
      5 min    X   
  7 min   X    
    10 min    x   
12 min   X    
    15 min    X   
20 min   X    
40 min   X    
  1 hr   X    
  2 hr 
(Meal) 
  X    
  4 hr   X  2-4 hr 
TV: _____ 
Actual Collection 
Time 
  
  6 hr   X  4-6hr 
TV: 
Actual Collection 
Time 
  
  8 hr   X  6-24hr 
TV: 
Actual Collection 
Time 
  
24 hr       
   BP (supine 5min)_____\______  HR_______ 
RR_____ Temp ______C 
 
Nurse Signature/initials:  _________________ 
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APPENDIX E.1b 
Final Study Flowsheet  
 
Protocol # 13424  PIs: Garnett, W., Barr, W., & Edwards, E.  
Development of a novel model to assess qualitative & quantitative injectable 
delivery dynamics  
 
□ Study Period 1           □ Study Period 2           Date:__________ Unit Arrival Time:________ 
ID#________________   HT  ______cm  WT  _____ kg    □ Fasting except water,etc x4hr (see 
order sheet):  Yes____No____ 
□ Review Exclusion Criteria (Study Questionnaire)   □ Pt to wear shorts   □Place Saline Lock 
□ Quick Vue Urine Pregnancy Test (females):________  □ Urine and Lt GrnTT on wet 
ice/refrigerate during collection* 
□ 45-60 Minutes prior to Dosing – obtain pre-dose Blood Draw, followed by Pre-dose Urine 
□ VS (within 60 min predosing) Time: _____ BP( supine 5 min)_____\______  HR_______ 
RR_____ Temp ______C 
□ Transport to Radiology 30 minutes prior to Scheduled Dosing Time 
□ Pt to remain sitting or lying in bed for 6 hours post dosing (Bath Room Privileges Only) 
□ Encourage water and non-caffeinated beverages post dosing
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Time 
 
Rel 
Time 
Actual 
Time 
PK 
Lt 
GrnTT* 
4.5ml 
CT 
Scan 
Urine*        
2 ml (collection 
ends prior to  
blood draw) 
Staff 
Initials 
Comments 
Pre-
injection  
  X  X  (spot) 
TV: 
  
Pre-
injection 
Scan 
   X  
Period 
1 only 
   
Injection 
SubCut (0 
min) 
Prefilled syringe or Auto-injector 
(N) 
Site: (Right or Left  Thigh?  
1.0 ml @  __________              
X 
 
0-2hr  
TV:_____ 
 
Actual Collection 
Time:__________ 
 Dose 
Check 
/ 
 
 
30 sec    X   
15 min   X    
10 min    X   
20 min   X   
30 min   X    
40 min   X   
  1 hr   X   
  1.5 hr   X   
  2 hr 
(Meal) 
  X  X     2-3 hr 
TV: _____ 
Actual Collection 
Time 
  
   
  4hr   
X 
 X      3-4 hr 
TV: _____ 
Actual Collection 
Time 
  
 X     4-6 hr 
TV: _____ 
Actual Collection 
Time 
 
  6 hr   
X 
   
 X      6-8 hr 
TV: _____ 
Actual Collection 
Time 
  
  8 hr   
X 
 
 X      8-24 hr 
TV: _____ 
Actual Collection 
Time 
BP (supine 
5min)_____\______  
HR_______ RR_____  
Temp ______C 
10 hr   X  
24 hr    
05.02.2011rev                      S:\Data\users\Nurses\13424Flowsheet7.doc
  
  
196 
APPENDIX E.2 
Adverse Event Reporting Form 
 
 
 
ADVERSE EVENTS 
 
Subject Initials:                 ________ 
 
 
Subject Number:               ________ 
 
 
Page _______  of ________ 
Has the subject complained of any adverse event? Yes    No  *If there are more than 4 AE’s use another form.        
** If YES, complete a SERIOUS ADVERSE EVENT form.                
Adverse Event* 
(one per line) 
 
Whenever possible, 
signs and symptoms 
should be grouped 
together as syndromes 
or diagnoses 
Occurrence 
 
 
Onset and Resolution 
Of Adverse Event 
 
 
Date                                 Time 
MM / DD / YY (24-hr Clock) 
Is the 
adverse 
event 
serious? 
 
1 = no 
 
2 = **yes 
Intensity 
 
1 = Mild 
2 = Moderate 
3 = Severe 
4= Life threatening 
5= Death 
Action Taken 
 
1 = None 
2 = 
Permanently 
discontinued 
from Study 
Con Med 
Taken for 
this AE? 
 
1= No 
2 = Yes 
Outcome 
 
1 = 
Resolved 
without 
sequelae 
2 = 
Resolved 
with 
sequelae 
3= Not 
resolved 
4= Death 
Relationship 
to study 
drug/device 
 
1= Possibly 
Related 
2 = Probably 
Related 
3= Not 
Related 
M.D. 
Initial 
and 
Date 
Staff Init. ___  date __ 
#    ___ 
 
Staff Init ________  
date ________ 
 
Onset        __  / __    / __             _  : ___     
 
Resolved    __    / __    / __          _     : ___     
  
MD 
INIT. 
  
MD 
INIT. 
  
MD INIT. 
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Staff Init. ______  date 
________ 
 
#    ___ 
 
Staff Init _______  date 
_________ 
 
Onset        __  / __    / __             _  : ___     
 
Resolution   __    / __    / __          _     : ___     
  
MD 
INIT. 
  
MD 
INIT. 
  
MD INIT. 
   
Staff Init. ______  date 
_________ 
 
#    ___ 
 
Staff Init _______  date 
_________ 
 
Onset        __  / __    / __             _  : ___     
 
Resolution   __    / __    / __          _     : ___     
  
MD 
INIT. 
  
MD 
INIT. 
  
MD INIT. 
   
Staff Init ______   date 
_________ 
 
#    ___ 
 
Staff Init _______  date 
_________ 
 
Onset        __  / __    / __             _  : ___     
 
Resolution   __    / __    / __          _     : ___     
  
MD 
INIT. 
  
MD 
INIT. 
  
MD INIT. 
   
 
Q. C. ON______BY_______ 
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Adverse Events Observation Form 
Subject Initials:  _______     Subject Number:  _________    
           
 
Event # 
 
Entry Date 
 
Entry Time 
 
    
    
    
    
    
    
    
    
Attach Additional Pages As Needed. 
Page______  of  _______ 
 
Q. C. ON______BY_______ 
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Subject Initials:  __________                                                                 Subject Number:   __________ 
 
INSTRUCTIONS:  Record Vital Signs according to investigator instructions if deemed necessary for an adverse event. 
Date Study Day Actual Time 
(24-hour clock) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Respiratory 
Rate 
(per min) 
Oral Temp 
(°F) 
Staff 
Initials 
M.D. 
Review 
   /      
   /      
   /      
   /      
   /      
   /      
   /      
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APPENDIX E.3 
Screening and Demographic Form 
 
DOB:  ____________________Screen Date:  ________ 
Age:  _____________________ 
 Volunteer ID verified by: _________ 
 Race:  _____________________    Ethnicity:   Hispanic: Yes £    No   £   ID 
Document:_________ 
 Sex:  _____________________                         Latino:     Yes £    No   £    
Consent form Signed date:                                 Signed time:                                         
  
This is a confidential record.  Information contained herein will not be released unless authorized 
by the patient.  The volunteer has been given sufficient time to read, ask questions and sign the 
ICF prior to study related procedures being performed. The volunteer has been given a copy of 
the signed consent.     Staff Init: __________ Time: _____________   ________ 
 
VITAL SIGNS 
 
 Height   __________cm. /   in.            Time: __________ 
Weight  __________kg.  /   lbs.          Time: __________                        
BMI:_____________    
Oral Temperature __________°F                       Time: __________           
 Respiration Rate  __________/Min              Time: __________ 
Thigh Circumference: _____________cm     Time: __________ 
Vital Signs (supine 5 min.)   BP_____/ _____  P____________        Time: __________ 
Urine Pregnancy Quick Vue Results:_______________                    Time:__________ 
ECG: ________________                                                                   Time:__________ 
Repeated: Yes £    No   £                                                        
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Yes £    No   £   Oral Temperature  __________°F                     Time: __________           
Yes £    No   £   Respiration Rate  __________/Min      Time: __________ 
Yes £    No   £           Vital Signs Seated 10min.   BP_____/ P_____        Time: __________ 
 
 
M.D. 
Orders:________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
___________________ 
 
Date:____________ 
 
MD. Signature:____________________________   
Nurse Initials/Signature:_________________
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APPENDIX E.4 
Physical Examination Form 
 
This is a confidential record.  Information contained herein will not be released 
unless authorized by the patient. 
 
Date: ____________ Subject Initials:  _________ Subject Number: __________ 
 
System Normal  Abnormal Not Done Findings if Abnormal 
 
 General Appearance    __________________________ 
 Skin    ¨  __________________________ 
 EENT    ¨  __________________________  
 Head/Neck/Thyroid  ¨  __________________________ 
 Lymphatic   ¨  __________________________ 
 Lungs/Chest   ¨¨  __________________________ 
 Cardiovascular           ¨¨         __________________________ 
 Abdomen    ¨  __________________________
 Genitourinary   ¨  __________________________ 
 Extremities   ¨  __________________________ 
 Neurological   ¨  __________________________ 
 Musculoskeletal  ¨  __________________________ 
 Other: _______________ ¨  __________________________ 
 
Comments:     
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
                  
Physician Signature: ___________________________           Date: _____/ ______ /  ______  
 
Physician Printed Name: ___________________________  
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APPENDIX E.5 
Medical History Evaluation Form 
 
Screening Date: ______________Screening Number:__________Subject Initials:___________                      
MEDICAL HISTORY 
This is a confidential record.  Information contained herein will not be released unless authorized 
by the patient.    
If the answer is Yes to any of the questions, please indicate the specific disease condition, the 
date of occurrence, the duration of the illness and any other information available. 
Please initial and date the bottom of each page to indicate you have reviewed each Condition on 
the page. 
 
Y or N      Condition 
_______ CARDIOVASCULAR - Have you ever had any heart related diseases 
including angina, arrhythmia, congestive heart failure, hypertension, 
hypotension, myocardial infarction (heart attack), peripheral vascular 
disease, coronary artery bypass graft, angioplasty, hyperlipedemia or heart 
murmur? 
_______ 
 
GASTROINTESTINAL - Have you ever had any diseases pertaining to the 
stomach or intestine including ulcerative colitis, Crohns disease, gastritis, 
ulcers, or hernias? 
_______ HEPATIC - Have you ever had any liver related diseases (e.g. hepatitis or jaundice)?  
_______ ENDOCRINE - Have you ever had any endocrine or metabolic diseases 
including diabetes (Type I or Type II), hyperthyroidism, or hypothyroidism? 
 
_______ GENITOURINARY - Have you ever had any genitourinary diseases 
including impaired renal (kidney) function, pyelonephritis, kidney stones, 
kidney or bladder diseases?  If female, have you had a hysterectomy? 
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_______ HEMATOLOGICAL - Have you ever had any blood related diseases 
including anemia or tendency to bleed (such as easy bruising or prolonged 
bleeding after tooth extraction, etc.)? 
 
_______ NEUROLOGICAL- Have you ever had any neurological diseases 
including transient ischemic attach (a temporary interference with blood 
supply to the brain), CONVULSIONS, SEIZURES, STROKE, EPILEPSY, 
HEAD TRAUMA, INTRACRANIAL HEMMORRHAGE? 
 
_______ MUSCULOSKELETAL- Have you ever had any musculoskeletal 
problems such as broken bones or diseases including arthritis or muscular 
dystrophy? 
 
_______ RESPIRATORY- Have you ever had any respiratory or pulmonary 
diseases including asthma, bronchitis, or chronic obstructive lung disease? 
 
_______ IMMUNOLOGICAL- Have you ever had any immunological diseases 
including, immunodeficiency, or connective tissue disease (such as 
generalized inflammation of connective tissue & blood vessels)? 
 
_______ NEOPLASTIC- Have you ever had any neoplastic disease including 
cancer, Leukemia, or lymphoma? 
 
_______ DERMATOLOGICAL- Have you ever had any problems related to the skin? 
 
_______ SERIOUS ILLNESS, INJURY, OR SURGERY- Have you ever had 
any other serious illness, injury or surgery not yet reported? 
 
_______ EAR, EYES. NOSE, THROAT or MOUTH - Have you had EENT 
procedures not previously reported (I.E. tonsillitis, tonsillectomy, adnoid 
problems, deviated septum, chronic dental problems etc.)?Do you wear eye 
glasses, contacts, dental work or hearing aid, etc? 
 
_______PSYCHIATRIC - Have you ever been hospitalized for any psychiatric problems? 
 
_______ OTHER - Have you ever had any other physical or medical conditions 
which have not been mentioned in the preceding questions? 
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_______ MEDICATIONS - Have you taken any medications in the past 30 days?  
Include all medications either  prescription or over the counter (OTC), 
taken on a regular basis. Include any medications taken seasonally for 
allergies. 
 
_______ ALLERGIES- Are you allergic to any drugs or medications, either 
Prescription or Over the Counter.  This would include having a bad 
reaction to any drug or form of medicine.   
Do you have any other allergies (Environmental, Food, Immunizations, 
Vitamins, or XRay dyes). 
 
_______ HIV- Have you ever tested positive for the HIV virus?  If yes, indicate the 
date you tested positive and any other pertinent information. 
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APPENDIX E.6 
Personal Habits Form 
The following questions concern your personal habits and other general information.  If the answer is Yes to any  
of the questions, please fill out the information requested in the table that follows each question. 
Please initial the bottom of each page to indicate you have reviewed each question on the page. 
Yes/No            Condition 
 
________ Do you currently use, or have you ever used any form of TOBACCO (cigarettes, cigars, pipe or  
chewing)? 
 Form  # per day         Unit         Start Date     Stop Date 
  |_____________|____________|________|_____________|_____________| 
                 |_____________|____________|________|_____________|_____________| 
                 |_____________|____________|________|_____________|_____________| 
________ Do you drink ALCOHOL?  If yes indicate the type (beer, wine, liquor), how much you drink  
per day, week or month and the most recent date of alcohol consumption. 
|_________________|_____________|_____________|____________|_______________________| 
|_________________|_____________|_____________|____________|_______________________| 
|_________________|_____________|_____________|____________|_______________________| 
 ________ Have you ever been treated for ALCOHOL or SUBSTANCE ABUSE? 
Date Date Treated Type      Where Treated      Detail Notes 
|____________|______________|__________|______________________|______________________| 
|____________|______________|__________|______________________|______________________| 
|____________|______________|__________|______________________|______________________| 
Type Amount        Per                Most recent             Detail Notes 
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________ Have you used any ILLICIT DRUGS in the past 6 months? 
If yes, please give date of last usage and what type (marijuana, cocaine, speed, acid etc.) 
(PLEASE BE HONEST, WE MAY REQUIRE A URINE DRUG SCREEN.  IF YOU SHOULD TEST 
POSITIVE FOR ANY ILLICIT DRUGS, YOU MAY BE DISQUALIFIED FOR FUTURE STUDIES 
WITH VCU.) 
Date of last usage          Drug Type                                       Detail Notes 
|__________________|______________________|_________________________________________| 
|__________________|______________________|_________________________________________| 
|__________________|______________________|_________________________________________| 
________ Do you drink CAFFEINATED BEVERAGES?  If yes indicate what type (Tea, Cola, Coffee),  
the amount per day, week, or month, and the most recent date of caffeine consumption. 
Type    Amount             Per               Most recent                   Detail Notes 
|____________|_____________|____________|_____________|_____________________________| 
|____________|_____________|____________|_____________|_____________________________| 
|____________|_____________|____________|_____________|_____________________________| 
 ________ Are you a vegetarian or do you have special DIET RESTRICTIONS (due to allergies, etc.)? 
Diet Restriction 
|___________________________________________________________________________________| 
|___________________________________________________________________________________| 
|___________________________________________________________________________________| 
________ Do you have a ROUTINE EXERCISE program? 
Type of Exercise Frequency          Detail Notes 
|_____________________|_____________|_________________________________________| 
|_____________________|_____________|_________________________________________| 
|_____________________|_____________|_________________________________________| 
________ If any, when was the last time you received, donated or had a loss of blood or blood products?  
Indicate type (whole blood, plasma, platelet), when and where. 
Type      When                   Where                                     Detail Notes 
|__________________|_____________|___________________|______________________________| 
|__________________|_____________|___________________|______________________________| 
|__________________|_____________|___________________|______________________________| 
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 If any, when is the last time you participated in an experimental DRUG or experimental MEDICAL DEVICE 
STUDY? 
Study Name        Completion Code     Last Dosing Date    Study Location 
|__________________|_____________|___________________|______________________________| 
|__________________|_____________|___________________|______________________________| 
|__________________|_____________|___________________|______________________________| 
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APPENDIX F 
 
Iohexol Inter-run Precision and Accuracy Results for the Quality Controls and 
Back Calculated Values for the Calibration Standards 
Back-Calculated Values for 
Plasma Iohexol      
 Iohexol Concentration (µg/mL) 
RUN 2.50 10.00 25.00 50.00 100.00 
14 APR11 STD CTRL CHECK A 9.98 25.42 48.52 96.87 
 2.42 9.26 24.75 50.05 104.36 
29 APR11 306 307 V2 2.11 A 24.44 53.13 101.88 
 2.43 9.11 26.40 49.11 98.56 
18 MAY11 V1 10 SUBJ 2.51 11.48 27.88 60.23 60.23 
 2.82 9.38 25.65 52.82 109.03 
20MAY11 V2 10 SUBJ 2.24 9.54 24.71 48.43 95.54 
 2.81 10.09 26.63 45.62 93.34 
08 JUN11 V1 AND V2 10 SUBJ 2.47 9.91 28.96 48.31 88.65 
 2.49 9.92 26.29 50.65 99.21 
      
Mean 2.5 9.9 26.1 50.7 94.8 
StdDev 0.23 0.70 1.5 4.0 13.4 
%RSD 9.3 7.1 5.6 7.9 14.1 
%DFN -1.0 -1.5 4.5 1.4 -5.2 
A = deleted from calculations per SOP criteria of ± 15%    
Back-Calculated Values for  
Urine Iohexol      
 Iohexol concentration (µg/mL) 
RUN 2.50 10.00 25.00 50.00 100.00 
25 APR11 306 307 PU A 10.6 26.0 53.9 93.1 
 2.4 10.2 25.2 50.3 88.0 
25 APR11 306 307 URINE 2.6 A 28.6 54.4 108.8 
 A 7.3 23.3 48.4 99.6 
30 APR11 306 307 URINEV2 2.3 10.2 25.6 51.9 96.2 
 A 14.5 25.0 45.0 102.1 
      
Mean 2.45 10.57 25.60 50.65 97.95 
StdDev 0.19 2.56 1.72 3.54 7.27 
%RSD 7.7 24.2 6.7 7.0 7.4 
%DFN -2.2 5.7 2.4 1.3 -2.0 
A = deleted from calculations per SOP criteria of ± 15%    
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Plasma Inter-run Quality Control 
        
 
Iohexol concentration 
(µg/mL) 
RUN 5.00 30.00 75.00 
    
08 JUN11 V1 AND V2 10 SUBJ 6.0 28.2 75.8 
 5.7 29.1 75.8 
14 APR11 STD CTRL CHECK 4.6 30.0 74.4 
 5.2 25.4 73.5 
 5.6 26.1 66.7 
18 MAY11 V1 10 SUBJ 5.2 18.8 44.9 
 4.4 13.4 69.9 
20MAY11 V2 10 SUBJ 4.0 20.5 68.8 
 4.4 28.6 78.0 
29 APR11 306 307 V2 4.6 30.3 78.8 
 4.4 33.8 76.0 
    
Mean 4.9 25.8 71.1 
StdDev 0.65 6.0 9.5 
%RSD 13.2 23.2 13.3 
%DFN -1.7 -13.9 -5.1 
 
Urine Inter-run Quality Control 
    
 
Iohexol concentration 
(µg/mL) 
RUN 5.00 30.00 75.00 
    
25 APR11 306 307 PU 5.3 22.7 81.9 
 5.2 30.3 79.4 
25 APR11 306 307 URINE 5.9 24.8 64.5 
 5.1 25.7 68.5 
30 APR11 306 307 URINEV2 5.1 33.2 77.1 
 4.9 28.9 75.9 
    
Mean 5.21 27.93 74.62 
StdDev 0.33 3.66 6.09 
%RSD 6.3 13.1 8.2 
%DFN 4.3 -6.9 -0.5 
  
  
211 
APPENDIX G 
Sample Chromatograms 
Sample Chromatogram:  Calibration Standard 3 (Note: I2 was used for quantification) 
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Sample Chromatogram:  Sample 307-Period 2- Sampling Time - 2 hours 
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APPENDIX H.1 
Demographics – Continuous Variables 
 
 
Treatment Sequence 
________________________________________ 
 Statistic 
AP 
N = 6 
PA 
N = 6 
Total 
N = 12 
Age (years) N 6 6 12 
 Mean 27.17 33.0 30.08 
 SD 8.30 12.85 10.76 
 Median 24 27.5 24 
 Min 22 22 22 
 Max 44 51 51 
     
Height (cm) N 6 6 12 
 Mean 174.88 173.10 173.99 
 SD 8.25 11.53 9.60 
 Median 177.05 171.25 174.55 
 Min 161.7 160.1 160.1 
 Max 184.6 187.5 187.5 
     
Weight (kg) N 6 6 12 
 Mean 69.9 68.4 69.15 
 SD 8.46 13.44 10.73 
 Median 69.45 65.3 68.05 
 Min 58.9 55.0 55.0 
 Max 80.4 90.0 90.0 
     
BMI (kg/m²) N 6 6 12 
 Mean 22.82 22.59 22.70 
 SD 1.83 1.77 1.72 
 Median 22.65 21.81 21.9 
 Min 20.64 21.45 20.64 
 Max 25.13 26.01 26.01 
 
Thigh circumference (cm) N 6 6 12 
 Mean 47.21 51.72 49.47 
 SD 13.09 3.15 9.38 
 Median 50.7 51.0 50.7 
 Min 21.1 48.5 21.1 
 Max 57.5 57.5 57.5 
A= Auto-injector, P= Pre-filled Syringe 
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APPENDIX H.2 
Demographics – Categorical Variables 
 
 
Treatment Sequence 
______________________________________  
 
AP 
N = 6 
PA 
N = 6 
Total 
N = 12 
Race    
    Black or African American 2 (33.3%) 2 (33.3%) 4 (33.3%) 
    Asian 1 (16.7%) 0 (0.0%) 1 (8.3%) 
    White 3 (50.0%) 4 (66.6%) 7 (58.3%) 
    American Indian or Alaska Native 0 (0.0%) 0 (0.0%) 0 (0.0%) 
    
Gender    
    Female 3 (50.0%) 3 (50.0%) 6 (50.0%) 
    Male 3 (50.0%) 3 (50.0%) 6 (50.0%) 
    
A= Auto-injector, P= Pre-filled Syringe 
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APPENDIX I 
Assumptions Utilized for the Calculation of Lamda z (λz) 
 
Terminal Elimination Rate Constant Data Point Range Selection by Subject 
Subject # Auto-injector Pre-filled Syringe 
304 last 3 points (Cmax included) last 3 points 
309 acceptable as run last 4 points 
310 last 4 points included no terminal phase - excluded 
311 last 3 points included (except Cmax) acceptable as run 
312 acceptable as run last 3 points 
313 No terminal phase - excluded acceptable as run 
314 last 3 points (Cmax included) acceptable as run 
315 acceptable as run acceptable as run 
317 last 3 points included (except Cmax) acceptable as run 
318 last 3 points (Cmax included) 
last 3 points (Cmax 
included) 
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APPENDIX J 
 
Individual Subject Plasma Concentration-Time Profiles for the Auto-injector and Pre-
filled Syringe Treatment Groups (Linear and Semi-log Scales) by Subject 
 
 
Treatment Group: Auto-Injector 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
  
  
217 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\Autoinj plots.pco (07-Oct-2011) 
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Treatment Group: Pre-Filled Syringe 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
  
  
231 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
 
 
X vs. Observed Y and Predicted Y 
C:\Eric Edwards\PFS plots.pco (07-Oct-2011) 
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APPENDIX K 
Non-Compartmental Analyses Output Files for the Auto-Injector and Pre-filled Syringe 
Treatment Groups by Subject 
 
Auto-Injector Results 
 
Input File: Workbook - [C:\Er...\Data HM13424.xls] 
Subject_ID=304-auto  
                                                  Date:   10/06/2011 
                                                  Time:     12:15:34 
 
                  WINNONLIN NONCOMPARTMENTAL ANALYSIS PROGRAM 
                        Version 5.1  Build 200607251915 
                            Core Version 18Apr2006 
Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   9 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression
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Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        5.677                            42.58      1277. 
      40.00        9.100                            116.5      3949. 
      60.00        11.74                            324.9 1.463e+004 
      90.00        15.35                            731.3 4.593e+004 
      120.0 *      15.54      14.85     0.6829      1195. 9.462e+004      1.000 
      240.0 *      6.333      6.929    -0.5958      2425. 3.052e+005      1.000 
      360.0 *      3.381      3.232     0.1486      2990. 4.710e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9897 
Rsq_adjusted                                              0.9794 
Corr_XY                                                  -0.9948 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0064 
Lambda_z_lower                          min             120.0000 
Lambda_z_upper                          min             360.0000 
HL_Lambda_z                             min             109.0909 
Tlag                                    min              15.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              15.5350 
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Cmax_D                             ug/mL/mg               0.0518 
Tlast                                   min             360.0000 
Clast                                 ug/mL               3.3810 
AUClast                           min*ug/mL            2989.6819 
AUCall                            min*ug/mL            2989.6819 
AUCINF_obs                        min*ug/mL            3521.8002 
AUCINF_D_obs                   min*ug/mL/mg              11.7393 
AUC_%Extrap_obs                           %              15.1093 
Vz_F_obs                                 mL           13406.6285 
Cl_F_obs                             mL/min              85.1837 
AUCINF_pred                       min*ug/mL            3498.4095 
AUCINF_D_pred                  min*ug/mL/mg              11.6614 
AUC_%Extrap_pred                          %              14.5417 
Vz_F_pred                                mL           13496.2665 
Cl_F_pred                            mL/min              85.7533 
AUMClast                      min*min*ug/mL          471040.4496 
AUMCINF_obs                   min*min*ug/mL          746350.4260 
AUMC_%Extrap_obs                          %              36.8875 
AUMCINF_pred                  min*min*ug/mL          734248.4225 
AUMC_%Extrap_pred                         %              35.8473 
MRTlast                                 min             157.5554 
MRTINF_obs                              min             211.9230 
MRTINF_pred                             min             209.8806 
AUC0_30                           min*ug/mL              42.5775 
AUC0_40                           min*ug/mL             116.4625 
AUC0_60                           min*ug/mL             324.8925 
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Input File: Workbook - [C:\Er...\Data HM13424.xls] 
Subject_ID=309-auto  
                                                  Date:   10/06/2011 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00        3.180                            23.85      357.8 
      30.00        7.600                            104.7      2426. 
      40.00        10.64                            195.9      5694. 
      60.00        14.72                            449.5 1.878e+004 
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      90.00        15.70                            905.8 5.322e+004 
      120.0        15.49                            1374. 1.023e+005 
      240.0 *      12.77      13.38    -0.6132      3064. 4.033e+005      1.000 
      360.0 *      8.440      7.684     0.7557      4319. 7.746e+005      1.000 
      480.0 *      4.210      4.412    -0.2022      5049. 1.076e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9790 
Rsq_adjusted                                              0.9580 
Corr_XY                                                  -0.9895 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0046 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min             149.9188 
Tlag                                    min               0.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              15.7000 
Cmax_D                             ug/mL/mg               0.0523 
Tlast                                   min             480.0000 
Clast                                 ug/mL               4.2100 
AUClast                           min*ug/mL            5048.5278 
AUCall                            min*ug/mL            5048.5278 
AUCINF_obs                        min*ug/mL            5959.0967 
AUCINF_D_obs                   min*ug/mL/mg              19.8637 
AUC_%Extrap_obs                           %              15.2803 
Vz_F_obs                                 mL           10888.5869 
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Cl_F_obs                             mL/min              50.3432 
AUCINF_pred                       min*ug/mL            6002.8202 
AUCINF_D_pred                  min*ug/mL/mg              20.0094 
AUC_%Extrap_pred                          %              15.8974 
Vz_F_pred                                mL           10809.2763 
Cl_F_pred                            mL/min              49.9765 
AUMClast                      min*min*ug/mL         1076054.5534 
AUMCINF_obs                   min*min*ug/mL         1710071.9343 
AUMC_%Extrap_obs                          %              37.0755 
AUMCINF_pred                  min*min*ug/mL         1740516.0405 
AUMC_%Extrap_pred                         %              38.1761 
MRTlast                                 min             213.1422 
MRTINF_obs                              min             286.9683 
MRTINF_pred                             min             289.9497 
AUC0_30                           min*ug/mL             104.7000 
AUC0_40                           min*ug/mL             195.9000 
AUC0_60                           min*ug/mL             449.5000 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    360.00,    600.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        4.240                            31.80      954.0 
      40.00        5.170                            78.85      2624. 
      60.00        8.710                            217.7      9918. 
      90.00        12.02                            528.6 3.398e+004 
      120.0        16.20                            951.9 7.937e+004 
      240.0        13.09                            2703. 3.908e+005 
      360.0 *      7.220      7.429    -0.2092      3887. 7.389e+005      1.000 
      480.0 *      6.500      6.139     0.3610      4709. 1.084e+006      1.000 
      600.0 *      4.930      5.073    -0.1429      5390. 1.450e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
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Final Parameters 
--------------- 
Rsq                                                       0.9370 
Rsq_adjusted                                              0.8739 
Corr_XY                                                  -0.9680 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0016 
Lambda_z_lower                          min             360.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             436.0376 
Tlag                                    min              15.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              16.2000 
Cmax_D                             ug/mL/mg               0.0540 
Tlast                                   min             600.0000 
Clast                                 ug/mL               4.9300 
AUClast                           min*ug/mL            5390.4627 
AUCall                            min*ug/mL            5390.4627 
AUCINF_obs                        min*ug/mL            8491.7746 
AUCINF_D_obs                   min*ug/mL/mg              28.3059 
AUC_%Extrap_obs                           %              36.5214 
Vz_F_obs                                 mL           22223.9537 
Cl_F_obs                             mL/min              35.3283 
AUCINF_pred                       min*ug/mL            8581.6518 
AUCINF_D_pred                  min*ug/mL/mg              28.6055 
AUC_%Extrap_pred                          %              37.1862 
Vz_F_pred                                mL           21991.1981 
Cl_F_pred                            mL/min              34.9583 
AUMClast                      min*min*ug/mL         1449614.1824 
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AUMCINF_obs                   min*min*ug/mL         5261341.5774 
AUMC_%Extrap_obs                          %              72.4478 
AUMCINF_pred                  min*min*ug/mL         5371806.9349 
AUMC_%Extrap_pred                         %              73.0144 
MRTlast                                 min             268.9220 
MRTINF_obs                              min             619.5809 
MRTINF_pred                             min             625.9642 
AUC0_30                           min*ug/mL              31.8000 
AUC0_40                           min*ug/mL              78.8500 
AUC0_60                           min*ug/mL             217.6500 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
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Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    240.00,    480.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        5.983                            44.87      1346. 
      40.00        7.935                            114.5      3831. 
      60.00        14.74                            341.2 1.585e+004 
      90.00        16.40                            808.3 5.125e+004 
      120.0        16.60                            1303. 1.033e+005 
      240.0 *      12.27      11.34     0.9303      3022. 4.076e+005      1.000 
      360.0 *      5.341      6.253    -0.9121      4022. 6.993e+005      1.000 
      480.0 *      3.730      3.447     0.2827      4561. 9.235e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9501 
Rsq_adjusted                                              0.9001 
Corr_XY                                                  -0.9747 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0050 
Lambda_z_lower                          min             240.0000 
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Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min             139.6778 
Tlag                                    min              15.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              16.5980 
Cmax_D                             ug/mL/mg               0.0553 
Tlast                                   min             480.0000 
Clast                                 ug/mL               3.7300 
AUClast                           min*ug/mL            4560.8009 
AUCall                            min*ug/mL            4560.8009 
AUCINF_obs                        min*ug/mL            5312.4423 
AUCINF_D_obs                   min*ug/mL/mg              17.7081 
AUC_%Extrap_obs                           %              14.1487 
Vz_F_obs                                 mL           11379.6494 
Cl_F_obs                             mL/min              56.4712 
AUCINF_pred                       min*ug/mL            5255.4651 
AUCINF_D_pred                  min*ug/mL/mg              17.5182 
AUC_%Extrap_pred                          %              13.2179 
Vz_F_pred                                mL           11503.0219 
Cl_F_pred                            mL/min              57.0834 
AUMClast                      min*min*ug/mL          923508.6062 
AUMCINF_obs                   min*min*ug/mL         1435761.5577 
AUMC_%Extrap_obs                          %              35.6781 
AUMCINF_pred                  min*min*ug/mL         1396930.9317 
AUMC_%Extrap_pred                         %              33.8902 
MRTlast                                 min             202.4883 
MRTINF_obs                              min             270.2639 
MRTINF_pred                             min             265.8054 
AUC0_30                           min*ug/mL              44.8725 
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AUC0_40                           min*ug/mL             114.4625 
AUC0_60                           min*ug/mL             341.1825 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
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      15.00        4.240                            31.80      477.0 
      30.00        5.440                            104.4      2178. 
      40.00        7.400                            168.6      4474. 
      60.00        14.42                            386.8 1.609e+004 
      90.00        16.10                            844.6 5.080e+004 
      120.0        17.72                            1352. 1.044e+005 
      240.0        17.23                            3449. 4.813e+005 
      360.0 *      12.03      12.08   -0.04574      5186. 9.961e+005      1.000 
      480.0 *      7.060      7.007    0.05338      6305. 1.460e+006      1.000 
      600.0 *      4.050      4.065   -0.01540      6955. 1.808e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9999 
Rsq_adjusted                                              0.9997 
Corr_XY                                                  -0.9999 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0045 
Lambda_z_lower                          min             360.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             152.8037 
Tlag                                    min               0.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              17.7200 
Cmax_D                             ug/mL/mg               0.0591 
Tlast                                   min             600.0000 
Clast                                 ug/mL               4.0500 
AUClast                           min*ug/mL            6954.7163 
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AUCall                            min*ug/mL            6954.7163 
AUCINF_obs                        min*ug/mL            7847.5352 
AUCINF_D_obs                   min*ug/mL/mg              26.1585 
AUC_%Extrap_obs                           %              11.3771 
Vz_F_obs                                 mL            8427.4528 
Cl_F_obs                             mL/min              38.2286 
AUCINF_pred                       min*ug/mL            7850.9298 
AUCINF_D_pred                  min*ug/mL/mg              26.1698 
AUC_%Extrap_pred                          %              11.4154 
Vz_F_pred                                mL            8423.8089 
Cl_F_pred                            mL/min              38.2120 
AUMClast                      min*min*ug/mL         1807581.5842 
AUMCINF_obs                   min*min*ug/mL         2540094.0415 
AUMC_%Extrap_obs                          %              28.8380 
AUMCINF_pred                  min*min*ug/mL         2542879.1700 
AUMC_%Extrap_pred                         %              28.9159 
MRTlast                                 min             259.9073 
MRTINF_obs                              min             323.6805 
MRTINF_pred                             min             323.8953 
AUC0_30                           min*ug/mL             104.4000 
AUC0_40                           min*ug/mL             168.6000 
AUC0_60                           min*ug/mL             386.8000 
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                  WINNONLIN NONCOMPARTMENTAL ANALYSIS PROGRAM 
                        Version 5.1  Build 200607251915 
                            Core Version 18Apr2006 
Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    500.00,    504.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00       0.0000                           0.0000     0.0000 
      40.00       0.0000                           0.0000     0.0000 
      60.00       0.0000                           0.0000     0.0000 
      90.00        3.811                            57.17      5145. 
      120.0        6.312                            209.0 2.165e+004 
      240.0        7.267                            1024. 1.717e+005 
      360.0        3.727                            1660. 3.584e+005 
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      480.0        4.976                            2182. 5.822e+005 
*) Starred values were included in the estimation of Lambda_z. 
*** Warning 14530: Lambda_z could not be estimated. 
No parameters could be extrapolated to infinity. 
 
Final Parameters 
--------------- 
Rsq                                                      Missing 
Rsq_adjusted                                             Missing 
Corr_XY                                                  Missing 
No_points_lambda_z                                        0 
Lambda_z                              1/min              Missing 
Lambda_z_lower                          min              Missing 
Lambda_z_upper                          min              Missing 
HL_Lambda_z                             min              Missing 
Tlag                                    min              60.0000 
Tmax                                    min             240.0000 
Cmax                                  ug/mL               7.2670 
Cmax_D                             ug/mL/mg               0.0242 
Tlast                                   min             480.0000 
Clast                                 ug/mL               4.9760 
AUClast                           min*ug/mL            2182.1058 
AUCall                            min*ug/mL            2182.1058 
AUCINF_obs                        min*ug/mL              Missing 
AUCINF_D_obs                   min*ug/mL/mg              Missing 
AUC_%Extrap_obs                           %              Missing 
Vz_F_obs                                 mL              Missing 
Cl_F_obs                             mL/min              Missing 
AUCINF_pred                       min*ug/mL              Missing 
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AUCINF_D_pred                  min*ug/mL/mg              Missing 
AUC_%Extrap_pred                          %              Missing 
Vz_F_pred                                mL              Missing 
Cl_F_pred                            mL/min              Missing 
AUMClast                      min*min*ug/mL          582190.4834 
AUMCINF_obs                   min*min*ug/mL              Missing 
AUMC_%Extrap_obs                          %              Missing 
AUMCINF_pred                  min*min*ug/mL              Missing 
AUMC_%Extrap_pred                         %              Missing 
MRTlast                                 min             266.8021 
MRTINF_obs                              min              Missing 
MRTINF_pred                             min              Missing 
AUC0_30                           min*ug/mL               0.0000 
AUC0_40                           min*ug/mL               0.0000 
AUC0_60                           min*ug/mL               0.0000 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
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Number of nonmissing observations:   8 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        4.098                            30.74      922.1 
      40.00        5.413                            78.29      2619. 
      60.00        10.92                            241.6 1.134e+004 
      90.00 *      15.05      16.11     -1.062      631.1 4.148e+004      1.000 
      120.0 *      13.86      12.72      1.133      1064. 8.688e+004      1.000 
      240.0 *      4.871      4.955   -0.08381      2096. 2.619e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9845 
Rsq_adjusted                                              0.9691 
Corr_XY                                                  -0.9922 
No_points_lambda_z                                        3 
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Lambda_z                              1/min               0.0079 
Lambda_z_lower                          min              90.0000 
Lambda_z_upper                          min             240.0000 
HL_Lambda_z                             min              88.1924 
Tlag                                    min              15.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              15.0450 
Cmax_D                             ug/mL/mg               0.0502 
Tlast                                   min             240.0000 
Clast                                 ug/mL               4.8710 
AUClast                           min*ug/mL            2095.7810 
AUCall                            min*ug/mL            2095.7810 
AUCINF_obs                        min*ug/mL            2715.5416 
AUCINF_D_obs                   min*ug/mL/mg               9.0518 
AUC_%Extrap_obs                           %              22.8227 
Vz_F_obs                                 mL           14056.2876 
Cl_F_obs                             mL/min             110.4752 
AUCINF_pred                       min*ug/mL            2726.2047 
AUCINF_D_pred                  min*ug/mL/mg               9.0873 
AUC_%Extrap_pred                          %              23.1246 
Vz_F_pred                                mL           14001.3089 
Cl_F_pred                            mL/min             110.0431 
AUMClast                      min*min*ug/mL          261941.5317 
AUMCINF_obs                   min*min*ug/mL          489539.1875 
AUMC_%Extrap_obs                          %              46.4922 
AUMCINF_pred                  min*min*ug/mL          493455.0403 
AUMC_%Extrap_pred                         %              46.9168 
MRTlast                                 min             124.9852 
MRTINF_obs                              min             180.2731 
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MRTINF_pred                             min             181.0044 
AUC0_30                           min*ug/mL              30.7350 
AUC0_40                           min*ug/mL              78.2900 
AUC0_60                           min*ug/mL             241.6200 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
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------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00        7.830                            58.73      880.9 
      30.00        14.53                            226.4      5031. 
      40.00        19.29                            395.5 1.107e+004 
      60.00        27.74                            865.8 3.543e+004 
      90.00 *      29.80      32.27     -2.475      1729. 1.006e+005      1.000 
      120.0 *      28.73      27.88     0.8540      2607. 1.927e+005      1.000 
      240.0 *      17.48      15.51      1.967      5324. 6.683e+005      1.000 
      360.0 *      8.520      8.633    -0.1134      6820. 1.107e+006      1.000 
      480.0 *      4.290      4.805    -0.5146      7560. 1.412e+006      1.000 
      600.0 *      2.830      2.674     0.1562      7981. 1.638e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9923 
Rsq_adjusted                                              0.9904 
Corr_XY                                                  -0.9962 
No_points_lambda_z                                        6 
Lambda_z                              1/min               0.0049 
Lambda_z_lower                          min              90.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             141.9265 
Tlag                                    min               0.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              29.8000 
Cmax_D                             ug/mL/mg               0.0993 
Tlast                                   min             600.0000 
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Clast                                 ug/mL               2.8300 
AUClast                           min*ug/mL            7980.8092 
AUCall                            min*ug/mL            7980.8092 
AUCINF_obs                        min*ug/mL            8560.2706 
AUCINF_D_obs                   min*ug/mL/mg              28.5342 
AUC_%Extrap_obs                           %               6.7692 
Vz_F_obs                                 mL            7175.8245 
Cl_F_obs                             mL/min              35.0456 
AUCINF_pred                       min*ug/mL            8528.2974 
AUCINF_D_pred                  min*ug/mL/mg              28.4277 
AUC_%Extrap_pred                          %               6.4197 
Vz_F_pred                                mL            7202.7272 
Cl_F_pred                            mL/min              35.1770 
AUMClast                      min*min*ug/mL         1637858.6360 
AUMCINF_obs                   min*min*ug/mL         2104184.0302 
AUMC_%Extrap_obs                          %              22.1618 
AUMCINF_pred                  min*min*ug/mL         2078453.3510 
AUMC_%Extrap_pred                         %              21.1982 
MRTlast                                 min             205.2246 
MRTINF_obs                              min             245.8081 
MRTINF_pred                             min             243.7126 
AUC0_30                           min*ug/mL             226.4250 
AUC0_40                           min*ug/mL             395.5250 
AUC0_60                           min*ug/mL             865.8250 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    120.00,    480.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00        5.830                            43.73      655.9 
      30.00        13.85                            191.3      4428. 
      40.00        15.99                            340.5      9704. 
      60.00        22.57                            726.1 2.964e+004 
      90.00        27.03                            1470. 8.645e+004 
      120.0 *      24.92      24.54     0.3799      2249. 1.681e+005      1.000 
  
  
260 
      240.0 *      12.29      12.97    -0.6797      4393. 5.390e+005      1.000 
      360.0 *      7.290      6.855     0.4354      5542. 8.776e+005      1.000 
      480.0 *      3.540      3.623   -0.08275      6165. 1.135e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9963 
Rsq_adjusted                                              0.9945 
Corr_XY                                                  -0.9982 
No_points_lambda_z                                        4 
Lambda_z                              1/min               0.0053 
Lambda_z_lower                          min             120.0000 
Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min             130.4356 
Tlag                                    min               0.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              27.0300 
Cmax_D                             ug/mL/mg               0.0901 
Tlast                                   min             480.0000 
Clast                                 ug/mL               3.5400 
AUClast                           min*ug/mL            6164.7490 
AUCall                            min*ug/mL            6164.7490 
AUCINF_obs                        min*ug/mL            6830.9019 
AUCINF_D_obs                   min*ug/mL/mg              22.7697 
AUC_%Extrap_obs                           %               9.7520 
Vz_F_obs                                 mL            8264.4484 
Cl_F_obs                             mL/min              43.9181 
AUCINF_pred                       min*ug/mL            6846.4745 
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AUCINF_D_pred                  min*ug/mL/mg              22.8216 
AUC_%Extrap_pred                          %               9.9573 
Vz_F_pred                                mL            8245.6506 
Cl_F_pred                            mL/min              43.8182 
AUMClast                      min*min*ug/mL         1134804.9002 
AUMCINF_obs                   min*min*ug/mL         1579914.1439 
AUMC_%Extrap_obs                          %              28.1730 
AUMCINF_pred                  min*min*ug/mL         1590319.4221 
AUMC_%Extrap_pred                         %              28.6430 
MRTlast                                 min             184.0797 
MRTINF_obs                              min             231.2892 
MRTINF_pred                             min             232.2830 
AUC0_30                           min*ug/mL             191.3250 
AUC0_40                           min*ug/mL             340.5250 
AUC0_60                           min*ug/mL             726.1250 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   9 
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Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal Rule for Increasing Values, 
                     Log Trapezoidal Rule for Decreasing Values 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        4.402                            33.02      990.5 
      40.00        4.116                            75.59      2478. 
      60.00        4.909                            165.8      7070. 
      90.00        5.344                            319.6 1.870e+004 
      120.0 *      9.467      10.70     -1.230      541.8 4.296e+004      1.000 
      240.0 *      7.823      6.128      1.695      1576. 2.272e+005      1.000 
      360.0 *      3.107      3.511    -0.4035      2189. 4.054e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.8740 
Rsq_adjusted                                              0.7480 
Corr_XY                                                  -0.9349 
No_points_lambda_z                                        3 
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Lambda_z                              1/min               0.0046 
Lambda_z_lower                          min             120.0000 
Lambda_z_upper                          min             360.0000 
HL_Lambda_z                             min             149.3108 
Tlag                                    min              15.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL               9.4670 
Cmax_D                             ug/mL/mg               0.0316 
Tlast                                   min             360.0000 
Clast                                 ug/mL               3.1070 
AUClast                           min*ug/mL            2188.9236 
AUCall                            min*ug/mL            2188.9236 
AUCINF_obs                        min*ug/mL            2858.2024 
AUCINF_D_obs                   min*ug/mL/mg               9.5273 
AUC_%Extrap_obs                           %              23.4161 
Vz_F_obs                                 mL           22609.6644 
Cl_F_obs                             mL/min             104.9611 
AUCINF_pred                       min*ug/mL            2945.1281 
AUCINF_D_pred                  min*ug/mL/mg               9.8171 
AUC_%Extrap_pred                          %              25.6765 
Vz_F_pred                                mL           21942.3384 
Cl_F_pred                            mL/min             101.8631 
AUMClast                      min*min*ug/mL          405430.9329 
AUMCINF_obs                   min*min*ug/mL          790540.6716 
AUMC_%Extrap_obs                          %              48.7147 
AUMCINF_pred                  min*min*ug/mL          840558.5746 
AUMC_%Extrap_pred                         %              51.7665 
MRTlast                                 min             185.2193 
MRTINF_obs                              min             276.5867 
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MRTINF_pred                             min             285.4065 
AUC0_30                           min*ug/mL              33.0150 
AUC0_40                           min*ug/mL              75.5890 
AUC0_60                           min*ug/mL             165.8390 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    240.00,    480.00 
 
Summary Table 
------------- 
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      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        6.150                            46.13      1384. 
      40.00        9.750                            125.6      4256. 
      60.00        14.94                            372.5 1.712e+004 
      90.00        19.53                            889.6 5.693e+004 
      120.0        20.62                            1492. 1.204e+005 
      240.0 *      11.83      11.63     0.2027      3439. 4.392e+005      1.000 
      360.0 *      5.860      6.066    -0.2061      4500. 7.362e+005      1.000 
      480.0 *      3.220      3.165    0.05519      5045. 9.555e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9979 
Rsq_adjusted                                              0.9958 
Corr_XY                                                  -0.9989 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0054 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min             127.8420 
Tlag                                    min              15.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              20.6200 
Cmax_D                             ug/mL/mg               0.0687 
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Tlast                                   min             480.0000 
Clast                                 ug/mL               3.2200 
AUClast                           min*ug/mL            5045.0250 
AUCall                            min*ug/mL            5045.0250 
AUCINF_obs                        min*ug/mL            5638.9121 
AUCINF_D_obs                   min*ug/mL/mg              18.7964 
AUC_%Extrap_obs                           %              10.5319 
Vz_F_obs                                 mL            9812.3715 
Cl_F_obs                             mL/min              53.2018 
AUCINF_pred                       min*ug/mL            5628.7340 
AUCINF_D_pred                  min*ug/mL/mg              18.7624 
AUC_%Extrap_pred                          %              10.3702 
Vz_F_pred                                mL            9830.1148 
Cl_F_pred                            mL/min              53.2980 
AUMClast                      min*min*ug/mL          955469.2500 
AUMCINF_obs                   min*min*ug/mL         1350069.8480 
AUMC_%Extrap_obs                          %              29.2282 
AUMCINF_pred                  min*min*ug/mL         1343307.0860 
AUMC_%Extrap_pred                         %              28.8719 
MRTlast                                 min             189.3884 
MRTINF_obs                              min             239.4203 
MRTINF_pred                             min             238.6517 
AUC0_30                           min*ug/mL              46.1250 
AUC0_40                           min*ug/mL             125.6250 
AUC0_60                           min*ug/mL             372.5250 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    120.00,    480.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        3.180                            23.85      715.5 
      40.00        7.257                            76.04      2644. 
      60.00        9.093                            239.5 1.100e+004 
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      90.00        13.90                            584.4 3.794e+004 
      120.0 *      13.28      13.89    -0.6092      992.0 8.061e+004      1.000 
      240.0 *      11.18      11.29    -0.1110      2460. 3.373e+005      1.000 
      360.0 *      10.72      9.184      1.532      3774. 7.298e+005      1.000 
      480.0 *      6.760      7.468    -0.7078      4822. 1.156e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.8565 
Rsq_adjusted                                              0.7848 
Corr_XY                                                  -0.9255 
No_points_lambda_z                                        4 
Lambda_z                              1/min               0.0017 
Lambda_z_lower                          min             120.0000 
Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min             402.1420 
Tlag                                    min              15.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              13.8950 
Cmax_D                             ug/mL/mg               0.0463 
Tlast                                   min             480.0000 
Clast                                 ug/mL               6.7600 
AUClast                           min*ug/mL            4822.2600 
AUCall                            min*ug/mL            4822.2600 
AUCINF_obs                        min*ug/mL            8744.1972 
AUCINF_D_obs                   min*ug/mL/mg              29.1473 
AUC_%Extrap_obs                           %              44.8519 
Vz_F_obs                                 mL           19904.6825 
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Cl_F_obs                             mL/min              34.3085 
AUCINF_pred                       min*ug/mL            9154.8334 
AUCINF_D_pred                  min*ug/mL/mg              30.5161 
AUC_%Extrap_pred                          %              47.3255 
Vz_F_pred                                mL           19011.8664 
Cl_F_pred                            mL/min              32.7696 
AUMClast                      min*min*ug/mL         1155912.3000 
AUMCINF_obs                   min*min*ug/mL         5313825.5747 
AUMC_%Extrap_obs                          %              78.2471 
AUMCINF_pred                  min*min*ug/mL         5749169.0011 
AUMC_%Extrap_pred                         %              79.8943 
MRTlast                                 min             239.7034 
MRTINF_obs                              min             607.6974 
MRTINF_pred                             min             627.9927 
AUC0_30                           min*ug/mL              23.8500 
AUC0_40                           min*ug/mL              76.0350 
AUC0_60                           min*ug/mL             239.5350 
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Settings 
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Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   9 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00       0.0000                           0.0000     0.0000 
      40.00       0.0000                           0.0000     0.0000 
      60.00        4.934                            49.34      2960. 
      90.00        5.249                            202.1 1.449e+004 
      120.0        9.066                            416.8 3.789e+004 
      240.0        9.170                            1511. 2.352e+005 
      360.0        7.200                            2493. 5.228e+005 
*) Starred values were included in the estimation of Lambda_z. 
*** Warning 14530: Lambda_z could not be estimated. 
No parameters could be extrapolated to infinity. 
 
Final Parameters 
--------------- 
Rsq                                                      Missing 
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Rsq_adjusted                                             Missing 
Corr_XY                                                  Missing 
No_points_lambda_z                                        0 
Lambda_z                              1/min              Missing 
Lambda_z_lower                          min              Missing 
Lambda_z_upper                          min              Missing 
HL_Lambda_z                             min              Missing 
Tlag                                    min              40.0000 
Tmax                                    min             240.0000 
Cmax                                  ug/mL               9.1700 
Cmax_D                             ug/mL/mg               0.0306 
Tlast                                   min             360.0000 
Clast                                 ug/mL               7.2000 
AUClast                           min*ug/mL            2493.1700 
AUCall                            min*ug/mL            2493.1700 
AUCINF_obs                        min*ug/mL              Missing 
AUCINF_D_obs                   min*ug/mL/mg              Missing 
AUC_%Extrap_obs                           %              Missing 
Vz_F_obs                                 mL              Missing 
Cl_F_obs                             mL/min              Missing 
AUCINF_pred                       min*ug/mL              Missing 
AUCINF_D_pred                  min*ug/mL/mg              Missing 
AUC_%Extrap_pred                          %              Missing 
Vz_F_pred                                mL              Missing 
Cl_F_pred                            mL/min              Missing 
AUMClast                      min*min*ug/mL          522783.3000 
AUMCINF_obs                   min*min*ug/mL              Missing 
AUMC_%Extrap_obs                          %              Missing 
AUMCINF_pred                  min*min*ug/mL              Missing 
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AUMC_%Extrap_pred                         %              Missing 
MRTlast                                 min             209.6862 
MRTINF_obs                              min              Missing 
MRTINF_pred                             min              Missing 
AUC0_30                           min*ug/mL               0.0000 
AUC0_40                           min*ug/mL               0.0000 
AUC0_60                           min*ug/mL              49.3400 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
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      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        5.350                            40.13      1204. 
      40.00        7.400                            103.9      3486. 
      60.00        11.72                            295.1 1.348e+004 
      90.00        15.08                            697.1 4.438e+004 
      120.0        11.14                            1090. 8.479e+004 
      240.0 *      12.37      12.57    -0.2008      2501. 3.431e+005      1.000 
      360.0 *      8.430      8.161     0.2694      3749. 7.033e+005      1.000 
      480.0 *      5.210      5.298   -0.08758      4567. 1.035e+006      1.000 
      600.0 *      3.440      3.439  0.0009791      5086. 1.309e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9983 
Rsq_adjusted                                              0.9974 
Corr_XY                                                  -0.9991 
No_points_lambda_z                                        4 
Lambda_z                              1/min               0.0036 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             192.5130 
Tlag                                    min              15.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              15.0800 
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Cmax_D                             ug/mL/mg               0.0503 
Tlast                                   min             600.0000 
Clast                                 ug/mL               3.4400 
AUClast                           min*ug/mL            5086.3750 
AUCall                            min*ug/mL            5086.3750 
AUCINF_obs                        min*ug/mL            6041.7923 
AUCINF_D_obs                   min*ug/mL/mg              20.1393 
AUC_%Extrap_obs                           %              15.8135 
Vz_F_obs                                 mL           13790.8212 
Cl_F_obs                             mL/min              49.6541 
AUCINF_pred                       min*ug/mL            6041.5204 
AUCINF_D_pred                  min*ug/mL/mg              20.1384 
AUC_%Extrap_pred                          %              15.8097 
Vz_F_pred                                mL           13791.4419 
Cl_F_pred                            mL/min              49.6564 
AUMClast                      min*min*ug/mL         1309370.2500 
AUMCINF_obs                   min*min*ug/mL         2147975.9443 
AUMC_%Extrap_obs                          %              39.0417 
AUMCINF_pred                  min*min*ug/mL         2147737.2615 
AUMC_%Extrap_pred                         %              39.0349 
MRTlast                                 min             257.4270 
MRTINF_obs                              min             355.5197 
MRTINF_pred                             min             355.4962 
AUC0_30                           min*ug/mL              40.1250 
AUC0_40                           min*ug/mL             103.8750 
AUC0_60                           min*ug/mL             295.0750 
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Settings 
-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    360.00,    600.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00       0.0000                           0.0000     0.0000 
      40.00       0.0000                           0.0000     0.0000 
      60.00       0.0000                           0.0000     0.0000 
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      90.00        4.956                            74.34      6691. 
      120.0        8.370                            274.2 2.845e+004 
      240.0        12.78                            1543. 2.728e+005 
      360.0 *      11.51      13.45     -1.943      3001. 7.055e+005      1.000 
      480.0 *      11.76      8.606      3.150      4397. 1.293e+006      1.000 
      600.0 *      4.710      5.505    -0.7949      5385. 1.801e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.7323 
Rsq_adjusted                                              0.4647 
Corr_XY                                                  -0.8558 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0037 
Lambda_z_lower                          min             360.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             186.1599 
Tlag                                    min              60.0000 
Tmax                                    min             240.0000 
Cmax                                  ug/mL              12.7830 
Cmax_D                             ug/mL/mg               0.0426 
Tlast                                   min             600.0000 
Clast                                 ug/mL               4.7100 
AUClast                           min*ug/mL            5385.0300 
AUCall                            min*ug/mL            5385.0300 
AUCINF_obs                        min*ug/mL            6650.0040 
AUCINF_D_obs                   min*ug/mL/mg              22.1667 
AUC_%Extrap_obs                           %              19.0222 
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Vz_F_obs                                 mL           12116.0218 
Cl_F_obs                             mL/min              45.1128 
AUCINF_pred                       min*ug/mL            6863.4998 
AUCINF_D_pred                  min*ug/mL/mg              22.8783 
AUC_%Extrap_pred                          %              21.5410 
Vz_F_pred                                mL           11739.1412 
Cl_F_pred                            mL/min              43.7095 
AUMClast                      min*min*ug/mL         1800842.4000 
AUMCINF_obs                   min*min*ug/mL         2899563.3856 
AUMC_%Extrap_obs                          %              37.8926 
AUMCINF_pred                  min*min*ug/mL         3084999.8783 
AUMC_%Extrap_pred                         %              41.6259 
MRTlast                                 min             334.4164 
MRTINF_obs                              min             436.0243 
MRTINF_pred                             min             449.4791 
AUC0_30                           min*ug/mL               0.0000 
AUC0_40                           min*ug/mL               0.0000 
AUC0_60                           min*ug/mL               0.0000 
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-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00       0.0000                           0.0000     0.0000 
      40.00        3.240                            16.20      648.0 
      60.00        5.990                            108.5      5538. 
      90.00        8.990                            333.2 2.307e+004 
      120.0        12.02                            648.4 5.684e+004 
      240.0        8.040                            1852. 2.592e+005 
      360.0 *      8.180      8.276   -0.09590      2825. 5.516e+005      1.000 
      480.0 *      6.290      6.145     0.1449      3693. 9.095e+005      1.000 
      600.0 *      4.510      4.563   -0.05287      4341. 1.253e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
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Rsq                                                       0.9954 
Rsq_adjusted                                              0.9908 
Corr_XY                                                  -0.9977 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0025 
Lambda_z_lower                          min             360.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             279.4033 
Tlag                                    min              30.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              12.0200 
Cmax_D                             ug/mL/mg               0.0401 
Tlast                                   min             600.0000 
Clast                                 ug/mL               4.5100 
AUClast                           min*ug/mL            4341.3500 
AUCall                            min*ug/mL            4341.3500 
AUCINF_obs                        min*ug/mL            6159.3028 
AUCINF_D_obs                   min*ug/mL/mg              20.5310 
AUC_%Extrap_obs                           %              29.5156 
Vz_F_obs                                 mL           19633.4111 
Cl_F_obs                             mL/min              48.7068 
AUCINF_pred                       min*ug/mL            6180.6159 
AUCINF_D_pred                  min*ug/mL/mg              20.6021 
AUC_%Extrap_pred                          %              29.7586 
Vz_F_pred                                mL           19565.7078 
Cl_F_pred                            mL/min              48.5389 
AUMClast                      min*min*ug/mL         1252974.0000 
AUMCINF_obs                   min*min*ug/mL         3076551.0815 
AUMC_%Extrap_obs                          %              59.2734 
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AUMCINF_pred                  min*min*ug/mL         3097930.0839 
AUMC_%Extrap_pred                         %              59.5545 
MRTlast                                 min             288.6139 
MRTINF_obs                              min             499.4966 
MRTINF_pred                             min             501.2332 
AUC0_30                           min*ug/mL               0.0000 
AUC0_40                           min*ug/mL              16.2000 
AUC0_60                           min*ug/mL             108.5000 
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Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   11 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
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Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00        3.750                            28.13      421.9 
      30.00        7.880                            115.4      2617. 
      40.00        8.160                            195.6      5431. 
      60.00        9.860                            375.8 1.461e+004 
      90.00        13.06                            719.6 4.112e+004 
      120.0        16.04                            1156. 8.762e+004 
      240.0 *      12.78      12.45     0.3291      2885. 3.871e+005      1.000 
      360.0 *      7.380      7.472   -0.09176      4095. 7.306e+005      1.000 
      480.0 *      4.250      4.484    -0.2338      4793. 1.012e+006      1.000 
      600.0 *      2.800      2.691     0.1093      5216. 1.236e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9960 
Rsq_adjusted                                              0.9939 
Corr_XY                                                  -0.9980 
No_points_lambda_z                                        4 
Lambda_z                              1/min               0.0043 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             162.8814 
Tlag                                    min               0.0000 
  
  
282 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              16.0400 
Cmax_D                             ug/mL/mg               0.0535 
Tlast                                   min             600.0000 
Clast                                 ug/mL               2.8000 
AUClast                           min*ug/mL            5215.6500 
AUCall                            min*ug/mL            5215.6500 
AUCINF_obs                        min*ug/mL            5873.6168 
AUCINF_D_obs                   min*ug/mL/mg              19.5787 
AUC_%Extrap_obs                           %              11.2021 
Vz_F_obs                                 mL           12002.2201 
Cl_F_obs                             mL/min              51.0759 
AUCINF_pred                       min*ug/mL            5847.9331 
AUCINF_D_pred                  min*ug/mL/mg              19.4931 
AUC_%Extrap_pred                          %              10.8121 
Vz_F_pred                                mL           12054.9329 
Cl_F_pred                            mL/min              51.3002 
AUMClast                      min*min*ug/mL         1235586.7500 
AUMCINF_obs                   min*min*ug/mL         1784981.2110 
AUMC_%Extrap_obs                          %              30.7787 
AUMCINF_pred                  min*min*ug/mL         1763535.6685 
AUMC_%Extrap_pred                         %              29.9370 
MRTlast                                 min             236.8999 
MRTINF_obs                              min             303.8981 
MRTINF_pred                             min             301.5656 
AUC0_30                           min*ug/mL             115.3500 
AUC0_40                           min*ug/mL             195.5500 
AUC0_60                           min*ug/mL             375.7500 
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Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   10 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  User-specified lambda_z range,  Log regression 
User's lambda_z bounds:    240.00,    480.00 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00        2.721                            20.41      306.1 
      30.00        8.883                            107.4      2611. 
      40.00        11.32                            208.4      6207. 
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      60.00        17.85                            500.1 2.144e+004 
      90.00        23.38                            1119. 6.907e+004 
      120.0        26.37                            1865. 1.481e+005 
      240.0 *      21.03      20.83     0.1977      4708. 6.408e+005      1.000 
      360.0 *      8.343      8.502    -0.1591      6471. 1.124e+006      1.000 
      480.0 *      3.503      3.470    0.03293      7182. 1.405e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9997 
Rsq_adjusted                                              0.9993 
Corr_XY                                                  -0.9998 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0075 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             480.0000 
HL_Lambda_z                             min              92.8176 
Tlag                                    min               0.0000 
Tmax                                    min             120.0000 
Cmax                                  ug/mL              26.3680 
Cmax_D                             ug/mL/mg               0.0879 
Tlast                                   min             480.0000 
Clast                                 ug/mL               3.5030 
AUClast                           min*ug/mL            7181.5775 
AUCall                            min*ug/mL            7181.5775 
AUCINF_obs                        min*ug/mL            7650.6553 
AUCINF_D_obs                   min*ug/mL/mg              25.5022 
AUC_%Extrap_obs                           %               6.1312 
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Vz_F_obs                                 mL            5250.8227 
Cl_F_obs                             mL/min              39.2123 
AUCINF_pred                       min*ug/mL            7646.2452 
AUCINF_D_pred                  min*ug/mL/mg              25.4875 
AUC_%Extrap_pred                          %               6.0771 
Vz_F_pred                                mL            5253.8511 
Cl_F_pred                            mL/min              39.2349 
AUMClast                      min*min*ug/mL         1404876.7500 
AUMCINF_obs                   min*min*ug/mL         1692847.0969 
AUMC_%Extrap_obs                          %              17.0110 
AUMCINF_pred                  min*min*ug/mL         1690139.7144 
AUMC_%Extrap_pred                         %              16.8781 
MRTlast                                 min             195.6223 
MRTINF_obs                              min             221.2682 
MRTINF_pred                             min             221.0418 
AUC0_30                           min*ug/mL             107.4375 
AUC0_40                           min*ug/mL             208.4425 
AUC0_60                           min*ug/mL             500.1125 
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-------- 
Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   9 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00        6.355                            47.66      1430. 
      40.00        9.037                            124.6      4191. 
      60.00        12.21                            337.1 1.513e+004 
      90.00        21.18                            837.9 5.471e+004 
      120.0 *      12.07      12.04    0.02577      1337. 1.050e+005      1.000 
      240.0 *      5.983      6.009   -0.02563      2420. 2.781e+005      1.000 
      360.0 *      3.004      2.998   0.006413      2959. 4.291e+005      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       1.0000 
Rsq_adjusted                                              0.9999 
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Corr_XY                                                  -1.0000 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0058 
Lambda_z_lower                          min             120.0000 
Lambda_z_upper                          min             360.0000 
HL_Lambda_z                             min             119.6131 
Tlag                                    min              15.0000 
Tmax                                    min              90.0000 
Cmax                                  ug/mL              21.1770 
Cmax_D                             ug/mL/mg               0.0706 
Tlast                                   min             360.0000 
Clast                                 ug/mL               3.0040 
AUClast                           min*ug/mL            2959.0025 
AUCall                            min*ug/mL            2959.0025 
AUCINF_obs                        min*ug/mL            3477.3885 
AUCINF_D_obs                   min*ug/mL/mg              11.5913 
AUC_%Extrap_obs                           %              14.9073 
Vz_F_obs                                 mL           14887.4864 
Cl_F_obs                             mL/min              86.2716 
AUCINF_pred                       min*ug/mL            3476.2818 
AUCINF_D_pred                  min*ug/mL/mg              11.5876 
AUC_%Extrap_pred                          %              14.8802 
Vz_F_pred                                mL           14892.2261 
Cl_F_pred                            mL/min              86.2991 
AUMClast                      min*min*ug/mL          429125.0250 
AUMCINF_obs                   min*min*ug/mL          705199.3926 
AUMC_%Extrap_obs                          %              39.1484 
AUMCINF_pred                  min*min*ug/mL          704609.9809 
AUMC_%Extrap_pred                         %              39.0975 
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MRTlast                                 min             145.0235 
MRTINF_obs                              min             202.7957 
MRTINF_pred                             min             202.6907 
AUC0_30                           min*ug/mL              47.6625 
AUC0_40                           min*ug/mL             124.6225 
AUC0_60                           min*ug/mL             337.0925 
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Model:  Plasma Data, Extravascular Administration 
Number of nonmissing observations:   8 
Dose time:      0.00 
Dose amount:      300.00 
Calculation method:  Linear Trapezoidal with Linear Interpolation 
Weighting for lambda_z calculations:  Uniform weighting 
Lambda_z method:  Find best fit for lambda_z,  Log regression 
 
Summary Table 
------------- 
      Time         Conc.      Pred.    Residual      AUC       AUMC      Weight 
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        min       ug/mL       ug/mL       ug/mL   min*ug/mL min*min*ug/mL 
------------------------------------------------------------------------------- 
     0.0000       0.0000                           0.0000     0.0000 
      15.00       0.0000                           0.0000     0.0000 
      30.00       0.0000                           0.0000     0.0000 
      40.00        3.590                            17.95      718.0 
      90.00        11.09                            385.0 2.926e+004 
      240.0 *      16.79      17.25    -0.4550      2476. 4.063e+005      1.000 
      360.0 *      11.21      10.77     0.4408      4156. 8.903e+005      1.000 
      600.0 *      4.144      4.200   -0.05578      5998. 1.673e+006      1.000 
*) Starred values were included in the estimation of Lambda_z. 
 
Final Parameters 
--------------- 
Rsq                                                       0.9976 
Rsq_adjusted                                              0.9952 
Corr_XY                                                  -0.9988 
No_points_lambda_z                                        3 
Lambda_z                              1/min               0.0039 
Lambda_z_lower                          min             240.0000 
Lambda_z_upper                          min             600.0000 
HL_Lambda_z                             min             176.6614 
Tlag                                    min              30.0000 
Tmax                                    min             240.0000 
Cmax                                  ug/mL              16.7900 
Cmax_D                             ug/mL/mg               0.0560 
Tlast                                   min             600.0000 
Clast                                 ug/mL               4.1440 
AUClast                           min*ug/mL            5998.4300 
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AUCall                            min*ug/mL            5998.4300 
AUCINF_obs                        min*ug/mL            7054.6054 
AUCINF_D_obs                   min*ug/mL/mg              23.5154 
AUC_%Extrap_obs                           %              14.9714 
Vz_F_obs                                 mL           10838.3911 
Cl_F_obs                             mL/min              42.5254 
AUCINF_pred                       min*ug/mL            7068.8220 
AUCINF_D_pred                  min*ug/mL/mg              23.5627 
AUC_%Extrap_pred                          %              15.1424 
Vz_F_pred                                mL           10816.5932 
Cl_F_pred                            mL/min              42.4399 
AUMClast                      min*min*ug/mL         1672890.0000 
AUMCINF_obs                   min*min*ug/mL         2575781.1328 
AUMC_%Extrap_obs                          %              35.0531 
AUMCINF_pred                  min*min*ug/mL         2587934.5180 
AUMC_%Extrap_pred                         %              35.3581 
MRTlast                                 min             278.8880 
MRTINF_obs                              min             365.1205 
MRTINF_pred                             min             366.1055 
AUC0_30                           min*ug/mL               0.0000 
AUC0_40                           min*ug/mL              17.9500 
AUC0_60                           min*ug/mL             119.7500 
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VITA 
Eric S. Edwards 
________________________________________________________________________ 
Eric S. Edwards is the Co-founder and Chief Science Officer at Intelliject, Inc., a 
pharmaceutical company in Richmond, VA developing novel medicines for the treatment of a 
variety or chronic and acute-care diseases. In 2011, the Company announced tentative Food and 
Drug Administration approval of their first product, e-cue™, an epinephrine auto-injector for 
life-threatening allergic emergencies (anaphylaxis).  In November 2009, Intelliject signed a 
commercial licensing agreement with Sanofi for commercialization of e-cue™ in the United 
States and Canada. The novel drug/device combination platforms that Mr. Edwards and his 
identical twin brother engineer, Evan, invented are being incorporated into the development of 
several life-saving or life-enhancing medicines at Intelliject. 
Mr. Edwards is named on over 25 issued and 75 pending patent applications domestically 
and abroad and is a published author on more than half a dozen scientific publications. At 
Intelliject, he is responsible for overseeing the Company’s innovative pharmaceutical research 
and development pipeline, managing the company’s clinical program strategy, assisting with 
pharmaceutical development and regulatory affairs efforts, and leading all aspects of medical 
affairs. Prior to joining Intelliject, Mr. Edwards completed two years of formal medical school 
education at Virginia Commonwealth University and Step I of the United States Medical 
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Licensing Examination. Prior to this, he obtained a B.S. in Biology, Magna Cum Laude, with 
honors from VCU.    
Mr. Edwards has won numerous awards recognizing his entrepreneurial spirit, innovative 
approach to pharmaceutical product development and dedication to research and community 
service, including being recognized as one of the top collegiate inventors by the National 
Collegiate Inventors and Innovators Alliance, being named one of the Top 25 Entrepreneurs of 
the Past 25 Years in Richmond, VA and receiving the Charles T. Rector and Thomas W. Rorrer, 
Jr. Dean's Award for Excellence in Graduate Pharmaceutical Science Research at VCU.  He 
currently lives in Richmond, Virginia, U.S.A. with his wife, Autum, and three children. 
 
